WO2006073940A2 - Multi-route administration of immune response modifier compounds - Google Patents

Multi-route administration of immune response modifier compounds Download PDF

Info

Publication number
WO2006073940A2
WO2006073940A2 PCT/US2005/047069 US2005047069W WO2006073940A2 WO 2006073940 A2 WO2006073940 A2 WO 2006073940A2 US 2005047069 W US2005047069 W US 2005047069W WO 2006073940 A2 WO2006073940 A2 WO 2006073940A2
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
amines
substituted
aryl
heteroaryl
Prior art date
Application number
PCT/US2005/047069
Other languages
French (fr)
Other versions
WO2006073940A3 (en
Inventor
Herbert B. Slade
Cynthia A. Guy
Original Assignee
3M Innovative Properties Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 3M Innovative Properties Company filed Critical 3M Innovative Properties Company
Priority to AU2005323024A priority Critical patent/AU2005323024A1/en
Priority to US11/722,585 priority patent/US20080119508A1/en
Priority to EP05855599A priority patent/EP1830880A4/en
Priority to CA002592573A priority patent/CA2592573A1/en
Priority to JP2007549552A priority patent/JP2008526752A/en
Publication of WO2006073940A2 publication Critical patent/WO2006073940A2/en
Publication of WO2006073940A3 publication Critical patent/WO2006073940A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to administration of immune response modifier (IRM) compounds for use in treating disease.
  • IRM immune response modifier
  • IRM immunostimulatory receptor for modulating the immunostimulatory activity of these IRM compounds.
  • cytokines e.g., interferons, interleukins, tumor necrosis factor, etc.
  • IFN interferon
  • cytokines such as, for example, tumor necrosis factor (TNF), Interleukin-1 (IL-I), IL-6, and IL- 12 also have potentially beneficial activities and are believed to contribute to the antiviral, antitumor, and other properties of these compounds.
  • TNF tumor necrosis factor
  • IL-I Interleukin-1
  • IL-6 IL-6
  • IL- 12 also have potentially beneficial activities and are believed to contribute to the antiviral, antitumor, and other properties of these compounds.
  • IRM compounds where one or more IRM compounds is administered via at least two distinct routes of delivery in combination, for example systemically (e.g., by injection) and locally (e.g., topically). It is believed that this provides a way of synergistically targeting the immune system directly to the disease while boosting the immune response throughout the body, e.g., so as to treat or prevent metastasized cancers or infections that may have spread.
  • local administration to a tumor or infection site directly can be used as an opportunity to sensitize the immune system to the specific disease being treated, while the broad immune response induced by non-local application can seek out and target the disease elsewhere in the body.
  • the present invention is directed to multi-route dosing regimes for administration of one or more IRM compounds.
  • the present invention provides a method of treating disease with an immune response modifier including administering at least one IRM to a subject topically in combination with separately administering at least one IRM to the subject systemically.
  • Such multi-route regimens are useful for treating a variety of diseases including cancer (e.g., melanoma and carcinomas) as well as viral, fungal, protazoal, or bacterial infections.
  • Such multi-route regimens are particularly useful for treating melanoma, in particular, by applying at least one IRM topically (or locally via, e.g., subcutaneous, intra- dermal, or intra-tumoral injection) to a melanoma lesion and separately administering at least one IRM systemically.
  • topical application involves application to dermal and mucosal tissues, including vaginal, rectal, nasal, buccal, and pulmonary applications.
  • systemic application involves oral and parenteral (including subcutaneous (subQ or SC) if the intended result is systemic distribution as opposed to local delivery into a lesion), intramuscular (IM), intraperitoneal (IP), intravenous (IV), intrathecal, intraventricular, etc.) administration.
  • subcutaneous subcutaneous
  • IP intraperitoneal
  • IV intravenous
  • intrathecal intraventricular, etc.
  • the IRM can be selected from the group consisting of imidazoquinoline amines, tetrahydroimidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, 1,2 -bridged imidazoquinoline amines, imidazonaphthyridine amines, imidazotetrahydronaphthyridine amines, oxazoloquinoline amines, thiazoloquinoline amines, oxazolopyridine amines, thiazolopyridine amines, oxazolonaphthyridine amines, thiazolonaphthyridine amines, 1/f-imidazo dimers fused to pyridine amines, quinoline amines, tetrahydroquinoline amines, naphthyridine amines, tetrahydronaphthyridine
  • the present invention also provides an aqueous pharmaceutical composition suitable for parental administration.
  • the composition includes: an immune response modifier compound (IRM); a pharmaceutically acceptable acid (e.g., citric acid, hydrochloric acid, lactic acid, acetic acid, or aspartic acid); a tonicity adjuster (e.g., mannitol, glycerin, sorbitol, or dextrose); sterile water; and optionally a pH adjuster (e.g., NaOH); with the proviso that the IRM is other than l-(2-methylpropyl)-lH-imidazo[4,5- c]quinolin-4-amine or 4-amino- ⁇ , ⁇ -dimethyl-lH-imidazo[4,5-c]quinoline-l-ethanol.
  • IRM immune response modifier compound
  • a pharmaceutically acceptable acid e.g., citric acid, hydrochloric acid, lactic acid, acetic acid, or aspartic acid
  • the invention includes, but is not limited to, the following embodiments: 1.
  • IRMs immune response modifiers
  • routes of delivery include local delivery and systemic delivery.
  • a method of treating melanoma with an immune response modifier comprising: applying at least one IRM topically to a melanoma lesion on a subject in combination with separately administering at least one IRM to the subject systemically.
  • the IRM is a compound having a 2-aminopyridine fused to a five membered nitrogen-containing heterocyclic ring.
  • the immune response modifier is selected from the group consisting of imidazoquinoline amines, tetrahydroimidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, 1,2-bridged imidazoquinoline amines, imidazonaphthyridine amines, imidazotetrahydronaphthyridine amines, oxazoloquinoline amines, thiazoloquinoline amines, oxazolopyridine amines, thiazolopyridine amines, oxazolonaphthyridine amines, thiazolonaphthyridine amines, IH- imidazo dimers fused to
  • the immune response modifier is selected from the group consisting of imidazoquinoline amines, tetrahydroimidazoquinoline amines, imidazopyridine amines, and combinations thereof.
  • the immune response modifier is selected from the group consisting of amide substituted imidazoquinoline amines, sulfonamide substituted imidazoquinoline amines, urea substituted imidazoquinoline amines, aryl ether substituted imidazoquinoline amines, heterocyclic ether substituted imidazoquinoline amines, amido ether substituted imidazoquinoline amines, sulfonamido ether substituted imidazoquinoline amines, urea substituted imidazoquinoline ethers, thioether substituted imidazoquinoline amines, 6-, 7-, 8-, or 9-aryl or heteroaryl substituted imidazoquinoline amines, amide substituted tetrahydroimidazoquinoline amines, sulfonamide substituted tetrahydroimidazoquinoline amines, urea substituted tetrahydroimidazoquinoline amines, aryl
  • the immune response modifier is selected from the group consisting of amide substituted imidazoquinoline amines, sulfonamide substituted imidazoquinoline amines, urea substituted imidazoquinoline amines, thioether substituted imidazoquinoline amines, 7-aryl substituted imidazoquinoline amines, 7- heteroaryl substituted imidazoquinoline amines, sulfonamide substituted tetrahydroimidazoquinoline amines, and combinations thereof.
  • the immune response modifier is selected from the group consisting of N-[4-(4-amino-2-ethyl-lH-imidazo[4,5-c]quinolin-l- yl)butyl]methanesulfonamide, N- ⁇ 2-[4-amino-2-(ethoxymethyl)-lH-imidazo[4,5- cjquinolin- 1 -yl)butyl]- 1 , 1 -dimethyleethyl ⁇ methanesulfonamide, pharmaceutically acceptable salts thereof, and combinations thereof.
  • an IRM is administered systemically in a formulation comprising: a pharmaceutically acceptable acid; a tonicity adjuster; sterile water; and optionally a pH adjuster; with the proviso that the IRM is other than l-(2-methylpropyl)-l/i-imidazo[4,5- c]quinolin-4-amine or 4-amino- ⁇ , ⁇ -dimethyl-l/- r -imidazo[4,5-c]quinoline-l-ethanol.
  • An aqueous pharmaceutical composition suitable for parental administration comprising: an immune response modifier compound (IRM); a pharmaceutically acceptable acid; a tonicity adjuster; sterile water; and optionally a pH adjuster; with the proviso that the IRM is other than l-(2-methylpropyl)-lH-imidazo[4,5- c]quinolin-4-amine or 4-amino- ⁇ , ⁇ -dimethyl-l//-imidazo[4,5-c]quinoline-l-ethanol.
  • IRM immune response modifier compound
  • the present invention provides a multi-route dosing regime for administration of one or more IRM compounds.
  • the present invention provides a method of treating disease with an immune response modifier including administering at least one IRM to a subject locally (e.g., topically or via injection into a lesion) in combination with separately administering at least one IRM to the subject systemically.
  • the subject is typically a mammal, and may be a human.
  • the IRM administered by one route may be the same or different than the IRM administered via another route (e.g., systemically).
  • the IRM may be the same compound, or may be the same compound active moiety but in a different salt form thereof.
  • the multi-route regimens of the present invention are useful for treating a variety of diseases including cancer (e.g., melanoma and carcinomas) as well as viral, fungal, protazoal, or bacterial infections.
  • treating includes therapeutic and/or prophylactic treating.
  • Such multi-route regimens are particularly useful for treating melanoma, although other types of cancers can be treated.
  • an IRM is injected directly into a tumor for local effect and especially to target the immune system to the tumor, and an IRM is also delivered systemically to boost body-wide immune response to the tumor (especially if there is a risk it has metastasized).
  • Non-limiting examples of other cancers for which the present invention may be useful include breast cancer, stomach cancer, colorectal cancer, prostate cancer, testicular cancer, head and neck cancer, lung cancer, etc. Any cancer where there is a localized tumor site to which an IRM can be delivered, in combination with administration via a different route of delivery (which will often be systemic delivery, but could be other routes as well).
  • IRMs of the present invention may be administered to the subject in combination with other modes of treatment. This is particularly true for cancer therapy.
  • Such other modes of cancer therapy include, but are not limited to, radiation treatment, brachytherapy, external beam radiation, chemotheraphy, hormone therapy, immunomodulatory therapy, therapeutic vaccine therapy, and antibody therapy.
  • the administration of the agents of the present invention can take place before, during, or after the other therapy.
  • the IRMs may be delivered via different routes simultaneously or at different times.
  • the efficacy of treatment may be assessed by various parameters well known in the art. This includes, but is not limited to, determination of tumor size, location and vascularization, as determined by such methods including, but not limited to, X-rays, scans, magnetic resonance imaging, computerized tomography, and/or various nuclear medicine techniques and algorithms to evaluate tumor size and burden in three dimensions. Angiography can be used to evaluate vascularization of tumors and other tissues. Other methods of determining tumor location, stage, and grade include, but are not limited to, gene arrays, immuno-histochemistry, and/or other techniques for measuring biomarkers relevant to assessing a disease.
  • the efficacy of the administration of an IRM effective for the treatment of cancer may be demonstrated by such means, including, but not limited to, the inhibition of tumor growth, the inhibition of tumor progression, the inhibition of tumor spread, the inhibition of tumor invasiveness, the inhibition of tumor vascularization, the inhibition of tumor angiogenesis, and/or the inhibition of tumor metastasis.
  • the inhibition of tumor growth is a decrease in the growth rate of a tumor. It includes, but is not limited to, at least one of a decrease in tumor weight or tumor volume, a decrease in tumor doubling time, a decrease in the growth fraction or number of tumor cells that are replicating, a decrease in the rate in which tumor cells are shed, and/or a decrease in the ratio of cell production to cell loss within a tumor.
  • the inhibition of tumor growth can also include the inhibition of tumor growth of primary lesions and/or any metastatic lesions.
  • the inhibition of tumor progression includes the disruption or halting of the progression of premalignant lesions, also called leukoplakia, to malignant carcinoma.
  • the inhibition of tumor spread is the decrease in the dissemination of a tumor to other locations. This dissemination to other locations can be the result of the seeding of a body cavity or surface with cancerous cells from a tumor and/or the transport of tumor cells through the lymphatic system and/or circulatory system.
  • the inhibition of tumor spread can also include the inhibition of tumor spread in primary lesions and/or any metastatic lesions.
  • the inhibition of tumor invasiveness is the decrease in the infiltration, invasion, and/or destruction of the surrounding local tissues, including, but not limited to organs, blood vessels, lymphatics, and/or body cavities.
  • the inhibition of tumor invasiveness can also include the inhibition of tumor invasiveness in primary lesions and/or any metastatic lesions.
  • the inhibition of tumor vascularization is the decrease in the formation of blood vessels and lymphatic vessels within a tumor and to and from a tumor.
  • the inhibition of tumor vascularization can also include the inhibition of tumor vascularization in primary lesions and/or any metastatic lesions.
  • the inhibition of tumor angiogenesis is a decrease in the formation of new capillaries and microvessels within a tumor.
  • the inhibition of tumor angiogenesis can also include the inhibition of tumor angiogenesis in primary lesions and/or any metastatic lesions.
  • the inhibition of tumor metastasis is a decrease in the formation of tumor lesions that are discontinuous with the primary tumor.
  • tumor cells break loose from the primary lesion, enter blood vessels or lymphatics and produce a secondary growth at a distant site.
  • the distribution of the metastases may be the result of the natural pathways of the drainage of the lymphatic and/or circulatory system.
  • the distribution of metastases may be the result of a tropism of the tumor to a specific tissue or organ.
  • prostate tumors may preferentially metastasis to the bone.
  • the tumor cells of a metastatic lesion may in turn metastasize to additional locations. This may be referred to as a metastatic cascade.
  • Tumor cells may metastasize to sites including, but not limited to, liver, bone, lung, lymph node, spleen, brain or other nervous tissue, bone marrow, or an organ other than the original tissue of origin.
  • the inhibition of tumor metastasis includes the inhibition of tumor metastasis in primary lesions and/or any metastatic lesions.
  • local application includes, e.g., topical application as well as injectable applications (e.g., intra-dermal, intra-tumoral, or subcutaneous) intended for local distribution only, without substantial systemic delivery.
  • topical application involves application to dermal and mucosal tissues, including vaginal, rectal, nasal, buccal, and pulmonary applications.
  • systemic application involves oral and parenteral (including subcutaneous (subQ or SC) if intended for systemic distribution as opposed to local administration), intramuscular (IM), intraperitoneal (IP), intravenous (IV), intrathecal, intraventricular, etc.) administration.
  • formulations of the present invention can be administered to a subject (e.g., mammal, particularly a human) in various ways, for example, by spraying, injection, inhalation (e.g., from a nebulizer or spray pump atomizer), gel, cream, foam, transdermal patch, suppository, etc.
  • a subject e.g., mammal, particularly a human
  • inhalation e.g., from a nebulizer or spray pump atomizer
  • gel e.g., cream, foam, transdermal patch, suppository, etc.
  • Formulations of the present invention suitable for topical administration are disclosed in, e.g., U.S. Patent Publication No. US 2003/0199538 and International Publication No. WO 2003/045391.
  • a typical formulation for topical administration includes, for example, isostearic acid (e.g., 15-35 wt-%), medium-chain triglycerides (e.g., 5-10 wt-%), propylene glycol (e.g., 5-10 wt-%), parabens (e.g., methyl, ethyl, and mixtures thereof) (e.g., 0.1-0.5 wt-%), edetate disodium (e.g., 0.01-0.1 wt-%), polymers such as CARBOMERS and POLOXAMERS (e.g., 4.0-5.0 wt-%), and water (preferably sterile water), wherein the formulation is optionally adjusted to a desired pH, preferably a pH of 5.8 (e
  • Formulations of the present invention suitable for parenteral administration conveniently include a sterile aqueous preparation of the desired compound, or dispersions of sterile powders including the desired compound, which are preferably isotonic with the blood of the subject.
  • Isotonic agents that can be included in the liquid preparation include sugars, buffers, and salts such as sodium chloride.
  • Solutions of the desired compound can be prepared in water, optionally mixed with a nontoxic surfactant.
  • Dispersions of the desired compound can be prepared in water, ethanol, a polyol (such as glycerol, propylene glycol, liquid polyethylene glycols, and the like), vegetable oils, glycerol esters, and mixtures thereof.
  • a typical formulation for systemic administration includes, for example, citric acid or other pharmaceutically acceptable acid (e.g., hydrochloric acid, lactic acid, acetic acid, aspartic acid), mannitol or other tonicity adjuster (e.g., glycerin, sorbitol, dextrose), and water (preferably, sterile water), wherein the formulation is optionally adjusted to a desired pH, preferably a pH of 5, by a suitable pH adjuster (e.g., by NaOH).
  • citric acid or other pharmaceutically acceptable acid e.g., hydrochloric acid, lactic acid, acetic acid, aspartic acid
  • mannitol or other tonicity adjuster e.g., glycerin, sorbitol, dextrose
  • water preferably, sterile water
  • the pharmaceutically acceptable acid is preferably present in the formulation (i.e., composition) in an amount of at least 0.4 wt-%, although lower concentrations, such as 0.3%, may also be used, , and preferably no more than 0.5 wt-%, based on the total weight of the formulation.
  • the tonicity adjuster is preferably present in the formulation in an amount of at least 4 wt-%, and preferably no more than 5 wt-%, based on the total weight of the formulation. Additional information regarding formulations for injection can be found in co-pending application attorney docket number 61658WO003, entitled Immune Response Modifier Formulations and Methods, filed even date herewith.
  • the IRM can be incorporated into such a formulation in a variety of concentrations.
  • Typical formulations include one or more IRMs in amounts of at least 0.001 wt-%, and preferably at least 0.2 wt-%, and even up to 1.5 wt-%, based on the total weight of the formulation.
  • An IRM can be incorporated into such a formulation in a variety of concentrations.
  • Formulations of the present invention suitable for oral administration can include those discussed above for systemic administration, wherein the formulations are suitably diluted.
  • such formulations can be diluted with dextrose or other suitable diluents to a total volume of 10 mL.
  • oral formulations may include discrete units such as tablets, troches, capsules, lozenges, wafers, or cachets, each containing a predetermined amount of the IRM, as a powder, in granular form, incorporated within liposomes, or as a solution or suspension in an aqueous liquid or non-aqueous liquid such as a syrup, an elixir, an emulsion, or a draught.
  • discrete units such as tablets, troches, capsules, lozenges, wafers, or cachets, each containing a predetermined amount of the IRM, as a powder, in granular form, incorporated within liposomes, or as a solution or suspension in an aqueous liquid or non-aqueous liquid such as a syrup, an elixir, an emulsion, or a draught.
  • the tablets, troches, pills, capsules, and the like may also contain one or more of the following: a binder such as gum tragacanth, acacia, corn starch, or gelatin; an excipient such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid, and the like; a lubricant such as magnesium stearate; a sweetening agent such as sucrose, fructose, lactose, or aspartame; and a natural or artificial flavoring agent.
  • a binder such as gum tragacanth, acacia, corn starch, or gelatin
  • an excipient such as dicalcium phosphate
  • a disintegrating agent such as corn starch, potato starch, alginic acid, and the like
  • a lubricant such as magnesium stearate
  • a sweetening agent such as sucrose, fructose, lactose, or aspartame
  • Various other materials may be present as coatings or to otherwise modify the physical form of the solid unit dosage form.
  • tablets, pills, or capsules may be coated with gelatin, wax, shellac, sugar, and the like.
  • a syrup or elixir may contain one or more of a sweetening agent, a preservative such as methyl- or propylparaben, an agent to retard crystallization of the sugar, an agent to increase the solubility of any other ingredient, such as a polyhydric alcohol, for example glycerol or sorbitol, a dye, and flavoring agent.
  • the material used in preparing any unit dosage form is substantially nontoxic in the amounts employed.
  • the compound may be incorporated into sustained-release preparations and devices if desired.
  • Formulations for rectal or vaginal administration may be presented as a suppository with a suitable carrier such as cocoa butter, or hydrogenated fats or hydro genated fatty carboxylic acids.
  • Nasal spray formulations can include purified aqueous solutions of the desired compound with preservative agents and isotonic agents. Such formulations are preferably adjusted to a pH and isotonic state compatible with the nasal mucous membranes. Preferably, such formulations are in solution form at room temperature (i.e., 25°C-30°C). Also, such formulations are sufficiently low in viscosity (less than 100 centipoise (cps)) at room temperature. At such low viscosity level, the compositions are typically and preferably sprayable. In this context, "sprayable" means the formulation can be delivered using a conventional pump spray device.
  • an IRM compound that will be therapeutically effective in a specific situation will depend on such things as the activity of the particular compound, the dosing regimen, the application site, the particular formulation, and the condition being treated. As such, specific administration amounts described herein are only exemplary. Those skilled in the art will be able to determine appropriate therapeutically effective amounts based on the guidance provided herein, information available in the art pertaining to those compounds, and routine testing.
  • Typical topical formulations include one or more IRMs in amounts of at least 0.01 wt-%, and even up to 3.0 wt-%, based on the total weight of the formulation.
  • a preferred systemic formulation includes one or more IRMs in amounts of 0.1 wt-% to 1.6 wt-%, based on the total weight of the formulation.
  • the methods of the present invention include systemically administering sufficient formulation to provide a dose of IRM compound of, for example, from 10 ng/kg to 50 mg/kg to the subject, although in some embodiments the methods may be performed by administering IRM compound in concentrations outside this range.
  • the method includes systemically administering sufficient formulation to provide a dose of IRM compound of from 100 ng/kg to 5 mg/kg to the subject, for example, a dose of from 1 ⁇ g/kg to 1 mg/kg.
  • the methods of the present invention include topically administering sufficient formulation of IRM compound, for example, from 0.0001 wt-% to 10wt-% to the subject, although in some embodiments the methods may be performed by administering IRM compound in concentrations outside this range.
  • the method includes topically administering sufficient formulation of IRM compound from 0.001wt-% to 5wt-% to the subject, for example, from 0.01wt-% to 3wt- %.
  • IRM compounds used herein are generally agonists of toll-like receptors (TLRs) 7, 8, and/or 9.
  • TLRs toll-like receptors
  • Some IRM oligonucleotide sequences contain cytosine-guanine dinucleotides (CpG) and are described, for example, in U.S. Patent Nos. 6,194,388; 6,207,646; 6,239,116; 6,339,068; and 6,406,705.
  • CpG-containing oligonucleotides can include synthetic immunomodulatory structural motifs such as those described, for example, in U.S. Patent Nos. 6,426,334 and 6,476,000.
  • Other IRM nucleotide sequences lack CpG sequences and are described, for example, in International Patent Publication No. WO 00/75304.
  • Other IRMs include biological molecules such as aminoalkyl glucosaminide phosphates (AGPs) and are described, for example, in U.
  • CpGs and other biological IRMs are considered relatively large molecules and many are TLR 9 agonists.
  • TLR 7 and/or 8 agonists may be preferred, and small-molecule IRMs are generally preferred for methods involving multi-route administration including topical delivery.
  • small organic molecule IRMs e.g., molecular weight under about 1000 Daltons, preferably under about 500 Daltons, as opposed to large biologic protein, peptides, and the like
  • IRM compounds suitable for use in the invention preferably include small- molecule IRM compounds having a 2-aminopyridine fused to a five membered nitrogen- containing heterocyclic ring.
  • Such compounds include, for example, imidazoquinoline amines, including but not limited to, substituted imidazoquinoline amines such as, for example, amide substituted imidazoquinoline amines, sulfonamide substituted imidazoquinoline amines, urea substituted imidazoquinoline amines, aryl ether substituted imidazoquinoline amines, heterocyclic ether substituted imidazoquinoline amines, amido ether substituted imidazoquinoline amines, sulfonamido ether substituted imidazoquinoline amines, urea substituted imidazoquinoline ethers, thioether substituted imidazoquinoline amines, and 6-, 7-, 8-, or 9-aryl or heteroaryl substituted imidazoquinoline amines; tetrahydroimidazoquinoline amines, including but not limited to, amide substituted tetrahydroimidazoquinoline amines, sulfonamide
  • the immune response modifier is selected from the group consisting of imidazoquinoline amines, tetrahydroimidazoquinoline amines, imidazopyridine amines, and combinations thereof.
  • the immune response modifier is selected from the group consisting of amide substituted imidazoquinoline amines, sulfonamide substituted imidazoquinoline amines, urea substituted imidazoquinoline amines, aryl ether substituted imidazoquinoline amines, heterocyclic ether substituted imidazoquinoline amines, amido ether substituted imidazoquinoline amines, sulfonamide ether substituted imidazoquinoline amines, urea substituted imidazoquinoline ethers, thioether substituted imidazoquinoline amines, 6-, 7-, 8-, or 9-aryl or heteroaryl substituted imidazoquinoline amines, amide substituted tetrahydroimidazoquinoline amines, sulfonamide substituted tetrahydroimidazoquinoline amines, urea substituted tetrahydroimidazoquinoline amines, aryl ether substituted t
  • the immune response modifier is selected from the group consisting of amide substituted imidazoquinoline amines, sulfonamide substituted imidazoquinoline amines, urea substituted imidazoquinoline amines, thioether substituted imidazoquinoline amines, 7-aryl substituted imidazoquinoline amines, 7-heteroaryl substituted imidazoquinoline amines, sulfonamide substituted tetrahydroimidazoquinoline amines, and combinations thereof.
  • the immune response modifier is an imidazoquinoline amine. In certain embodiments, the immune response modifier is a sulfonamide substituted imidazoquinoline amine. In certain embodiments, the immune response modifier is selected from the group consisting of N- [4-(4-amino-2-ethyl- 1 H-imidazo [4,5 -c] quinolin- 1 - yl)butyl]methanesulfonamide, N- ⁇ 2-[4-ammo-2-(ethoxymethyl)-lH-imidazo[4,5- c] quinolin- 1 -yl)butyl]- 1 , 1 -dimethyleethyllmethanesulfonamide, 4- amino- ⁇ , ⁇ -dimethyl -2-ethoxymethyl-lH-imidazo[4,5-c]quinolin-l-ethanol, pharmaceutically acceptable salts thereof, and combinations thereof.
  • the IRM compounds and salts thereof described herein include any of their pharmaceutically acceptable forms, such as isomers (e.g., diastereomers and enantiomers), solvates, polymorphs, and the like.
  • the invention specifically includes the use of each of the compound's enantiomers as well as racemic combinations of the enantiomers.
  • the immune response modifier can, for example, be a salt of an acid selected from the group consisting of a carboxylic acid, a halo acid, sulfuric acid, phosphoric acid, dicarboxylic acid, tricarboxylic acid, and combinations thereof.
  • the salt of the immune response modifier can be a salt of an acid selected from the group consisting of hydrobromic acid, hydrochloric acid, lactic acid, glutamic acid, gluconic acid, tartaric acid, succinic acid, and combinations thereof.
  • IRM compound can be chosen from lH-imidazo[4,5-c]quinolin-4-amines defined by one of Formulas I-V below:
  • R 11 is selected from alkyl of one to ten carbon atoms, hydroxyalkyl of one to six carbon atoms, acyloxyalkyl wherein the acyloxy moiety is alkanoyloxy of two to four carbon atoms or benzoyloxy, and the alkyl moiety contains one to six carbon atoms, benzyl, (phenyl)ethyl and phenyl, said benzyl, (phenyl)ethyl or phenyl substiruent being optionally substituted on the benzene ring by one or two moieties independently selected from alkyl of one to four carbon atoms, alkoxy of one to four carbon atoms and halogen, with the proviso that if said benzene ring is substituted by two of said moieties, then said moieties together contain no more than six carbon atoms;
  • R 2I is selected from hydrogen, alkyl of one to eight carbon atoms, benzyl, (phenyl)ethyl and phenyl, the benzyl, (phenyl)ethyl or phenyl substituent being optionally substituted on the benzene ring by one or two moieties independently selected from alkyl of one to four carbon atoms, alkoxy of one to four carbon atoms and halogen, with the proviso that when the benzene ring is substituted by two of said moieties, then the moieties together contain no more than six carbon atoms; and each Ri is independently selected from alkoxy of one to four carbon atoms, halogen, and alkyl of one to four carbon atoms, and n is an integer from 0 to 2, with the proviso that if n is 2, then said R 1 groups together contain no more than six carbon atoms;
  • R 12 is selected from straight chain or branched chain alkenyl containing two to ten carbon atoms and substituted straight chain or branched chain alkenyl containing two to ten carbon atoms, wherein the substituent is selected from straight chain or branched chain alkyl containing one to four carbon atoms and cycloalkyl containing three to six carbon atoms; and cycloalkyl containing three to six carbon atoms substituted by straight chain or branched chain alkyl containing one to four carbon atoms; and
  • R 22 is selected from hydrogen, straight chain or branched chain alkyl containing one to eight carbon atoms, benzyl, (phenyl)ethyl and phenyl, the benzyl, (phenyl)ethyl or phenyl substituent being optionally substituted on the benzene ring by one or two moieties independently selected from straight chain or branched chain alkyl containing one to four carbon atoms, straight chain or branched chain alkoxy containing one to four carbon atoms, and halogen, with the proviso that when the benzene ring is substituted by two such moieties, then the moieties together contain no more than six carbon atoms; and each R 2 is independently selected from straight chain or branched chain alkoxy containing one to four carbon atoms, halogen, and straight chain or branched chain alkyl containing one to four carbon atoms, and n is an integer from zero to 2, with the proviso that if n is 2, then said
  • R 23 is selected from hydrogen, straight chain or branched chain alkyl of one to eight carbon atoms, benzyl, (phenyl)ethyl and phenyl, the benzyl, (phenyl)ethyl or phenyl substituent being optionally substituted on the benzene ring by one or two moieties independently selected from straight chain or branched chain alkyl of one to four carbon atoms, straight chain or branched chain alkoxy of one to four carbon atoms, and halogen, with the proviso that when the benzene ring is substituted by two such moieties, then the moieties together contain no more than six carbon atoms; and each R 3 is independently selected from straight chain or branched chain alkoxy of one to four carbon atoms, halogen, and straight chain or branched chain alkyl of one to four carbon atoms, and n is an integer from zero to 2, with the proviso that if n is 2, then said R 3 groups together contain
  • R 14 is -CHR x Ry wherein R y is hydrogen or a carbon-carbon bond, with the proviso that when R y is hydrogen R x is alkoxy of one to four carbon atoms, hydroxyalkoxy of one to four carbon atoms, 1-alkynyl of two to ten carbon atoms, tetrahydropyranyl, alkoxyalkyl wherein the alkoxy moiety contains one to four carbon atoms and the alkyl moiety contains one to four carbon atoms, or 2-, 3-, or 4-pyridyl, and with the further proviso that when R y is a carbon-carbon bond R y and R x together form a tetrahydrofuranyl group optionally substituted with one or more substituents independently selected from hydroxy and hydroxyalkyl of one to four carbon atoms;
  • R 24 is selected from hydrogen, alkyl of one to four carbon atoms, phenyl, and substituted phenyl wherein the substituent is selected from alkyl of one to four carbon atoms, alkoxy of one to four carbon atoms, and halogen;
  • R 4 is selected from hydrogen, straight chain or branched chain alkoxy containing one to four carbon atoms, halogen, and straight chain or branched chain alkyl containing one to four carbon atoms;
  • R 15 is selected from hydrogen; straight chain or branched chain alkyl containing one to ten carbon atoms and substituted straight chain or branched chain alkyl containing one to ten carbon atoms, wherein the substituent is selected from cycloalkyl containing three to six carbon atoms and cycloalkyl containing three to six carbon atoms substituted by straight chain or branched chain alkyl containing one to four carbon atoms; straight chain or branched chain alkenyl containing two to ten carbon atoms and substituted straight chain or branched chain alkenyl containing two to ten carbon atoms, wherein the substituent is selected from cycloalkyl containing three to six carbon atoms and cycloalkyl containing three to six carbon atoms substituted by straight chain or branched chain alkyl containing one to four carbon atoms; hydroxyalkyl of one to six carbon atoms; alkoxyalkyl wherein the alkoxy moiety contains one to four carbon
  • Rs and RT are independently selected from hydrogen, alkyl of one to four carbon atoms, phenyl, and substituted phenyl wherein the substituent is selected from alkyl of one to four carbon atoms, alkoxy of one to four carbon atoms, and halogen;
  • X is selected from alkoxy containing one to four carbon atoms, alkoxyalkyl wherein the alkoxy moiety contains one to four carbon atoms and the alkyl moiety contains one to four carbon atoms, hydroxyalkyl of one to four carbon atoms, haloalkyl of one to four carbon atoms, alkylamido wherein the alkyl group contains one to four carbon atoms, amino, substituted amino wherein the substituent is alkyl or hydroxyalkyl of one to four carbon atoms, azido, chloro, hydroxy, 1-morpholino, 1-pyrrolidino, alkylthio of one to four carbon atoms; and
  • R 5 is selected from hydrogen, straight chain or branched chain alkoxy containing one to four carbon atoms, halogen, and straight chain or branched chain alkyl containing one to four carbon atoms; and pharmaceutically acceptable salts of any of the foregoing.
  • the IRM compound can be chosen from 6,7 fused cycloalkylimidazopyridine amines defined by Formula VI below:
  • R 16 is selected from hydrogen; cyclic alkyl of three, four, or five carbon atoms; straight chain or branched chain alkyl containing one to ten carbon atoms and substituted straight chain or branched chain alkyl containing one to ten carbon atoms, wherein the substituent is selected from cycloalkyl containing three to six carbon atoms and cycloalkyl containing three to six carbon atoms substituted by straight chain or branched chain alkyl containing one to four carbon atoms; fluoro- or chloroalkyl containing from one to ten carbon atoms and one or more fluorine or chlorine atoms; straight chain or branched chain alkenyl containing two to ten carbon atoms and substituted straight chain or branched chain alkenyl containing two to ten carbon atoms, wherein the substituent is selected from cycloalkyl containing three to six carbon atoms and cycloalkyl containing three to six carbon atoms substituted by straight
  • Ry is hydrogen or a carbon-carbon bond
  • R x is alkoxy of one to four carbon atoms, hydroxyalkoxy of one to four carbon atoms, 1- alkynyl of two to ten carbon atoms, tetrahydropyranyl, alkoxyalkyl wherein the alkoxy moiety contains one to four carbon atoms and the alkyl moiety contains one to four carbon atoms, 2-, 3-, or 4-pyridyl, and with the further proviso that when R y is a carbon-carbon bond Ry and R x together form a tetrahydrofuranyl group optionally substituted with one or more substituents independently selected from hydroxy and hydroxyalkyl of one to four carbon atoms;
  • R 26 is selected from hydrogen; straight chain or branched chain alkyl containing one to eight carbon atoms; straight chain or branched chain hydroxyalkyl containing one to six carbon atoms; morpholinoalkyl;
  • X is selected from alkoxy containing one to four carbon atoms, alkoxyalkyl wherein the alkoxy moiety contains one to four carbon atoms and the alkyl moiety contains one to four carbon atoms, haloalkyl of one to four carbon atoms, alkylamido wherein the alkyl group contains one to four carbon atoms, amino, substituted amino wherein the substituent is alkyl or hydroxyalkyl of one to four carbon atoms, azido, alkylthio of one to four carbon atoms, and morpholinoalkyl wherein the alkyl moiety contains one to four carbon atoms; and
  • R 6 is selected from hydrogen, fluoro, chloro, straight chain or branched chain alkyl containing one to four carbon atoms, and straight chain or branched chain fluoro- or chloroalkyl containing one to four carbon atoms and at least one fluorine or chlorine atom; and pharmaceutically acceptable salts thereof.
  • the IRM compound can be chosen from imidazopyridine amines defined by Formula VII below:
  • R 67 and R 77 are independently selected from hydrogen and alkyl of one to five carbon atoms, with the proviso that R 67 and R 77 taken together contain no more than six carbon atoms, and with the further proviso that when R 77 is hydrogen then R 67 is other than hydrogen and R 27 is other than hydrogen or morpholinoalkyl, and with the further proviso that when R 67 is hydrogen then R 77 and R 27 are other than hydrogen; and pharmaceutically acceptable salts thereof.
  • the IRM compound can be chosen from 1 ,2 bridged imidazoquinoline amines defined by Formula VIII below:
  • Z is selected from -(CH 2 ) p - wherein p is 1 to 4;
  • RD is hydrogen or alkyl of one to four carbon atoms
  • RE is selected from alkyl of one to four carbon atoms, hydroxy, -ORF wherein Rp is alkyl of one to four carbon atoms, and -NRGR' G wherein RG and R' G are independently hydrogen or alkyl of one to four carbon atoms
  • a and b are integers and a+b is 0 to 3
  • Y is O, S, or -NRj- wherein Rj is hydrogen or alkyl of one to four carbon atoms; q is 0 or 1 ; and R 8 is selected from alkyl of one to four carbon atoms, alkoxy of one to four carbon atoms, and halogen, and pharmaceutically acceptable salts thereof.
  • the IRM compound can be chosen from thiazoloquinoline amines, oxazoloquinoline amines, thiazolopyridine amines, oxazolopyridine amines, thiazolonaphthyridine amines and oxazolonaphthyridine amines defined by Formula IX below:
  • Ri 9 is selected from oxygen, sulfur and selenium; R 29 is selected from
  • R 39 and R 49 are each independently: -hydrogen; -X-alkyl; -halo; -haloalkyl;
  • R 39 and R 49 form a fused aromatic, heteroaromatic, cycloalkyl or heterocyclic ring;
  • X is selected from-0-, -S-, -NR 59 -, -C(O)-, -C(O)O-, -OC(O)-, and a bond; and each R 59 is independently H or C 1-8 alkyl; and pharmaceutically acceptable salts thereof.
  • the IRM compound can be chosen from imidazonaphthyridine amines and imidazotetrahydronaphthyridine amines defined by Formulas X and XI below:
  • R ⁇ o is selected from: - hydrogen
  • Y is -N- or -CR-;
  • R 2 io is selected from: -hydrogen;
  • each R 3 I 0 is independently selected from hydrogen and C 1-10 alkyl; and each R is independently selected from hydrogen, Ci -10 alkyl, C 1-10 alkoxy, halogen and trifluoromethyl;
  • B is -NR-C(R) 2 -C(R) 2 -C(R) 2 -; -C(R) 2 -NR-C(R) 2 -C(R) 2 -; -C(R) 2 -C(R) 2 -NR-C(R) 2 - or -C(R) 2 -C(R) 2 -C(R) 2 -NR-;
  • R 111 is selected from: - hydrogen
  • -0-C 1-20 alkyl -0-(C 1-20 alkyl)( M -aryl; -0-(C 1-20 alky I) 0-1 -heteroaryl; -0-(C 1-20 alky l)o- 1 -heterocyclyl ; -CO-O-C 1-20 alkyl;
  • R 411 is wherein Y is -N- or -CR-;
  • R 2I i is selected from:
  • the IRM compound can be chosen from lH-imidazo[4,5- c]quinolin-4-amines and tetrahydro- lH-imidazo[4,5-c]quinolin-4-amines defined by Formulas XII, XIII and XIV below:
  • R 112 is -alkyl-NR 312 -CO-R 4I2 or -alkenyl-NR 312 -CO- R 4I2 wherein R 412 is aryl, heteroaryl, alkyl or alkenyl, each of which may be unsubstituted or substituted by one or more substituents selected from:
  • R 412 is alkyl, alkenyl, or heterocyclyl, oxo; or R 412 is
  • R 512 is an aryl, (substituted aryl), heteroaryl, (substituted heteroaryl), heterocyclyl or (substituted heterocyclyl) group; R 212 is selected from:
  • each R 312 is independently selected from hydrogen; C 1-10 alkyl-heteroaryl; C 1-10 alkyl-(substituted heteroaryl); C 1-10 alkyl-aryl; C 1-10 alkyl-(substituted aryl) and C 1-10 alkyl; v is 0 to 4; and each R 12 present is independently selected from C 1-10 alkyl, C 1-1O alkoxy, halogen, and trifluoromethyl;
  • Ri 1 3 is -alkyl-NR 3 i 3 - SO 2 -X-R 4n or -alkenyl-NR 313 - SO 2 -X-R 413 ;
  • X is a bond or -NR 5 I 3 -;
  • R 4I3 is aryl, heteroaryl, heterocyclyl, alkyl or alkenyl, each of which may be unsubstituted or substituted by one or more substituents selected from: -alkyl;
  • R 413 is alkyl, alkenyl, or heterocyclyl, oxo
  • R 2 i 3 is selected from:
  • each R 313 is independently selected from hydrogen and Ci-I 0 alkyl; or when X is a bond R 3I3 and R 4I3 can join to form a 3 to 7 membered heterocyclic or substituted heterocyclic ring;
  • R 513 is selected from hydrogen and C 1-I0 alkyl, or R 413 and R 5 I 3 can combine to form a 3 to 7 membered heterocyclic or substituted heterocyclic ring; v is 0 to 4; and each Ri 3 present is independently selected from Ci -10 alkyl, C 1-10 alkoxy, halogen, and trifluoromethyl;
  • Ri H4 is ⁇ yI-NR 3I4 -CY-NR 5I4 -X-R 4I4 i or
  • X is a bond, -CO- or -SO 2 -;
  • R 414 is aryl, heteroaryl, heterocyclyl, alkyl or alkenyl, each of which may be unsubstituted or substituted by one or more substituents selected from:
  • R 4J4 is alkyl, alkenyl or heterocyclyl, oxo; with the proviso that when X is a bond R 4I4 can additionally be hydrogen;
  • R 2I4 is selected from:
  • each R 3 I4 is independently selected from hydrogen and Ci -10 alkyl;
  • R 5I4 is selected from hydrogen and Ci -I0 alkyl, or R 4I4 and R 514 can combine to form a 3 to 7 membered heterocyclic or substituted heterocyclic ring; v is 0 to 4; and each R 14 present is independently selected from C 1-10 alkyl, Cj.io alkoxy, halogen, and trifluoromethyl; and pharmaceutically acceptable salts thereof.
  • the IRM compound can be chosen from lH-imidazo[4,5- c]quinolin-4-amines and tetrahydro- lH-imidazo[4,5-c]quinolin-4-amines defined by Formulas XV, XVI, XVII, XVIII, XIX, XX, XXI, XXII, XXIII, XXIV, XXV, and XXVI below:
  • X is -CHR 5I5 -, -CHR 515 -alkyl-, or -CHR 5 i 5 -alkenyl-;
  • R 115 is selected from:
  • R 215 is selected from:
  • R 4I5 is alkyl or alkenyl, which may be interrupted by one or more -O- groups; each R 515 is independently H or C 1-10 alkyl;
  • R 615 is a bond, alkyl, or alkenyl, which may be interrupted by one or more - O- groups;
  • R 7I5 is H, C 1-10 alkyl, or arylalkyl; or R 415 and R 715 can join together to form a ring;
  • R 8I5 is H or C 1-10 alkyl; or R 7J5 and R 8I5 can join together to form a ring; Y is -O- or -S(O) 0-2 -; v is 0 to 4; and each R 15 present is independently selected from C 1-I0 alkyl, Ci -I0 alkoxy, hydroxy, halogen, and trifluoromethyl;
  • X is -CHR 516 -, -CHR 516 -alkyl-, or -CHR 5 i 6 -alkenyl-; Rn 6 is selected from:
  • R 216 is selected from:
  • R 416 is alkyl or alkenyl, which may be interrupted by one or more
  • each R 516 is independently H or C 1-10 alkyl
  • R 616 is a bond, alkyl, or alkenyl, which may be interrupted by one or more - O- groups;
  • R 716 is H, C 1-10 alkyl, arylalkyl; or R 416 and R 716 can join together to form a ring;
  • R 816 is H or C 1-10 alkyl; or R 716 and R 816 can join together to form a ring;
  • Y is -O- or -S(O) 0-2 -; v is 0 to 4; and each R 16 present is independently selected from C 1-10 alkyl, Ci -1O alkoxy, hydroxy, halogen, and trifiuoromethyl;
  • Ri 17 is selected from:
  • R 217 is selected from: -hydrogen; -alkyl; -alkenyl;
  • R 4I7 is alkyl or alkenyl, which may be interrupted by one or more -O- groups; each R 317 is independently H or C 1-10 alkyl; each Y is independently -O- or -S(O) 0-2 -; v is 0 to 4; and each R 17 present is independently selected from C 1-10 alkyl, Ci -10 alkoxy, hydroxy, halogen, and trifluoromethyl;
  • X is -CHR 318 -, -CHR 3 i 8 -alkyl-, or -CHR 3 i 8 -alkenyl-;
  • Rn 8 is selected from: -aryl;
  • R 218 is selected from: -hydrogen
  • R 418 is alkyl or alkenyl, which may be interrupted by one or more -O- groups; each R 318 is independently H or C 1-1O alkyl; each Y is independently -O- or -S(O) 0-2 -; v is 0 to 4; and each R 18 present is independently selected C 1-10 alkyl, Ci -I0 alkoxy, hydroxy, halogen, and trifluoromethyl;
  • X is -CHR 319 -, -CHR 319 -alkyl-, or -CHR 319 -alkenyl-;
  • R 119 is selected from:
  • R 219 is selected from:
  • R 419 is alkyl or alkenyl, which may be interrupted by one or more -O- groups; each R 319 is independently H or C 1 - I o alkyl; each Y is independently — O— or -S(0)o -2 -; v is 0 to 4; and each R 19 present is independently selected from C 1-10 alkyl, Ci -10 alkoxy, hydroxy, halogen, and trifluoromethyl;
  • Ri 20 is selected from:
  • R 22 0 is selected from:
  • R 420 is alkyl or alkenyl, which may be interrupted by one or more
  • each R 320 is independently H or C 1-1O alkyl; each Y is independently -O- or -S(O) 0-2 -; v is 0 to 4; and each R 20 present is independently selected from C 1-1O alkyl, C 1-1O alkoxy, hydroxy, halogen, and trifluoromethyl;
  • X is -CHR 521 -, -CHR 52 i-alkyl-, or -CHR 52J -alkenyl-;
  • R 121 is selected from:
  • R 221 is selected from:
  • Ri 22 is selected from: -R 422 - NR 322 - SO 2 - R 622 - alkyl; -R422— NR 322 - SO 2 - R ⁇ 22— alkenyl; -R 422 -NR 322 -SO 2 -R 622 -aryl; -R 422 -NR 322 -SO 2 -R 622 -heteroaryl;
  • R 222 is selected from:
  • Y is -O- or -S(O) 0-2 -;
  • R 322 is H, C 1-I0 alkyl, or arylalkyl; each R 422 is independently alkyl or alkenyl, which may be interrupted by one or more -O- groups; or R 322 and R 422 can join together to form a ring; each R 522 is independently H, C 1-10 alkyl, or C 2-10 alkenyl; R 622 is a bond, alkyl, or alkenyl, which may be interrupted by one or more
  • R 722 is C 1-10 alkyl; or R 322 and R 722 can join together to form a ring; v is 0 to 4; and each R 22 present is independently selected from C 1-J0 alkyl, C 1-1O alkoxy, hydroxy, halogen, and trifluoromethyl;
  • X is -CHR 323 -, -CHR 323 -alkyl-, or -CHR 323 -alkenyl-;
  • Z is -S-, -SO-, Or-SO 2 -;
  • R 123 is selected from:
  • R 223 is selected from: -hydrogen; -alkyl; -alkenyl;
  • each R 323 is independently H or C 1-10 alkyl; each R 423 is independently alkyl or alkenyl; each Y is independently -O- or -S(O) 0-2 -; v is 0 to 4; and each R 23 present is independently selected from Ci -10 alkyl, Ci -I0 alkoxy, hydroxy, halogen, and trifluoromethyl;
  • X is -CHR 324 -, -CHR 324 -alkyl-, or -CHR 324 -alkenyl-;
  • Z is -S-, -SO-, or -SO 2 -;
  • R 124 is selected from: -alkyl; -aryl;
  • R 224 is selected from:
  • each R 324 is independently H or C 1-I0 alkyl; each R 424 is independently alkyl or alkenyl; each Y is independently -O- or -S(O) 0-2 -; v is 0 to 4; and each R 24 present is independently selected from Ci -10 alkyl, C 1-1O alkoxy, hydroxy, halogen, and trifluoromethyl;
  • X is -CHR 525 -, -CHR 525 -alkyl-, or -CHR 525 -alkenyl-;
  • Ri 25 is selected from:
  • R 225 is selected from: -hydrogen;
  • R 725 is H or Ci -I0 alkyl which may be interrupted by a hetero atom, or R 725 can join with R 525 to form a ring;
  • R 825 is H, Ci -I0 alkyl, or arylalkyl; or R 425 and R 825 can join together to form a ring;
  • R 925 is C 1-10 alkyl which can join together with R 825 to form a ring; each Y is independently -O- or -S(0)o -2 -;
  • Z is a bond, -CO-, or -SO 2 -; v is 0 to 4; and each R 25 present is independently selected Ci -I0 alkyl, Ci -I0 alkoxy, hydroxy, halogen, and trifluoromethyl;
  • X is -CHR 526 -, -CHR 526 -alkyl-, or -CHR 526 -alkenyl-;
  • R 126 is selected from:
  • R 226 is selected from: -hydrogen; -alkyl; -alkenyl; -aryl;
  • R 626 is a bond, alkyl, or alkenyl, which may be interrupted by one or more - O- groups;
  • R 726 is H or Ci -10 alkyl which may be interrupted by a hetero atom, or R 726 can join with R 526 to form a ring;
  • R 826 is H, C 1-10 alkyl, or arylalkyl; or R 426 and R 826 can join together to form a ring;
  • R 926 is C 1-I0 alkyl which can join together with R 826 to form a ring; each Y is independently -O- or -S(O) 0-2 -; Z is a bond, -CO-, or -SO 2 -; v is 0 to 4; and each R 26 present is independently selected from C 1-10 alkyl, C 1-10 alkoxy, hydroxy, halogen, and trifluoromethyl; and pharmaceutically acceptable salts of any of the foregoing.
  • the IRM compound can be chosen from lH-imidazo[4,5- c]pyridin-4-amines defined by Formula XXVII below:
  • X is alkylene or alkenylene
  • Y is -CO- or -CS
  • Z is a bond, -O-, or -S-;
  • R 127 is aryl, heteroaryl, heterocyclyl, alkyl or alkenyl, each of which may be unsubstituted or substituted by one or more substituents independently selected from:
  • R 227 is selected from: 5 -hydrogen
  • R 327 and R 427 are independently selected from hydrogen, alkyl, alkenyl, halogen, alkoxy, amino, alkylamino, dialkylamino, and alkylthio;
  • R 527 is H or C 1-10 alkyl, or R 527 can join with X to form a ring that contains one or two heteroatoms; or when R 127 is alkyl, Rs 27 and R 127 can join to form a ring; each R 627 is independently H or C 1-lo alkyl; and pharmaceutically acceptable salts thereof.
  • the IRM compound can be chosen from lH-imidazo[4,5- c]pyridin-4-amines defined by Formula XXVIII below:
  • X is alkylene or alkenylene
  • Y is -SO 2 -
  • Z is a bond or -NR 628 -;
  • R 128 is aryl, heteroaryl, heterocyclyl, alkyl or alkenyl, each of which may be unsubstituted or substituted by one or more substituents independently selected from: -alkyl; -alkenyl;
  • R 228 is selected from: -hydrogen; -alkyl; -alkenyl; 15 -aryl;
  • R 328 and R 428 are independently selected from hydrogen, alkyl, alkenyl, halogen, alkoxy, amino, alkylamino, dialkylamino, and alkylthio;
  • R 528 is H or C 1-I o alkyl, or R 528 can join with X to form a ring; or when R 128 is alkyl, R 528 and R 128 can join to form a ring; each R 628 is independently H or C 1-10 alkyl; and pharmaceutically acceptable salts thereof.
  • the IRM compound can be chosen from lH-imidazo[4,5- c]pyridin-4-amines defined by Formula XXIX below:
  • X is alkylene or alkenylene
  • Y is -CO- or -CS
  • Z is -NR 629 -, -NR 629 -CO-, -NR 629 -SO 2 -, or -NR 729 -;
  • R 129 is aryl, heteroaryl, heterocyclyl, alkyl or alkenyl, each of which may be unsubstituted or substituted by one or more substituents independently selected from:
  • R 229 is selected from:
  • R 329 and R 429 are independently selected from hydrogen, alkyl, alkenyl, halogen, alkoxy, amino, alkylamino, dialkylamino, and alkylthio;
  • R 529 is H or Ci -1O alkyl, or R 529 can join with X to form a ring that contains one or two heteroatoms; each R 629 is independently H or Q-ioalkyl; R 729 is H or C 1-1 O alkyl which may be interrupted by a heteroatom; or when
  • R 129 is alkyl, R 729 and R 129 can join to form a ring; and pharmaceutically acceptable salts thereof.
  • the IRM compound can be chosen from 1 -position ether or thioether substituted lH-imidazo[4,5-c]pyridin-4-amines defined by Formula XXX below:
  • X is -CH(R 530 )-, -CH(R 530 )-alkylene-, -CH(R 530 )-alkenylene-, or CH(R 53O )-alkylene-Y-alkylene-; Y iS -O- Or -S(O) 0-2 -;
  • -W-Ri 30 is selected from -0-R 130-I-S and -S(O)O -2 -R 130-6 ;
  • R 130-1 - S is selected from
  • Z is-N(R 530 )-, -O- or -S-;
  • Q is a bond, -CO-, or -SO 2 -;
  • A represents the atoms necessary to provide a 5- or 6-membered heterocyclic or heteroaromatic ring that contains up to three heteroatoms;
  • Ri 3O-6 is selected from:
  • each R 53 o is independently hydrogen, C 1-10 alkyl, or C 2-1O alkenyl;
  • R 630 is alkylene, alkenylene, or alkynylene, which may be interrupted by one or more -O- groups;
  • R 830 is a bond, alkylene, alkenylene, or alkynylene, which may be interrupted by one or more -O- groups;
  • Rg 30 is hydrogen, C 1-10 alkyl, or arylalkyl; or Rg 30 can join together with any carbon atom OfR 630 to form a ring of the formula
  • Ri O30 is hydrogen or C 1-10 alkyl; or R 930 and R 1030 can join together to form a ring selected from
  • Rn 30 is C 1-10 alkyl; or R 930 and Rn 30 can join together to form a ring having the structure
  • R 123O is C 2-7 alkylene which is straight chain or branched, wherein the branching does not prevent formation of the ring;
  • R 230 , R 330 and R 430 are independently selected from hydrogen and non-interfering substitutents; and pharmaceutically acceptable salts thereof.
  • R 230 substituents include: -alkyl; -alkenyl; -aryl; -heteroaryl;
  • Illustrative non-interfering R 330 and R 430 substitutents include: Ci-I 0 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, CM O alkoxy, C 1-I0 alkylthio, amino, alkylamino, dialkylamino, halogen, and nitro.
  • the IRM compound can be chosen from lH-imidazo dimers of the formula (XXXI): wherein:
  • A is a divalent linking group selected from the group consisting of: straight or branched chain C 4-20 alkylene; straight or branched chain C 4-20 alkenylene; straight or branched chain C 4-20 alkynylene; and
  • each Z is independently selected from the group consisting of: straight or branched chain C 2-2 O alkylene; straight or branched chain C 4-20 alkenylene; and straight or branched chain C 4-20 alkynylene; any of which may be optionally interrupted by -O-, -N(R 531 )-, or -S(O) 2 -; each Y is independently selected from the group consisting of: a bond;
  • W is selected from the group consisting of: straight or branched chain C 2-20 alkylene; straight or branched chain C 2-20 alkenylene; straight or branched chain C 4-20 alkynylene; straight or branched chain perfluoro C 2-20 alkylene;
  • trans-5-norbornen-2,3-diyl wherein n is 0 - 4; each R is independently selected from the group consisting OfCj -4 alkyl, C 1-4 alkoxy, and halogen; and Q is selected from the group consisting of a bond, -CH 2 -, and -0-; R 231 is selected from the group consisting of: -hydrogen; -alkyl; -alkenyl; -aryl; -substituted aryl;
  • R 33 I and R 43I are each independently selected from the group consisting of:
  • R 331 and R 431 form a fused aryl or heteroaryl ring that is unsubstituted or substituted by one or more substituents selected from the group consisting of: -halogen; -alkyl; -alkenyl;
  • R 331 and R 431 form a fused 5 to 7 membered saturated ring, containing 0 to 2 heteroatoms and unsubstituted or substituted by one or more substituents selected from the group consisting of:
  • each R 53 i is independently selected from the group consisting of: hydrogen;
  • R 531 can join with Z to form a ring having the structure
  • each R 631 is independently hydrogen or C 1-1 O alkyl
  • R 731 is C 3-8 alkylene; and X is -O- or -S-; with the proviso that if W is -C(O)-, -S(O) 2 -, -OC(O)O-, or -N(R 531 )C(O)N(R 531 )- then each Y is a bond; and pharmaceutically acceptable salts thereof.
  • the IRM compound can be chosen from 6-, 7-, 8-, or 9- position aryl or heteroaryl substituted lH-imidazo[4,5-c]quinolin-4-amines of the following Formula (XXXII):
  • R 32 is selected from the group consisting of alkyl, alkoxy, hydroxy, and trifluoromethyl; n is O or 1 ;
  • Ri 32 and R 232 are independently selected from the group consisting of hydrogen and non-interfering substitutents
  • R 332 is selected from the group consisting of: -Z-Ar,
  • Ar is selected from the group consisting of aryl and heteroaryl both of which can be unsubstituted or can be substituted by one or more substituents independently selected from the group consisting of alkyl, alkenyl, alkoxy, methylenedioxy, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, hydroxyalkyl, mercapto, cyano, carboxy, formyl, aryl, aryloxy, arylalkoxy, heteroaryl, heteroaryloxy, heteroarylalkoxy, heterocyclyl, heterocyclylalkyl, amino, alkylamino, and dialkylamino;
  • Ar' is selected from the group consisting of arylene and heteroarylene both of which can be unsubstituted or can be substituted by one or more substituents independently selected from the group consisting of alkyl, alkenyl, alkoxy, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, hydroxyalkyl, mercapto, cyano, carboxy, formyl, aryl, aryloxy, arylalkoxy, heteroaryl, heteroaryloxy, heteroarylalkoxy, heterocyclyl, heterocyclylalkyl, amino, alkylamino, and dialkylamino;
  • X is selected from the group consisting of alkylene, alkenylene, alkynylene, arylene, heteroarylene, and heterocyclylene wherein the alkylene, alkenylene, and alkynylene groups can be optionally interrupted or terminated with arylene, heteroarylene, or heterocyclylene, and optionally interrupted by
  • Y is selected from the group consisting of: -S(O) 0-2 -,
  • Z is selected from the group consisting of a bond, alkylene, alkenylene, and alkynylene;
  • R 432 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl wherein the alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy, halogen
  • dialkylamino alkyleneoxy, and in the case of alkyl, alkenyl, alkynyl, and heterocyclyl, oxo;
  • R 532 is selected from the group consisting of:
  • R 932 is selected from the group consisting of hydrogen and alkyl; each R 1032 is independently C 3-8 alkylene;
  • A is selected from the group consisting of -O-, -C(O)-, -S(O) 0-2 -, -CH 2 -, and - N(R 432 )-;
  • Q is selected from the group consisting of a bond, -C(R 632 )-, -C(R 632 )-C(R 632 ), -S(O) 2 -, -C(R 632 )-N(R 832 )-W-, -S(O) 2 -N(R 832 )-, -C(R 632 )-O-, and - C(R 632 )-N(OR 932 )-;
  • V is selected from the group consisting of -C(R 632 )-, -0-C(R 632 )-, -N(R 832 K(R 632 )-, and -S(O) 2 -;
  • W is selected from the group consisting of a bond, -C(O)-, and -S(O) 2 -; and a and b are independently integers from 1 to 6 with the proviso that a + b is ⁇ 7; and pharmaceutically acceptable salts thereof.
  • R 132 substituents include: -Rm, -X-Rr ⁇ , -X-Y-R 432 ,
  • each X is independently selected from the group consisting of alkylene, alkenylene, alkynylene, arylene, heteroarylene, and heterocyclylene wherein the alkylene, alkenylene, and alkynylene groups can be optionally interrupted or terminated with arylene, heteroarylene, or heterocyclylene, and optionally interrupted by one or more -O- groups; each Y is independently selected from the group consisting of: -S(O) 0-2 -,
  • R 432 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl wherein the alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy, halogen
  • R 532 is selected from the group consisting of:
  • A is selected from the group consisting of -O-, -C(O)-, -S(0)o- 2 ⁇ , -CH 2 -, and - N(R 432 )-; each Q is independently selected from the group consisting of a bond, -C(R 632 )-, -C(R 632 K(R 632 )-, -S(O) 2 -, -C(R 632 )-N(R 832 )-W-, -S(O) 2 -N(R 832 )-, -C(R 632 )-O-, and -C(R 632 )-N(OR 932 )-; each V is independently selected from the group consisting of -C(R 632 )-, -0-C(R 632 )-, -N(R 832 )-C(R 632 )-, and -S(O) 2 -; each W is independently selected from the group consisting of a bond,
  • Illustrative non-interfering R 232 substitutents include:
  • X is selected from the group consisting of alkylene, alkenylene, alkynylene, arylene, heteroarylene, and heterocyclylene wherein the alkylene, alkenylene, and alkynylene groups can be optionally interrupted or terminated with arylene, heteroarylene, or heterocyclylene, and optionally interrupted by one or more -O- groups;
  • Y is selected from the group consisting of: -S(O) 0-2 -, -S(O) 2 -N(R 832 )-, -C(R 632 )-, -C(R 632 )-O-,
  • R 432 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl wherein the alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy, halogen
  • R 532 is selected from the group consisting of:
  • Q is selected from the group consisting of a bond, -C(R 632 )-, -C(R 632 )-C(R 632 )-, -S(O) 2 -, -C(R 632 )-N(R 832 )-W-, -S(O) 2 -N(R 832 )-, -C(R 632 )-O-, and - C(R 632 )-N(OR 932 )-;
  • V is selected from the group consisting Of-C(R 632 )-, -0-C(R 632 )-, -N(R 832 )-C(R6 32 K and -S(O) 2 -;
  • W is selected from the group consisting of a bond, -C(O)-, and -S(O) 2 -; and a and b are independently integers from 1 to 6 with the proviso that a + b is ⁇ 7;
  • non-interfering means that the ability of the compound or salt to modulate (e.g., induce or inhibit) the biosynthesis of one or more cytokines is not destroyed by the non-interfering substituent.
  • alkyl alkenyl
  • alkynyl alkynyl
  • alk- alk-
  • these groups have a total of up to 10 carbon atoms, up to 8 carbon atoms, up to 6 carbon atoms, or up to 4 carbon atoms.
  • Cyclic groups can be monocyclic or polycyclic and preferably have from 3 to 10 ring carbon atoms.
  • Exemplary cyclic groups include cyclopropyl, cyclopropylmethyl, cyclopentyl, cyclohexyl, adamantyl, and substituted and unsubstituted bornyl, norbornyl, and norbornenyl.
  • alkylene alkenylene
  • alkynylene are the divalent forms of the "alkyl”, “alkenyl”, and “alkynyl” groups defined above.
  • alkylenyl “alkenylenyl”, and “alkynylenyl” are the divalent forms of the “alkyl”, “alkenyl”, and “alkynyl” groups defined above.
  • an arylalkylenyl group comprises an alkylene moiety to which an aryl group is attached.
  • haloalkyl is inclusive of groups that are substituted by one or more halogen atoms, including perfluorinated groups. This is also true of other groups that include the prefix "halo-". Examples of suitable haloalkyl groups are chloromethyl, trifluoromethyl, and the like. Similarly, the term “fluoroalkyl” is inclusive of groups that are substituted by one or more fluorine atoms, including perfluorinated groups (e.g., trifluoromethyl) .
  • aryl as used herein includes carbocyclic aromatic rings or ring systems. Examples of aryl groups include phenyl, naphthyl, biphenyl, fluorenyl and indenyl.
  • heteroatom refers to the atoms O, S, or N.
  • heteroaryl includes aromatic rings or ring systems that contain at least one ring heteroatom (e.g., O, S, N).
  • Suitable heteroaryl groups include furyl, thienyl, pyridyl, quinolinyl, isoquinolinyl, indolyl, isoindolyl, triazolyl, pyrrolyl, tetrazolyl, imidazolyl, pyrazolyl, oxazolyl, thiazolyl, benzofuranyl, benzothiophenyl, carbazolyl, benzoxazolyl, pyrimidinyl, benzimidazolyl, quinoxalinyl, benzothiazolyl, naphthyridinyl, isoxazolyl, isothiazolyl, purinyl, quinazolinyl, pyrazinyl, 1-oxidopyridyl, pyridazinyl, triazinyl,
  • heterocyclyl includes non-aromatic rings or ring systems that contain at least one ring heteroatom (e.g., O, S, N) and includes all of the fully saturated and partially unsaturated derivatives of the above mentioned heteroaryl groups.
  • exemplary heterocyclic groups include pyrrolidinyl, tetrahydrofuranyl, morpholinyl, thiomorpholinyl, piperidinyl, piperazinyl, thiazolidinyl, imidazolidinyl, isothiazolidinyl, tetrahydropyranyl, quinuclidinyl, homopiperidinyl, homopiperazinyl, and the like.
  • arylene is the divalent forms of the "aryl,” “heteroaryl,” and “heterocyclyl” groups defined above.
  • arylenyl is the divalent forms of the "aryl,” “heteroaryl,” and “heterocyclyl” groups defined above.
  • an alkylarylenyl group comprises an arylene moiety to which an alkyl group is attached. Unless otherwise specified, the aryl, heteroaryl, and heterocyclyl groups of
  • Formulas IX-XXXI can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, methylenedioxy, ethylenedioxy, alkylthio, haloalkyl, haloalkoxy, haloalkylthio, halogen, nitro, hydroxy, mercapto, cyano, carboxy, formyl, aryl, aryloxy, arylthio, arylalkoxy, arylalkylthio, heteroaryl, heteroaryloxy, heteroarylthio, heteroarylalkoxy, heteroarylalkylthio, amino, alkylamino, dialkylamino, heterocyclyl, heterocycloalkyl, alkylcarbonyl, alkenylcarbonyl, alkoxycarbonyl, haloalkylcarbonyl, haloalkoxycarbonyl, alkylthiocarbonyl, arylcarbony
  • each group is independently selected, whether explicitly stated or not.
  • each R 631 group is independently selected.
  • each R 232 and an R 332 group both contain an R 432 group
  • each R 432 group is independently selected.
  • more than one Y group is present (i.e., R 232 and R 332 both contain a Y group) and each Y group contains one or more R 832 groups, then each Y group is independently selected, and each R 832 group is independently selected.
  • the immune response modifier is selected from the group consisting of imidazoquinoline amines, tetrahydroimidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, 1,2-bridged imidazoquinoline amines, imidazonaphthyridine amines, imidazotetrahydronaphthyridine amines, oxazoloquinoline amines, thiazoloquinoline amines, oxazolopyridine amines, thiazolopyridine amines, oxazolonaphthyridine amines, thiazolonaphthyridine amines, IH- imidazo dimers fused to pyridine amines, quinoline amines, tetrahydroquinoline amines, naphthyridine amines, or tetrahydronaphthyridine amine
  • Formulations of IRMl are prepared as described in Table 2 and Table 3 capable of being administered intra-venously or subcutaneously as follows:
  • IRM compounds are prepared as a 0.01, 0.3, 1.0, or 3% cream formulation as disclosed in US Patent Publication No. US 2003/0199538 and International Patent Publication No. WO 03/045391.
  • patients with melanoma cutaneous metastasis or lentigo maligna melanoma lesions are treated at the excision site with IRMl or IRM2 at a concentration of 0.01, 0.3, 1.0, or 3% cream formulation as disclosed in US Patent Publication No. US 2003/0199538 and International Patent Publication No. WO 03/045391.
  • the placebo, IRMl, or IRM2 cream formulation is applied three times a week for four weeks.
  • LV. intravenous
  • Example 2 Following surgical excision of their lesions, patients with melanoma cutaneous metastasis or lentigo maligna melanoma lesions are treated with the intra-venous (LV.) formulation as described above.
  • the I. V. formulation is injected three times a week for two weeks with the placebo or a dosing level of 0.004 to 0.108 mg/kg.
  • patients Following the two weeks of systemic administration of IRMl , patients are treated topically with IRMl or IRM2 at a concentration of 0.01, 0.3, 1.0, or 3% cream formulation as described above.
  • the placebo, IRMl, or IRM2 cream formulations is applied three times a week for four weeks.
  • Patients with melanoma cutaneous metastasis or lentigo maligna melanoma lesions are treated at the lesion site with IRMl or IRM2 at a concentration of 0.01, 0.3, 1.0, or 3% cream formulation as disclosed in US Patent Publication No. US 2003/0199538 and International Patent Publication No. WO 03/045391.
  • the placebo, IRMl , or IRM2 cream formulation is applied three times a week for four weeks.
  • LV. intravenous
  • LV. intra-venous
  • mice (Charles River Laboratories, Wilmington, MA) were injected intra-dermally with 5 ⁇ 10 5 mouse colon carcinoma-26 cells (MC26) expressing luciferase (ATCC, Manassas, VA) on day 0.
  • Mice were divided into five groups: topical vehicle, subcutaneous vehicle (SQ vehicle), IRMl topical (topical IRMl), IRMl subcutaneous (SQ IRMl), and IRMl topical and subcutaneous (topical + SQ IRMl). Eighteen hours after injection of the cells, 30 microliters of vehicle or 5% IRMl topical formulations, described in Table 3, was applied to the tumor site.
  • mice Six hours later, mice were injected subcutaneously with 10 millograms per kilogram of IRMl in a 1 milligram per milliliter IRMl, 0.03M citrate buffered saline solution or a vehicle 0.03M citrate buffered saline solution.
  • mice On days 1, 5, and 6 mice were anesthetized with vaporized 3% isoflurane and in vivo photon counts of luciferin were measured using a Xenogen IVIS imaging system (Alameda, CA) following the manufacturer's protocol.
  • the tumor growth index for each treatment group was calculated by dividing each group's day 5 or day 6 tumor photon counts by their day 1 tumor photon counts. The results indicate a surprising benefit when a combination of topical and systemic routes were used.
  • the results for the day 6 tumor growth are found in Figure 1 , in which the topical and SQ vehicles were averaged together (vehicles).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A method of treating disease with immune response modifier (IRM) compounds by using at least two different routes of administration, such as administering at least one IRM to a subject locally (e.g., topically) at a disease site in combination with separately administering at least one IRM to the subject systemically (e.g., orally or by injection).

Description

MULTI-ROUTE ADMINISTRATION OF IMMUNE RESPONSE MODIFIER COMPOUNDS
CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. provisional application 60/640873, filed December 30, 2004, the entire contents of which is hereby incorporated by reference.
FIELD OF THE INVENTION
The present invention relates to administration of immune response modifier (IRM) compounds for use in treating disease.
BACKGROUND
There has been a major effort in recent years, with substantial progress being made, to develop drugs that can beneficially modify the immune system. For examples, various imidazoquinoline amine, imidazopyridine amine, 6,7-fused cycloalkylimidazopyridine amine, 1,2-bridged imidazoquinoline amine, thiazoloquinoline amine, oxazoloquinoline amine, thiazolopyridine amine, oxazolopyridine amine, imidazonaphthyridine amine, imidazotetrahydronaphthyridine amine, and thiazolonaphthyridine amine compounds have demonstrated potent immunostimulating, antiviral and antitumor (including anticancer) activity, and have also been shown to be useful as vaccine adjuvants and treatment of TH2 -mediated diseases. The mechanism for the immunostimulatory activity of these IRM compounds is thought to be due in substantial part to enhancement of the immune response by induction of various important cytokines (e.g., interferons, interleukins, tumor necrosis factor, etc.). Such compounds have been shown to stimulate a rapid release of certain monocyte/macrophage-derived cytokines and are also capable of stimulating B cells to secrete antibodies, which play an important role in these IRM compounds' activities. One of the predominant immunostimulating responses to these compounds can be the induction of interferon (IFN)-α production, which is believed to be very important in the acute antiviral and antitumor activities seen. Moreover, up regulation of other cytokines such as, for example, tumor necrosis factor (TNF), Interleukin-1 (IL-I), IL-6, and IL- 12 also have potentially beneficial activities and are believed to contribute to the antiviral, antitumor, and other properties of these compounds. One area of particular interest for IRMs has been treatment of skin cancers, the incidence of which has been rapidly increasing worldwide. The drug product Aldara™ (containing the IRM compound imiquimod) has recently been approved for treatment of superficial basal cell carcinoma (BCC), as well as actinic keratosis.
However, surgical removal is still by far the most common treatment for skin cancers, including melanomas, BCCs, and SCCs. This can take the form of electrodesiccation and curettage, cryosurgery, simple wide excision, micrographic surgery, or laser therapy. Other treatments, used when the cancers are detected at a later stage of development, are external radiation therapy, chemotherapy, or to a lesser extent, bio- immunotherapy or photodynamic therapy. Unfortunately, though, there has been very limited success in treating or preventing recurrence of these cancers, especially malignant melanoma, once they have reached more advanced stages. Follow-up surgery is often necessary, with the risk of further disfigurement and scarring. And once the cancer has metastasized there is a high risk of mortality.
Accordingly, there is a continuing need for new treatment methods to provide the enhanced therapeutic benefit from IRM compounds, particularly for conditions such as life-threatening cancers.
SUMMARY
It is now believed that there is a benefit to treating conditions with IRM compounds where one or more IRM compounds is administered via at least two distinct routes of delivery in combination, for example systemically (e.g., by injection) and locally (e.g., topically). It is believed that this provides a way of synergistically targeting the immune system directly to the disease while boosting the immune response throughout the body, e.g., so as to treat or prevent metastasized cancers or infections that may have spread. In a sense, local administration to a tumor or infection site directly can be used as an opportunity to sensitize the immune system to the specific disease being treated, while the broad immune response induced by non-local application can seek out and target the disease elsewhere in the body.
While applicable for many diseases, it is believed that this new approach will provide benefits in treating malignant melanoma, which despite massive efforts has remained one of the most difficult cancers to treat. Although topical Aldara has shown some activity against melanoma skin lesions, surgery is the conventional treatment. However, it is believed that by administering IRMs locally to the melanoma lesion site on the skin (even after the main lesion has been surgically removed) in combination with systemic delivery, there is a better chance of addressing the high risk that the cancer has already metastasized at the time of initial surgery.
Thus, the present invention is directed to multi-route dosing regimes for administration of one or more IRM compounds. In one embodiment, the present invention provides a method of treating disease with an immune response modifier including administering at least one IRM to a subject topically in combination with separately administering at least one IRM to the subject systemically.
Such multi-route regimens are useful for treating a variety of diseases including cancer (e.g., melanoma and carcinomas) as well as viral, fungal, protazoal, or bacterial infections. Such multi-route regimens are particularly useful for treating melanoma, in particular, by applying at least one IRM topically (or locally via, e.g., subcutaneous, intra- dermal, or intra-tumoral injection) to a melanoma lesion and separately administering at least one IRM systemically.
Herein, topical application involves application to dermal and mucosal tissues, including vaginal, rectal, nasal, buccal, and pulmonary applications. Herein, systemic application involves oral and parenteral (including subcutaneous (subQ or SC) if the intended result is systemic distribution as opposed to local delivery into a lesion), intramuscular (IM), intraperitoneal (IP), intravenous (IV), intrathecal, intraventricular, etc.) administration.
The IRM can be selected from the group consisting of imidazoquinoline amines, tetrahydroimidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, 1,2 -bridged imidazoquinoline amines, imidazonaphthyridine amines, imidazotetrahydronaphthyridine amines, oxazoloquinoline amines, thiazoloquinoline amines, oxazolopyridine amines, thiazolopyridine amines, oxazolonaphthyridine amines, thiazolonaphthyridine amines, 1/f-imidazo dimers fused to pyridine amines, quinoline amines, tetrahydroquinoline amines, naphthyridine amines, tetrahydronaphthyridine amines, and combinations thereof.
The present invention also provides an aqueous pharmaceutical composition suitable for parental administration. The composition includes: an immune response modifier compound (IRM); a pharmaceutically acceptable acid (e.g., citric acid, hydrochloric acid, lactic acid, acetic acid, or aspartic acid); a tonicity adjuster (e.g., mannitol, glycerin, sorbitol, or dextrose); sterile water; and optionally a pH adjuster (e.g., NaOH); with the proviso that the IRM is other than l-(2-methylpropyl)-lH-imidazo[4,5- c]quinolin-4-amine or 4-amino-α,α-dimethyl-lH-imidazo[4,5-c]quinoline-l-ethanol.
The invention includes, but is not limited to, the following embodiments: 1. A method of treating disease with immune response modifiers (IRMs) by administering at least one IRM compound via at least two different routes of delivery. 2. The method of embodiment 1 , wherein there is only one IRM compound active moiety is used.
3. The method of embodiment 2, wherein two different salt forms of the IRM compound active moiety are used.
4. The method of embodiment 1 , wherein at least two different IRM compound active moieties are used.
5. The method of any preceding embodiment, wherein the routes of delivery include local delivery and systemic delivery.
6. The method in claim 5, wherein the local route of delivery is topical delivery.
7. The method of embodiment 6, wherein topical delivery is achieved using an IRM- containing gel or cream formulation.
8. The method of embodiments 5, 6 or 7, wherein systemic delivery is achieved by injection or oral delivery.
9. The method of any preceding embodiment, wherein the disease being treated is cancer. 10. The method of embodiment 9, wherein an IRM is delivered locally directly to the cancer and an IRM is delivered systemically to the entire body. 11. The method of embodiment 10, wherein the IRM delivered locally is injected directly into the cancer.
12. The method of any one of embodiments 1 through 8, wherein the disease is a viral, fungal, protazoal, or bacterial infection. 13. A method of treating melanoma with an immune response modifier (IRM), the method comprising: applying at least one IRM topically to a melanoma lesion on a subject in combination with separately administering at least one IRM to the subject systemically.
14. The method of embodiment 13 , wherein the IRM administered topically is administered to a dermal or mucosal tissue.
15. The method of embodiment 14 wherein the IRM administered topically is administered to a vaginal, rectal, nasal, buccal, or pulmonary surface.
16. The method of any preceding embodiment wherein the IRM is a compound having a 2-aminopyridine fused to a five membered nitrogen-containing heterocyclic ring. 17. The method of embodiment 16 wherein the immune response modifier is selected from the group consisting of imidazoquinoline amines, tetrahydroimidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, 1,2-bridged imidazoquinoline amines, imidazonaphthyridine amines, imidazotetrahydronaphthyridine amines, oxazoloquinoline amines, thiazoloquinoline amines, oxazolopyridine amines, thiazolopyridine amines, oxazolonaphthyridine amines, thiazolonaphthyridine amines, IH- imidazo dimers fused to pyridine amines, quinoline amines, tetrahydroquinoline amines, naphthyridine amines, or tetrahydronaphthyridine amines, and combinations thereof.
18. The method of embodiment 16, wherein the immune response modifier is selected from the group consisting of imidazoquinoline amines, tetrahydroimidazoquinoline amines, imidazopyridine amines, and combinations thereof.
19. The method of embodiment 16, wherein the immune response modifier is selected from the group consisting of amide substituted imidazoquinoline amines, sulfonamide substituted imidazoquinoline amines, urea substituted imidazoquinoline amines, aryl ether substituted imidazoquinoline amines, heterocyclic ether substituted imidazoquinoline amines, amido ether substituted imidazoquinoline amines, sulfonamido ether substituted imidazoquinoline amines, urea substituted imidazoquinoline ethers, thioether substituted imidazoquinoline amines, 6-, 7-, 8-, or 9-aryl or heteroaryl substituted imidazoquinoline amines, amide substituted tetrahydroimidazoquinoline amines, sulfonamide substituted tetrahydroimidazoquinoline amines, urea substituted tetrahydroimidazoquinoline amines, aryl ether substituted tetrahydroimidazoquinoline amines, heterocyclic ether substituted tetrahydroimidazoquinoline amines, amido ether substituted tetrahydroimidazoquinoline amines, sulfonamide ether substituted tetrahydroimidazoquinoline amines, urea substituted tetrahydroimidazoquinoline ethers, thioether substituted tetrahydroimidazoquinoline amines, amide substituted imidazopyridine amines, sulfonamide substituted imidazopyridine amines, urea substituted imidazopyridine amines, aryl ether substituted imidazopyridine amines, heterocyclic ether substituted imidazopyridine amines, amido ether substituted imidazopyridine amines, sulfonamido ether substituted imidazopyridine amines, urea substituted imidazopyridine ethers, thioether substituted imidazopyridine amines, and combinations thereof.
20. The method of embodiment 19, wherein the immune response modifier is selected from the group consisting of amide substituted imidazoquinoline amines, sulfonamide substituted imidazoquinoline amines, urea substituted imidazoquinoline amines, thioether substituted imidazoquinoline amines, 7-aryl substituted imidazoquinoline amines, 7- heteroaryl substituted imidazoquinoline amines, sulfonamide substituted tetrahydroimidazoquinoline amines, and combinations thereof.
21. The method of embodiment 17, wherein the immune response modifier is an imidazoquinoline amine.
22. The method of embodiment 19, wherein the immune response modifier is a sulfonamide substituted imidazoquinoline amine.
23. The method of embodiment 16, wherein the immune response modifier is selected from the group consisting of N-[4-(4-amino-2-ethyl-lH-imidazo[4,5-c]quinolin-l- yl)butyl]methanesulfonamide, N-{2-[4-amino-2-(ethoxymethyl)-lH-imidazo[4,5- cjquinolin- 1 -yl)butyl]- 1 , 1 -dimethyleethyl}methanesulfonamide, pharmaceutically acceptable salts thereof, and combinations thereof.
24. The method of any preceding embodiment, wherein an IRM is administered systemically in a formulation comprising: a pharmaceutically acceptable acid; a tonicity adjuster; sterile water; and optionally a pH adjuster; with the proviso that the IRM is other than l-(2-methylpropyl)-l/i-imidazo[4,5- c]quinolin-4-amine or 4-amino-α,α-dimethyl-l/-r-imidazo[4,5-c]quinoline-l-ethanol.
25. The method of embodiment 24, wherein the formulation comprises 0.4 wt-% to 0.5 wt-% citric acid, 4 wt-% to 5 wt-% mannitol, and water, wherein the formulation is adjusted to a pH of 5 with the pH adjuster.
26. An aqueous pharmaceutical composition suitable for parental administration comprising: an immune response modifier compound (IRM); a pharmaceutically acceptable acid; a tonicity adjuster; sterile water; and optionally a pH adjuster; with the proviso that the IRM is other than l-(2-methylpropyl)-lH-imidazo[4,5- c]quinolin-4-amine or 4-amino-α,α-dimethyl-l//-imidazo[4,5-c]quinoline-l-ethanol.
The terms "comprises" and variations thereof do not have a limiting meaning where these terms appear in the description and embodiments.
As used herein, "a," "an," "the," "at least one," and "one or more" are used interchangeably.
Also herein, the recitations of numerical ranges by endpoints include all numbers subsumed within that range (e.g., 1 to 5 includes 1, 1.5, 2, 2.75, 3, 3.80, 4, 5, etc.).
The above summary of the present invention is not intended to describe each disclosed embodiment or every implementation of the present invention. The description that follows more particularly exemplifies illustrative embodiments. In several places throughout the application, guidance is provided through lists of examples, which examples can be used in various combinations. In each instance, the recited list serves only as a representative group and should not be interpreted as an exclusive list.
DETAILED DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS
The present invention provides a multi-route dosing regime for administration of one or more IRM compounds. In one embodiment, the present invention provides a method of treating disease with an immune response modifier including administering at least one IRM to a subject locally (e.g., topically or via injection into a lesion) in combination with separately administering at least one IRM to the subject systemically. Herein, the subject is typically a mammal, and may be a human. The IRM administered by one route (e.g., topically) may be the same or different than the IRM administered via another route (e.g., systemically). Alternatively, the IRM may be the same compound, or may be the same compound active moiety but in a different salt form thereof.
The multi-route regimens of the present invention are useful for treating a variety of diseases including cancer (e.g., melanoma and carcinomas) as well as viral, fungal, protazoal, or bacterial infections. Herein, treating includes therapeutic and/or prophylactic treating.
Such multi-route regimens are particularly useful for treating melanoma, although other types of cancers can be treated. For example, in one approach, an IRM is injected directly into a tumor for local effect and especially to target the immune system to the tumor, and an IRM is also delivered systemically to boost body-wide immune response to the tumor (especially if there is a risk it has metastasized). Non-limiting examples of other cancers for which the present invention may be useful include breast cancer, stomach cancer, colorectal cancer, prostate cancer, testicular cancer, head and neck cancer, lung cancer, etc. Any cancer where there is a localized tumor site to which an IRM can be delivered, in combination with administration via a different route of delivery (which will often be systemic delivery, but could be other routes as well).
In some embodiments, IRMs of the present invention may be administered to the subject in combination with other modes of treatment. This is particularly true for cancer therapy. Such other modes of cancer therapy include, but are not limited to, radiation treatment, brachytherapy, external beam radiation, chemotheraphy, hormone therapy, immunomodulatory therapy, therapeutic vaccine therapy, and antibody therapy. The administration of the agents of the present invention can take place before, during, or after the other therapy. Likewise, the IRMs may be delivered via different routes simultaneously or at different times.
For cancer treatment, the efficacy of treatment may be assessed by various parameters well known in the art. This includes, but is not limited to, determination of tumor size, location and vascularization, as determined by such methods including, but not limited to, X-rays, scans, magnetic resonance imaging, computerized tomography, and/or various nuclear medicine techniques and algorithms to evaluate tumor size and burden in three dimensions. Angiography can be used to evaluate vascularization of tumors and other tissues. Other methods of determining tumor location, stage, and grade include, but are not limited to, gene arrays, immuno-histochemistry, and/or other techniques for measuring biomarkers relevant to assessing a disease.
The efficacy of the administration of an IRM effective for the treatment of cancer may be demonstrated by such means, including, but not limited to, the inhibition of tumor growth, the inhibition of tumor progression, the inhibition of tumor spread, the inhibition of tumor invasiveness, the inhibition of tumor vascularization, the inhibition of tumor angiogenesis, and/or the inhibition of tumor metastasis.
The inhibition of tumor growth is a decrease in the growth rate of a tumor. It includes, but is not limited to, at least one of a decrease in tumor weight or tumor volume, a decrease in tumor doubling time, a decrease in the growth fraction or number of tumor cells that are replicating, a decrease in the rate in which tumor cells are shed, and/or a decrease in the ratio of cell production to cell loss within a tumor. The inhibition of tumor growth can also include the inhibition of tumor growth of primary lesions and/or any metastatic lesions. For oral cancer, the inhibition of tumor progression includes the disruption or halting of the progression of premalignant lesions, also called leukoplakia, to malignant carcinoma.
The inhibition of tumor spread is the decrease in the dissemination of a tumor to other locations. This dissemination to other locations can be the result of the seeding of a body cavity or surface with cancerous cells from a tumor and/or the transport of tumor cells through the lymphatic system and/or circulatory system. The inhibition of tumor spread can also include the inhibition of tumor spread in primary lesions and/or any metastatic lesions.
The inhibition of tumor invasiveness is the decrease in the infiltration, invasion, and/or destruction of the surrounding local tissues, including, but not limited to organs, blood vessels, lymphatics, and/or body cavities. The inhibition of tumor invasiveness can also include the inhibition of tumor invasiveness in primary lesions and/or any metastatic lesions.
The inhibition of tumor vascularization is the decrease in the formation of blood vessels and lymphatic vessels within a tumor and to and from a tumor. The inhibition of tumor vascularization can also include the inhibition of tumor vascularization in primary lesions and/or any metastatic lesions.
The inhibition of tumor angiogenesis is a decrease in the formation of new capillaries and microvessels within a tumor. The inhibition of tumor angiogenesis can also include the inhibition of tumor angiogenesis in primary lesions and/or any metastatic lesions.
The inhibition of tumor metastasis is a decrease in the formation of tumor lesions that are discontinuous with the primary tumor. With metastasis, tumor cells break loose from the primary lesion, enter blood vessels or lymphatics and produce a secondary growth at a distant site. In some cases the distribution of the metastases may be the result of the natural pathways of the drainage of the lymphatic and/or circulatory system. In other cases, the distribution of metastases may be the result of a tropism of the tumor to a specific tissue or organ. For example, prostate tumors may preferentially metastasis to the bone. The tumor cells of a metastatic lesion may in turn metastasize to additional locations. This may be referred to as a metastatic cascade. Tumor cells may metastasize to sites including, but not limited to, liver, bone, lung, lymph node, spleen, brain or other nervous tissue, bone marrow, or an organ other than the original tissue of origin. The inhibition of tumor metastasis includes the inhibition of tumor metastasis in primary lesions and/or any metastatic lesions.
Herein, local application includes, e.g., topical application as well as injectable applications (e.g., intra-dermal, intra-tumoral, or subcutaneous) intended for local distribution only, without substantial systemic delivery. Herein, topical application involves application to dermal and mucosal tissues, including vaginal, rectal, nasal, buccal, and pulmonary applications. Herein, systemic application involves oral and parenteral (including subcutaneous (subQ or SC) if intended for systemic distribution as opposed to local administration), intramuscular (IM), intraperitoneal (IP), intravenous (IV), intrathecal, intraventricular, etc.) administration. Thus, formulations of the present invention can be administered to a subject (e.g., mammal, particularly a human) in various ways, for example, by spraying, injection, inhalation (e.g., from a nebulizer or spray pump atomizer), gel, cream, foam, transdermal patch, suppository, etc.
Formulations of the present invention suitable for topical administration are disclosed in, e.g., U.S. Patent Publication No. US 2003/0199538 and International Publication No. WO 2003/045391. A typical formulation for topical administration includes, for example, isostearic acid (e.g., 15-35 wt-%), medium-chain triglycerides (e.g., 5-10 wt-%), propylene glycol (e.g., 5-10 wt-%), parabens (e.g., methyl, ethyl, and mixtures thereof) (e.g., 0.1-0.5 wt-%), edetate disodium (e.g., 0.01-0.1 wt-%), polymers such as CARBOMERS and POLOXAMERS (e.g., 4.0-5.0 wt-%), and water (preferably sterile water), wherein the formulation is optionally adjusted to a desired pH, preferably a pH of 5.8 (e.g., by NaOH). An IRM can be incorporated into such a formulation in a variety of concentrations.
Formulations of the present invention suitable for parenteral administration conveniently include a sterile aqueous preparation of the desired compound, or dispersions of sterile powders including the desired compound, which are preferably isotonic with the blood of the subject. Isotonic agents that can be included in the liquid preparation include sugars, buffers, and salts such as sodium chloride. Solutions of the desired compound can be prepared in water, optionally mixed with a nontoxic surfactant. Dispersions of the desired compound can be prepared in water, ethanol, a polyol (such as glycerol, propylene glycol, liquid polyethylene glycols, and the like), vegetable oils, glycerol esters, and mixtures thereof.
A typical formulation for systemic administration (e.g., IV and SC) includes, for example, citric acid or other pharmaceutically acceptable acid (e.g., hydrochloric acid, lactic acid, acetic acid, aspartic acid), mannitol or other tonicity adjuster (e.g., glycerin, sorbitol, dextrose), and water (preferably, sterile water), wherein the formulation is optionally adjusted to a desired pH, preferably a pH of 5, by a suitable pH adjuster (e.g., by NaOH). The pharmaceutically acceptable acid is preferably present in the formulation (i.e., composition) in an amount of at least 0.4 wt-%, although lower concentrations, such as 0.3%, may also be used, , and preferably no more than 0.5 wt-%, based on the total weight of the formulation. The tonicity adjuster is preferably present in the formulation in an amount of at least 4 wt-%, and preferably no more than 5 wt-%, based on the total weight of the formulation. Additional information regarding formulations for injection can be found in co-pending application attorney docket number 61658WO003, entitled Immune Response Modifier Formulations and Methods, filed even date herewith.
The IRM can be incorporated into such a formulation in a variety of concentrations. Typical formulations include one or more IRMs in amounts of at least 0.001 wt-%, and preferably at least 0.2 wt-%, and even up to 1.5 wt-%, based on the total weight of the formulation. An IRM can be incorporated into such a formulation in a variety of concentrations.
Formulations of the present invention suitable for oral administration can include those discussed above for systemic administration, wherein the formulations are suitably diluted. For example, such formulations can be diluted with dextrose or other suitable diluents to a total volume of 10 mL.
Other oral formulations may include discrete units such as tablets, troches, capsules, lozenges, wafers, or cachets, each containing a predetermined amount of the IRM, as a powder, in granular form, incorporated within liposomes, or as a solution or suspension in an aqueous liquid or non-aqueous liquid such as a syrup, an elixir, an emulsion, or a draught.
The tablets, troches, pills, capsules, and the like may also contain one or more of the following: a binder such as gum tragacanth, acacia, corn starch, or gelatin; an excipient such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid, and the like; a lubricant such as magnesium stearate; a sweetening agent such as sucrose, fructose, lactose, or aspartame; and a natural or artificial flavoring agent. When the unit dosage form is a capsule, it may further contain a liquid carrier, such as a vegetable oil or a polyethylene glycol. Various other materials may be present as coatings or to otherwise modify the physical form of the solid unit dosage form. For instance, tablets, pills, or capsules may be coated with gelatin, wax, shellac, sugar, and the like. A syrup or elixir may contain one or more of a sweetening agent, a preservative such as methyl- or propylparaben, an agent to retard crystallization of the sugar, an agent to increase the solubility of any other ingredient, such as a polyhydric alcohol, for example glycerol or sorbitol, a dye, and flavoring agent. The material used in preparing any unit dosage form is substantially nontoxic in the amounts employed. The compound may be incorporated into sustained-release preparations and devices if desired. Formulations for rectal or vaginal administration may be presented as a suppository with a suitable carrier such as cocoa butter, or hydrogenated fats or hydro genated fatty carboxylic acids.
Nasal spray formulations can include purified aqueous solutions of the desired compound with preservative agents and isotonic agents. Such formulations are preferably adjusted to a pH and isotonic state compatible with the nasal mucous membranes. Preferably, such formulations are in solution form at room temperature (i.e., 25°C-30°C). Also, such formulations are sufficiently low in viscosity (less than 100 centipoise (cps)) at room temperature. At such low viscosity level, the compositions are typically and preferably sprayable. In this context, "sprayable" means the formulation can be delivered using a conventional pump spray device.
The amount of an IRM compound that will be therapeutically effective in a specific situation will depend on such things as the activity of the particular compound, the dosing regimen, the application site, the particular formulation, and the condition being treated. As such, specific administration amounts described herein are only exemplary. Those skilled in the art will be able to determine appropriate therapeutically effective amounts based on the guidance provided herein, information available in the art pertaining to those compounds, and routine testing.
Typical topical formulations include one or more IRMs in amounts of at least 0.01 wt-%, and even up to 3.0 wt-%, based on the total weight of the formulation. A preferred systemic formulation includes one or more IRMs in amounts of 0.1 wt-% to 1.6 wt-%, based on the total weight of the formulation. A typical injection volume of 1.5 mL.
In some embodiments, the methods of the present invention include systemically administering sufficient formulation to provide a dose of IRM compound of, for example, from 10 ng/kg to 50 mg/kg to the subject, although in some embodiments the methods may be performed by administering IRM compound in concentrations outside this range. In some of these embodiments, the method includes systemically administering sufficient formulation to provide a dose of IRM compound of from 100 ng/kg to 5 mg/kg to the subject, for example, a dose of from 1 μg/kg to 1 mg/kg. In some embodiments, the methods of the present invention include topically administering sufficient formulation of IRM compound, for example, from 0.0001 wt-% to 10wt-% to the subject, although in some embodiments the methods may be performed by administering IRM compound in concentrations outside this range. In some of these embodiments, the method includes topically administering sufficient formulation of IRM compound from 0.001wt-% to 5wt-% to the subject, for example, from 0.01wt-% to 3wt- %.
IRM Compounds
IRM compounds used herein are generally agonists of toll-like receptors (TLRs) 7, 8, and/or 9. Some IRM oligonucleotide sequences contain cytosine-guanine dinucleotides (CpG) and are described, for example, in U.S. Patent Nos. 6,194,388; 6,207,646; 6,239,116; 6,339,068; and 6,406,705. Some CpG-containing oligonucleotides can include synthetic immunomodulatory structural motifs such as those described, for example, in U.S. Patent Nos. 6,426,334 and 6,476,000. Other IRM nucleotide sequences lack CpG sequences and are described, for example, in International Patent Publication No. WO 00/75304. Other IRMs include biological molecules such as aminoalkyl glucosaminide phosphates (AGPs) and are described, for example, in U.S. Patent Nos. 6,113,918;
6,303,347; 6,525,028; and 6,649,172. CpGs and other biological IRMs are considered relatively large molecules and many are TLR 9 agonists.
However, TLR 7 and/or 8 agonists may be preferred, and small-molecule IRMs are generally preferred for methods involving multi-route administration including topical delivery. Examples of small organic molecule IRMs (e.g., molecular weight under about 1000 Daltons, preferably under about 500 Daltons, as opposed to large biologic protein, peptides, and the like) are disclosed in, for example, U.S. Patent Nos. 4,689,338; 4,929,624; 4,988,815; 5,037,986; 5,175,296; 5,238,944; 5,266,575; 5,268,376; 5,346,905; 5,352,784; 5,367,076; 5,389,640; 5,395,937; 5,446,153; 5,482,936; 5,693,811; 5,741,908; 5,756,747; 5,939,090; 6,039,969; 6,083,505; 6,110,929; 6,194,425; 6,245,776; 6,331,539; 6,376,669; 6,451,810; 6,525,064; 6,545,016; 6,545,017; 6,558,951; 6,573,273; 6,656,938; 6,660,735; 6,660,747; 6,664,260; 6,664,264; 6,664,265; 6,667,312; 6,670,372; 6,677,347; 6,677,348; 6,677,349; 6,683,088; 6,756,382; European Patent 0 394 026; U.S. Patent Publication Nos. 2002/0016332; 2002/0055517; 2002/0110840; 2003/0133913; 2003/0199538; and 2004/0014779; and International Patent Publication No. WO 04/058759. IRM compounds suitable for use in the invention preferably include small- molecule IRM compounds having a 2-aminopyridine fused to a five membered nitrogen- containing heterocyclic ring. Such compounds include, for example, imidazoquinoline amines, including but not limited to, substituted imidazoquinoline amines such as, for example, amide substituted imidazoquinoline amines, sulfonamide substituted imidazoquinoline amines, urea substituted imidazoquinoline amines, aryl ether substituted imidazoquinoline amines, heterocyclic ether substituted imidazoquinoline amines, amido ether substituted imidazoquinoline amines, sulfonamido ether substituted imidazoquinoline amines, urea substituted imidazoquinoline ethers, thioether substituted imidazoquinoline amines, and 6-, 7-, 8-, or 9-aryl or heteroaryl substituted imidazoquinoline amines; tetrahydroimidazoquinoline amines, including but not limited to, amide substituted tetrahydroimidazoquinoline amines, sulfonamide substituted tetrahydroimidazoquinoline amines, urea substituted tetrahydroimidazoquinoline amines, aryl ether substituted tetrahydroimidazoquinoline amines, heterocyclic ether substituted tetrahydroimidazoquinoline amines, amido ether substituted tetrahydroimidazoquinoline amines, sulfonamido ether substituted tetrahydroimidazoquinoline amines, urea substituted tetrahydroimidazoquinoline ethers, and thioether substituted tetrahydroimidazoquinoline amines; imidazopyridine amines, including but not limited to, amide substituted imidazopyridine amines, sulfonamide substituted imidazopyridine amines, urea substituted imidazopyridine amines, aryl ether substituted imidazopyridine amines, heterocyclic ether substituted imidazopyridine amines, amido ether substituted imidazopyridine amines, sulfonamido ether substituted imidazopyridine amines, urea substituted imidazopyridine ethers, and thioether substituted imidazopyridine amines; 1,2-bridged imidazoquinoline amines; 6,7-fused cycloalkylimidazopyridine amines; imidazonaphthyridine amines; imidazotetrahydronaphthyridine amines; oxazoloquinoline amines; thiazoloquinoline amines; oxazolopyridine amines; thiazolopyridine amines; oxazolonaphthyridine amines; thiazolonaphthyridine amines; and 1/f-imidazo dimers fused to pyridine amines, quinoline amines, tetrahydroquinoline amines, naphthyridine amines, or tetrahydronaphthyridine amines. Various combinations of these IRMs can be used if desired. In certain embodiments, the immune response modifier is selected from the group consisting of imidazoquinoline amines, tetrahydroimidazoquinoline amines, imidazopyridine amines, and combinations thereof.
In certain embodiments, the immune response modifier is selected from the group consisting of amide substituted imidazoquinoline amines, sulfonamide substituted imidazoquinoline amines, urea substituted imidazoquinoline amines, aryl ether substituted imidazoquinoline amines, heterocyclic ether substituted imidazoquinoline amines, amido ether substituted imidazoquinoline amines, sulfonamide ether substituted imidazoquinoline amines, urea substituted imidazoquinoline ethers, thioether substituted imidazoquinoline amines, 6-, 7-, 8-, or 9-aryl or heteroaryl substituted imidazoquinoline amines, amide substituted tetrahydroimidazoquinoline amines, sulfonamide substituted tetrahydroimidazoquinoline amines, urea substituted tetrahydroimidazoquinoline amines, aryl ether substituted tetrahydroimidazoquinoline amines, heterocyclic ether substituted tetrahydroimidazoquinoline amines, amido ether substituted tetrahydroimidazoquinoline amines, sulfonamido ether substituted tetrahydroimidazoquinoline amines, urea substituted tetrahydroimidazoquinoline ethers, thioether substituted tetrahydroimidazoquinoline amines, amide substituted imidazopyridine amines, sulfonamide substituted imidazopyridine amines, urea substituted imidazopyridine amines, aryl ether substituted imidazopyridine amines, heterocyclic ether substituted imidazopyridine amines, amido ether substituted imidazopyridine amines, sulfonamido ether substituted imidazopyridine amines, urea substituted imidazopyridine ethers, thioether substituted imidazopyridine amines, and combinations thereof.
In certain embodiments, the immune response modifier is selected from the group consisting of amide substituted imidazoquinoline amines, sulfonamide substituted imidazoquinoline amines, urea substituted imidazoquinoline amines, thioether substituted imidazoquinoline amines, 7-aryl substituted imidazoquinoline amines, 7-heteroaryl substituted imidazoquinoline amines, sulfonamide substituted tetrahydroimidazoquinoline amines, and combinations thereof.
In certain embodiments, the immune response modifier is an imidazoquinoline amine. In certain embodiments, the immune response modifier is a sulfonamide substituted imidazoquinoline amine. In certain embodiments, the immune response modifier is selected from the group consisting of N- [4-(4-amino-2-ethyl- 1 H-imidazo [4,5 -c] quinolin- 1 - yl)butyl]methanesulfonamide, N-{2-[4-ammo-2-(ethoxymethyl)-lH-imidazo[4,5- c] quinolin- 1 -yl)butyl]- 1 , 1 -dimethyleethyllmethanesulfonamide, 4- amino-α,α-dimethyl -2-ethoxymethyl-lH-imidazo[4,5-c]quinolin-l-ethanol, pharmaceutically acceptable salts thereof, and combinations thereof.
The IRM compounds and salts thereof described herein include any of their pharmaceutically acceptable forms, such as isomers (e.g., diastereomers and enantiomers), solvates, polymorphs, and the like. In particular, if a compound is optically active, the invention specifically includes the use of each of the compound's enantiomers as well as racemic combinations of the enantiomers.
The immune response modifier can, for example, be a salt of an acid selected from the group consisting of a carboxylic acid, a halo acid, sulfuric acid, phosphoric acid, dicarboxylic acid, tricarboxylic acid, and combinations thereof. In certain embodiments, the salt of the immune response modifier can be a salt of an acid selected from the group consisting of hydrobromic acid, hydrochloric acid, lactic acid, glutamic acid, gluconic acid, tartaric acid, succinic acid, and combinations thereof.
Exemplary IRM Compounds In certain embodiments of the present invention the IRM compound can be chosen from lH-imidazo[4,5-c]quinolin-4-amines defined by one of Formulas I-V below:
Figure imgf000018_0001
I wherein R11 is selected from alkyl of one to ten carbon atoms, hydroxyalkyl of one to six carbon atoms, acyloxyalkyl wherein the acyloxy moiety is alkanoyloxy of two to four carbon atoms or benzoyloxy, and the alkyl moiety contains one to six carbon atoms, benzyl, (phenyl)ethyl and phenyl, said benzyl, (phenyl)ethyl or phenyl substiruent being optionally substituted on the benzene ring by one or two moieties independently selected from alkyl of one to four carbon atoms, alkoxy of one to four carbon atoms and halogen, with the proviso that if said benzene ring is substituted by two of said moieties, then said moieties together contain no more than six carbon atoms;
R2I is selected from hydrogen, alkyl of one to eight carbon atoms, benzyl, (phenyl)ethyl and phenyl, the benzyl, (phenyl)ethyl or phenyl substituent being optionally substituted on the benzene ring by one or two moieties independently selected from alkyl of one to four carbon atoms, alkoxy of one to four carbon atoms and halogen, with the proviso that when the benzene ring is substituted by two of said moieties, then the moieties together contain no more than six carbon atoms; and each Ri is independently selected from alkoxy of one to four carbon atoms, halogen, and alkyl of one to four carbon atoms, and n is an integer from 0 to 2, with the proviso that if n is 2, then said R1 groups together contain no more than six carbon atoms;
II wherein
R12 is selected from straight chain or branched chain alkenyl containing two to ten carbon atoms and substituted straight chain or branched chain alkenyl containing two to ten carbon atoms, wherein the substituent is selected from straight chain or branched chain alkyl containing one to four carbon atoms and cycloalkyl containing three to six carbon atoms; and cycloalkyl containing three to six carbon atoms substituted by straight chain or branched chain alkyl containing one to four carbon atoms; and
R22 is selected from hydrogen, straight chain or branched chain alkyl containing one to eight carbon atoms, benzyl, (phenyl)ethyl and phenyl, the benzyl, (phenyl)ethyl or phenyl substituent being optionally substituted on the benzene ring by one or two moieties independently selected from straight chain or branched chain alkyl containing one to four carbon atoms, straight chain or branched chain alkoxy containing one to four carbon atoms, and halogen, with the proviso that when the benzene ring is substituted by two such moieties, then the moieties together contain no more than six carbon atoms; and each R2 is independently selected from straight chain or branched chain alkoxy containing one to four carbon atoms, halogen, and straight chain or branched chain alkyl containing one to four carbon atoms, and n is an integer from zero to 2, with the proviso that if n is 2, then said R2 groups together contain no more than six carbon atoms;
Figure imgf000020_0001
III wherein
R23 is selected from hydrogen, straight chain or branched chain alkyl of one to eight carbon atoms, benzyl, (phenyl)ethyl and phenyl, the benzyl, (phenyl)ethyl or phenyl substituent being optionally substituted on the benzene ring by one or two moieties independently selected from straight chain or branched chain alkyl of one to four carbon atoms, straight chain or branched chain alkoxy of one to four carbon atoms, and halogen, with the proviso that when the benzene ring is substituted by two such moieties, then the moieties together contain no more than six carbon atoms; and each R3 is independently selected from straight chain or branched chain alkoxy of one to four carbon atoms, halogen, and straight chain or branched chain alkyl of one to four carbon atoms, and n is an integer from zero to 2, with the proviso that if n is 2, then said R3 groups together contain no more than six carbon atoms;
Figure imgf000020_0002
IV wherein
R14 is -CHRxRy wherein Ry is hydrogen or a carbon-carbon bond, with the proviso that when Ry is hydrogen Rx is alkoxy of one to four carbon atoms, hydroxyalkoxy of one to four carbon atoms, 1-alkynyl of two to ten carbon atoms, tetrahydropyranyl, alkoxyalkyl wherein the alkoxy moiety contains one to four carbon atoms and the alkyl moiety contains one to four carbon atoms, or 2-, 3-, or 4-pyridyl, and with the further proviso that when Ry is a carbon-carbon bond Ry and Rx together form a tetrahydrofuranyl group optionally substituted with one or more substituents independently selected from hydroxy and hydroxyalkyl of one to four carbon atoms;
R24 is selected from hydrogen, alkyl of one to four carbon atoms, phenyl, and substituted phenyl wherein the substituent is selected from alkyl of one to four carbon atoms, alkoxy of one to four carbon atoms, and halogen; and
R4 is selected from hydrogen, straight chain or branched chain alkoxy containing one to four carbon atoms, halogen, and straight chain or branched chain alkyl containing one to four carbon atoms;
Figure imgf000021_0001
V wherein
R15 is selected from hydrogen; straight chain or branched chain alkyl containing one to ten carbon atoms and substituted straight chain or branched chain alkyl containing one to ten carbon atoms, wherein the substituent is selected from cycloalkyl containing three to six carbon atoms and cycloalkyl containing three to six carbon atoms substituted by straight chain or branched chain alkyl containing one to four carbon atoms; straight chain or branched chain alkenyl containing two to ten carbon atoms and substituted straight chain or branched chain alkenyl containing two to ten carbon atoms, wherein the substituent is selected from cycloalkyl containing three to six carbon atoms and cycloalkyl containing three to six carbon atoms substituted by straight chain or branched chain alkyl containing one to four carbon atoms; hydroxyalkyl of one to six carbon atoms; alkoxyalkyl wherein the alkoxy moiety contains one to four carbon atoms and the alkyl moiety contains one to six carbon atoms; acyloxyalkyl wherein the acyloxy moiety is alkanoyloxy of two to four carbon atoms or benzoyloxy, and the alkyl moiety contains one to six carbon atoms; benzyl; (phenyl)ethyl; and phenyl; said benzyl, (phenyl)ethyl or phenyl substituent being optionally substituted on the benzene ring by one or two moieties independently selected from alkyl of one to four carbon atoms, alkoxy of one to four carbon atoms, and halogen, with the proviso that when said benzene ring is substituted by two of said moieties, then the moieties together contain no more than six carbon atoms; R25 is
Figure imgf000022_0001
wherein
Rs and RT are independently selected from hydrogen, alkyl of one to four carbon atoms, phenyl, and substituted phenyl wherein the substituent is selected from alkyl of one to four carbon atoms, alkoxy of one to four carbon atoms, and halogen;
X is selected from alkoxy containing one to four carbon atoms, alkoxyalkyl wherein the alkoxy moiety contains one to four carbon atoms and the alkyl moiety contains one to four carbon atoms, hydroxyalkyl of one to four carbon atoms, haloalkyl of one to four carbon atoms, alkylamido wherein the alkyl group contains one to four carbon atoms, amino, substituted amino wherein the substituent is alkyl or hydroxyalkyl of one to four carbon atoms, azido, chloro, hydroxy, 1-morpholino, 1-pyrrolidino, alkylthio of one to four carbon atoms; and
R5 is selected from hydrogen, straight chain or branched chain alkoxy containing one to four carbon atoms, halogen, and straight chain or branched chain alkyl containing one to four carbon atoms; and pharmaceutically acceptable salts of any of the foregoing. In another embodiment, the IRM compound can be chosen from 6,7 fused cycloalkylimidazopyridine amines defined by Formula VI below:
Figure imgf000022_0002
VI wherein m is 1, 2, or 3;
R16 is selected from hydrogen; cyclic alkyl of three, four, or five carbon atoms; straight chain or branched chain alkyl containing one to ten carbon atoms and substituted straight chain or branched chain alkyl containing one to ten carbon atoms, wherein the substituent is selected from cycloalkyl containing three to six carbon atoms and cycloalkyl containing three to six carbon atoms substituted by straight chain or branched chain alkyl containing one to four carbon atoms; fluoro- or chloroalkyl containing from one to ten carbon atoms and one or more fluorine or chlorine atoms; straight chain or branched chain alkenyl containing two to ten carbon atoms and substituted straight chain or branched chain alkenyl containing two to ten carbon atoms, wherein the substituent is selected from cycloalkyl containing three to six carbon atoms and cycloalkyl containing three to six carbon atoms substituted by straight chain or branched chain alkyl containing one to four carbon atoms; hydroxyalkyl of one to six carbon atoms; alkoxy alkyl wherein the alkoxy moiety contains one to four carbon atoms and the alkyl moiety contains one to six carbon atoms; acyloxyalkyl wherein the acyloxy moiety is alkanoyloxy of two to four carbon atoms or benzoyloxy, and the alkyl moiety contains one to six carbon atoms, with the proviso that any such alkyl, substituted alkyl, alkenyl, substituted alkenyl, hydroxyalkyl, alkoxyalkyl, or acyloxyalkyl group does not have a fully carbon substituted carbon atom bonded directly to the nitrogen atom; benzyl; (phenyl)ethyl; and phenyl; said benzyl, (phenyl)ethyl or phenyl substituent being optionally substituted on the benzene ring by one or two moieties independently selected from alkyl of one to four carbon atoms, alkoxy of one to four carbon atoms, and halogen, with the proviso that when said benzene ring is substituted by two of said moieties, then the moieties together contain no more than six carbon atoms; and -CHRxRy wherein
Ry is hydrogen or a carbon-carbon bond, with the proviso that when Ry is hydrogen Rx is alkoxy of one to four carbon atoms, hydroxyalkoxy of one to four carbon atoms, 1- alkynyl of two to ten carbon atoms, tetrahydropyranyl, alkoxyalkyl wherein the alkoxy moiety contains one to four carbon atoms and the alkyl moiety contains one to four carbon atoms, 2-, 3-, or 4-pyridyl, and with the further proviso that when Ry is a carbon-carbon bond Ry and Rx together form a tetrahydrofuranyl group optionally substituted with one or more substituents independently selected from hydroxy and hydroxyalkyl of one to four carbon atoms; R26 is selected from hydrogen; straight chain or branched chain alkyl containing one to eight carbon atoms; straight chain or branched chain hydroxyalkyl containing one to six carbon atoms; morpholinoalkyl; benzyl; (phenyl)ethyl; and phenyl, the benzyl, (phenyl)ethyl, or phenyl substituent being optionally substituted on the benzene ring by a moiety selected from methyl, methoxy, and halogen; and -C(RS)(RT)(X) wherein Rs and RT are independently selected from hydrogen, alkyl of one to four carbon atoms, phenyl, and substituted phenyl wherein the substituent is selected from alkyl of one to four carbon atoms, alkoxy of one to four carbon atoms, and halogen;
X is selected from alkoxy containing one to four carbon atoms, alkoxyalkyl wherein the alkoxy moiety contains one to four carbon atoms and the alkyl moiety contains one to four carbon atoms, haloalkyl of one to four carbon atoms, alkylamido wherein the alkyl group contains one to four carbon atoms, amino, substituted amino wherein the substituent is alkyl or hydroxyalkyl of one to four carbon atoms, azido, alkylthio of one to four carbon atoms, and morpholinoalkyl wherein the alkyl moiety contains one to four carbon atoms; and
R6 is selected from hydrogen, fluoro, chloro, straight chain or branched chain alkyl containing one to four carbon atoms, and straight chain or branched chain fluoro- or chloroalkyl containing one to four carbon atoms and at least one fluorine or chlorine atom; and pharmaceutically acceptable salts thereof.
In another embodiment, the IRM compound can be chosen from imidazopyridine amines defined by Formula VII below:
Figure imgf000024_0001
VII wherein
R17 is selected from hydrogen; -CH2Rw wherein Rw is selected from straight chain, branched chain, or cyclic alkyl containing one to ten carbon atoms, straight chain or branched chain alkenyl containing two to ten carbon atoms, straight chain or branched chain hydroxyalkyl containing one to six carbon atoms, alkoxyalkyl wherein the alkoxy moiety contains one to four carbon atoms and the alkyl moiety contains one to six carbon atoms, and phenylethyl; and -CH=CRzRz wherein each Rz is independently straight chain, branched chain, or cyclic alkyl of one to six carbon atoms; R27 is selected from hydrogen; straight chain or branched chain alkyl containing one to eight carbon atoms; straight chain or branched chain hydroxyalkyl containing one to six carbon atoms; alkoxy alkyl wherein the alkoxy moiety contains one to four carbon atoms and the alkyl moiety contains one to six carbon atoms; benzyl, (phenyl)ethyl and phenyl, the benzyl, (phenyl)ethyl and phenyl being optionally substituted on the benzene ring by a moiety selected from methyl, methoxy, and halogen; and morpholinoalkyl wherein the alkyl moiety contains one to four carbon atoms;
R67 and R77 are independently selected from hydrogen and alkyl of one to five carbon atoms, with the proviso that R67 and R77 taken together contain no more than six carbon atoms, and with the further proviso that when R77 is hydrogen then R67 is other than hydrogen and R27 is other than hydrogen or morpholinoalkyl, and with the further proviso that when R67 is hydrogen then R77 and R27 are other than hydrogen; and pharmaceutically acceptable salts thereof.
In another embodiment, the IRM compound can be chosen from 1 ,2 bridged imidazoquinoline amines defined by Formula VIII below:
Figure imgf000025_0001
VIII wherein
Z is selected from -(CH2)p- wherein p is 1 to 4;
-(CH2)a-C(RDRE)(CH2)b~, wherein a and b are integers and a+b is 0 to 3, RD is hydrogen or alkyl of one to four carbon atoms, and RE is selected from alkyl of one to four carbon atoms, hydroxy, -ORF wherein Rp is alkyl of one to four carbon atoms, and -NRGR'G wherein RG and R'G are independently hydrogen or alkyl of one to four carbon atoms; and
-(CH2)a-(Y)-(CH2)b- wherein a and b are integers and a+b is 0 to 3, and Y is O, S, or -NRj- wherein Rj is hydrogen or alkyl of one to four carbon atoms; q is 0 or 1 ; and R8 is selected from alkyl of one to four carbon atoms, alkoxy of one to four carbon atoms, and halogen, and pharmaceutically acceptable salts thereof.
In another embodiment, the IRM compound can be chosen from thiazoloquinoline amines, oxazoloquinoline amines, thiazolopyridine amines, oxazolopyridine amines, thiazolonaphthyridine amines and oxazolonaphthyridine amines defined by Formula IX below:
Figure imgf000026_0001
IX wherein:
Ri9 is selected from oxygen, sulfur and selenium; R29 is selected from
-hydrogen; -alkyl;
-alkyl-OH;
-haloalkyl;
-alkenyl;
-alkyl-X-alkyl; -alkyl-X-alkenyl;
-alkenyl-X-alkyl;
-alkenyl-X-alkenyl;
-alkyl-N(R59)2;
-alkyl-N3; -alkyl-O-C(O)-N(R59)2;
-heterocyclyl;
-alkyl-X-heterocyclyl;
-alkenyl-X-heterocyclyl;
-aryl; -alkyl-X-aryl; -alkenyl-X-aryl; -heteroaryl;
-alkyl-X-heteroaryl; and -alkenyl-X-heteroaryl;
R39 and R49 are each independently: -hydrogen; -X-alkyl; -halo; -haloalkyl;
-N(R59)2; or when taken together, R39 and R49 form a fused aromatic, heteroaromatic, cycloalkyl or heterocyclic ring; X is selected from-0-, -S-, -NR59-, -C(O)-, -C(O)O-, -OC(O)-, and a bond; and each R59 is independently H or C1-8alkyl; and pharmaceutically acceptable salts thereof.
In another embodiment, the IRM compound can be chosen from imidazonaphthyridine amines and imidazotetrahydronaphthyridine amines defined by Formulas X and XI below:
Figure imgf000027_0001
X wherein
A is =N-CR=CR-CR=; ^CR-N=CR-CR=; ^CR-CR=N-CR=; or =CR-CR=CR-N=;
Rπo is selected from: - hydrogen;
-C1-20 alkyl or C2-20 alkenyl that is unsubstituted or substituted by one or more substituents selected from: -aryl;
-heteroaryl;
-heterocyclyl;
-0-C1-20 alkyl; -0-(C1-2O alkyl)0-i-aryl;
-0-(C1-20 alkyl)o-i-heteroaryl;
-0-(C1-2O alkyl)o-i-heterocyclyl;
-CO-O-C1-20 alkyl;
-S(O)0-2 -C1-20 alkyl; -S(O)0-2-(Ci-20 alkyl)0-i-aryl;
-S(O)0-2-(Ci-20 alkyl)0-1-heteroaryl;
-S(O)0-2 -(Ci-20 alky I)0-I -heterocyclyl;
-N(R3Io)2;
-N3; oxo;
-halogen;
-NO2;
-OH; and
-SH; and -C1-20 alky 1-NR3 K)-Q-X-R410 or -C2-20 alkenyl-NR31o-Q-X-R41o wherein Q is -CO- or -SO2-; X is a bond, -O- or -NR310- and R410 is aryl; heteroaryl; heterocyclyl; or -Ci-20 alkyl or C2-20 alkenyl that is unsubstituted or substituted by one or more substituents selected from:
-aryl; -heteroaryl;
-heterocyclyl;
-0-C1-20 alkyl;
-0-(Ci-2o alkyl)o.i-aryl;
-0-(C1-2O alkyl)0-1-heteroaryl; -0-(Ci-20 alkyl)0-i-heterocyclyl;
-CO-O-C1-20 alkyl;
-S(O)0-2 -C1-20 alkyl; -S(O)0-2-(Ci-20 alky I)0-I -aryl; -S(O)0-2 -(C i .20 alky I)0-I -heteroaryl; -S(O)0-2 -(C1-20 alkyl)o-i-heterocyclyl; -N(R3Io)2; -NR310-CO-O-C1-20 alkyl;
-N3; oxo;
-halogen; -NO2; -OH; and
-SH; or R4J0 is
Figure imgf000029_0001
wherein Y is -N- or -CR-; R2io is selected from: -hydrogen;
-C1-10 alkyl; -C2-1O alkenyl; -aryl;
-Ci-io alkyl-O-Ci.io alkyl; -C1-IO alkyl-0-C2-1o alkenyl; and
-Ci-io alkyl or C2-10 alkenyl substituted by one or more substituents selected from:
-OH; -halogen; -N(R31O)2;
-CO-N(R31O)2; -CO-Cio alkyl; -N3; -aryl;
-heteroaryl; -heterocyclyl; -CO-aryl; and -CO-heteroaryl; each R3I0 is independently selected from hydrogen and C1-10 alkyl; and each R is independently selected from hydrogen, Ci-10 alkyl, C1-10 alkoxy, halogen and trifluoromethyl;
Figure imgf000030_0001
XI wherein
B is -NR-C(R)2-C(R)2-C(R)2-; -C(R)2-NR-C(R)2-C(R)2-; -C(R)2-C(R)2-NR-C(R)2- or -C(R)2-C(R)2-C(R)2-NR-;
R111 is selected from: - hydrogen;
-Ci-2O alkyl or C2-20 alkenyl that is unsubstituted or substituted by one or more substituents selected from: -aryl;
-heteroaryl; -heterocyclyl;
-0-C1-20 alkyl; -0-(C1-20 alkyl)(M-aryl; -0-(C1-20 alky I)0-1 -heteroaryl; -0-(C1-20 alky l)o- 1 -heterocyclyl ; -CO-O-C1-20 alkyl;
-S(O)0-2 -C1-20 alkyl; -S(O)0-2-(C1-20 alkyl)0-1-aryl; -S(O)0-2 -(C1-20 alkyl)0-1-heteroaryl; -S(O)0-2 -(C1-20 alkyl)0-1-heterocyclyl; -N(R31O2;
-N3; oxo ;
-halogen; -NO2;
-OH; and
-SH; and
-Ci-20 alkyl-NRm-Q-X-FUπ or -C2-20 alkenyl-NR^-Q-X-Rm wherein Q is -CO- or -SO2-; X is a bond, -O- or -NR311- and R411 is aryl; heteroaryl; heterocyclyl; or -C1-20 alkyl or C2-20 alkenyl that is unsubstituted or substituted by one or more substituents selected from:
-aryl;
-heteroaryl;
-heterocyclyl; -0-C1-20 alkyl;
-0-(Ci-20 alkyl)o-i-aryl;
-0-(C1-2O alkyl)0-1-heteroaryl;
-0-(C i .20 alky I)0- 1 -heterocyclyl ;
-CO-O-C1-20 alkyl; -S(O)0-2 -C1-20 alkyl;
-S(O)0-2-(Ci-20 alkyl)0-i-aryl;
-S(O)0-2 -(C1-20 alkyl)0-1-heteroaryl;
-S(O)0-2 -(Ci-20 alkyl)0-i-heterocyclyl;
-N(R311)2; -NR311-CO-O-C1-20 alkyl;
-N3; oxo;
-halogen;
-NO2; -OH; and
-SH; Or R411 is
Figure imgf000032_0001
wherein Y is -N- or -CR-; R2I i is selected from:
-hydrogen; -Ci-I0 alkyl;
-C2-IO alkenyl; -aryl;
-Ci-I0 alkyl -O-d-io-alkyl; -Ci-io alkyl-0-C2-1o alkenyl; and -C1-10 alkyl or C2-1O alkenyl substituted by one or more substituents selected from:
-OH; -halogen; -N(R31O2; -CO-N(R311)2;
-CO-C1-10 alkyl; -N3; -aryl;
-heteroaryl; -heterocyclyl;
-CO-aryl; and -CO-heteroaryl; each R311 is independently selected from hydrogen and C1-10 alkyl; and each R is independently selected from hydrogen, C1-I0 alkyl, C1-I0 alkoxy, halogen, and trifluoromethyl; and pharmaceutically acceptable salts thereof. In another embodiment, the IRM compound can be chosen from lH-imidazo[4,5- c]quinolin-4-amines and tetrahydro- lH-imidazo[4,5-c]quinolin-4-amines defined by Formulas XII, XIII and XIV below:
Figure imgf000033_0001
XII
wherein
R112 is -alkyl-NR312-CO-R4I2 or -alkenyl-NR312-CO- R4I2 wherein R412 is aryl, heteroaryl, alkyl or alkenyl, each of which may be unsubstituted or substituted by one or more substituents selected from:
-alkyl;
-alkenyl;
-alkynyl;
-(alkyl)o-i-aryl; -(alkyl)0-1 -(substituted aryl);
-(alkytyo.i-heteroaryl;
-(alkyl)o-r(substituted heteroaryl);
-O-alkyl;
-O-(alkyl)0-1-aryl; -O-(alkyl)0-1-(substituted aryl);
-O-(alkyl)0-1-heteroaryl;
-0-(alkyl)o-1-(substituted heteroaryl);
-CO-aryl;
-CO-(substituted aryl); -CO-heteroaryl;
-CO-(substituted heteroaryl);
-COOH;
-CO-0-alkyl;
-CO-alkyl; -S(O)0-2 -alkyl;
-S(O)0-2 -(alkyl)o-i-aryl;
-S(O)0-2 -(alkyl)0-i -(substituted aryl);
-S(O)0-2 -(alkyl)o-i-heteroaryl; -S(O)0-2 -(alkyl)0-1 -(substituted heteroaryl);
-P(O)(OR312)2;
-NR312-CO-O-alkyl;
-N3;
-halogen; -NO2;
-CN;
-haloalkyl;
-O-haloalkyl;
-CO-haloalkyl; -OH;
-SH; and in the case that R412 is alkyl, alkenyl, or heterocyclyl, oxo; or R412 is
Figure imgf000034_0001
wherein R512 is an aryl, (substituted aryl), heteroaryl, (substituted heteroaryl), heterocyclyl or (substituted heterocyclyl) group; R212 is selected from:
-hydrogen;
-alkyl; -alkenyl;
-aryl;
-(substituted aryl);
-heteroaryl;
-(substituted heteroaryl); -heterocyclyl;
-(substituted heterocyclyl); -alkyl-O-alkyl; -alkyl-O-alkenyl; and
-alkyl or alkenyl substituted by one or more substituents selected from: -OH;
-halogen;
Figure imgf000035_0001
-CO-N(R312)2; -CO-C1-10 alkyl; -CO-O-C1-10 alkyl;
-N3; -aryl;
-(substituted aryl); -heteroaryl; -(substituted heteroaryl) ;
-heterocyclyl; -(substituted heterocyclyl); -CO-aryl; and -CO-heteroaryl; each R312 is independently selected from hydrogen; C1-10 alkyl-heteroaryl; C1-10 alkyl-(substituted heteroaryl); C1-10 alkyl-aryl; C1-10 alkyl-(substituted aryl) and C1-10 alkyl; v is 0 to 4; and each R12 present is independently selected from C1-10 alkyl, C1-1O alkoxy, halogen, and trifluoromethyl;
Figure imgf000035_0002
XIII wherein Ri 13 is -alkyl-NR3i3- SO2 -X-R4n or -alkenyl-NR313- SO2 -X-R413 ; X is a bond or -NR5I3-;
R4I3 is aryl, heteroaryl, heterocyclyl, alkyl or alkenyl, each of which may be unsubstituted or substituted by one or more substituents selected from: -alkyl;
-alkenyl;
-aryl;
-heteroaryl;
-heterocyclyl; -substituted cycloalkyl;
-substituted aryl;
-substituted heteroaryl;
-substituted heterocyclyl;
-O-alkyl; -O-(alkyl)0-1-aryl;
-O-(alkyl)0-i-substituted aryl;
-O-(alkyl)0-i -heteroaryl;
-0-(alkyl)o-1-substituted heteroaryl;
-O-(alkyl)0-1-heterocyclyl; -O-(alkyl)0-i-substituted heterocyclyl;
-COOH;
-CO-O-alkyl;
-CO-alkyl;
-S(O)0-2 -alkyl; -S(0)o-2-(alkyl)0-1-aryl;
-S(O)0-2 -(alkyl)o-i-substituted aryl;
-S(O)0-2 -(alkyl)0-1 -heteroaryl;
-S(0)o_2 -(alkyl)0-1 -substituted heteroaryl;
-S(O)0-2 — (alkyl)o-i -heterocyclyl; -S(O)0-2 -(alkyl)o-i-substituted heterocyclyl;
-(alkyl)0-i-NR313R313;
-(alkyl)0-1-NR313-CO-O-alkyl; -(alkyl)0-1-NR313-CO-alkyl;
-(alkyl)o-i-NR3i3-CO-aryl;
-(alkyl)0-1 -NR313-CO-substituted aryl;
-(alkyl)o-rNR3i3-CO-heteroaryl; -(alkyl)0-1-NR313-CO-substituted heteroaryl;
-N3;
-halogen;
-haloalkyl;
-haloalkoxy; -CO-haloalkyl;
-CO-haloalkoxy;
-NO2;
-CN;
-OH; -SH; and in the case that R413 is alkyl, alkenyl, or heterocyclyl, oxo;
R2i3 is selected from:
-hydrogen;
-alkyl;
-alkenyl; -aryl;
-substituted aryl;
-heteroaryl;
-substituted heteroaryl;
- alkyl-O-alkyl; - alkyl-O- alkenyl; and
- alkyl or alkenyl substituted by one or more substituents selected from:
-OH; -halogen; -N(R313)2;
-CO-N(R313)I; -CO-C1-10 alkyl; -CO-O-C1-10 alkyl; -N3; -aryl;
-substituted aryl; -heteroaryl;
-substituted heteroaryl; -heterocyclyl; -substituted heterocyclyl; -CO-aryl; -CO-(substituted aryl);
-CO-heteroaryl; and -CO-(substituted heteroaryl); each R313 is independently selected from hydrogen and Ci-I0 alkyl; or when X is a bond R3I3 and R4I3 can join to form a 3 to 7 membered heterocyclic or substituted heterocyclic ring;
R513 is selected from hydrogen and C1-I0 alkyl, or R413 and R5I3 can combine to form a 3 to 7 membered heterocyclic or substituted heterocyclic ring; v is 0 to 4; and each Ri3 present is independently selected from Ci-10 alkyl, C1-10 alkoxy, halogen, and trifluoromethyl;
Figure imgf000038_0001
XIV wherein
Ri H4 is ^yI-NR3I4-CY-NR5I4-X-R4I4 i or
-alkenyl-NR3 H-CY- NR514-X- R4I4 wherein
Y is =0 or =S;
X is a bond, -CO- or -SO2-; R414 is aryl, heteroaryl, heterocyclyl, alkyl or alkenyl, each of which may be unsubstituted or substituted by one or more substituents selected from:
-alkyl;
-alkenyl; -aryl;
-heteroaryl;
-heterocyclyl;
-substituted aryl;
-substituted heteroaryl; -substituted heterocyclyl;
-O-alkyl;
-0-(alkyl)o-i-aryl;
-O-(alkyl)0-i-substituted aryl;
-0-(alkyl)o.rheteroaryl; -O-(alkyl)0-1 -substituted heteroaryl;
-O-(alkyl)0-1-heterocyclyl;
-0-(alkyl)o.i-substituted heterocyclyl;
-COOH;
-CO-O-alkyl; -CO-alkyl;
-S(O)0-2 -alkyl;
-S(O)0-2 -(alkyl)0-1-aryl;
-S(O)0-2 -(alky^o-rsubstituted aryl;
-S(O)0-2 -(alkyl)0-1-heteroaryl; -S(O)0-2 -(alkyl)o-i-substituted heteroaryl;
-S(O)0-2 -(alkyl)0-1-heterocyclyl;
-S(O)0-2 -(alkyl)0-1-substituted heterocyclyl;
-(alkyl)0-1-NR314R3i4; -(alkyl)0.i-NR3i4-CO-O-alkyl; -(alkyl)0-1-NR314-CO-alkyl;
-(alkyl)o-i-NR3i4-CO-aiyl; -(alkyl)0-1-NR314-CO-substituted aryl; -(alkyl)o-i-NR3i4-CO-heteroaryl;
-(alkyl)0-1-NR3i4-CO-substituted heteroaryl;
-N3;
-halogen; -haloalkyl;
-haloalkoxy;
-CO-haloalkoxy;
-NO2;
-CN; -OH;
-SH; and, in the case that R4J4 is alkyl, alkenyl or heterocyclyl, oxo; with the proviso that when X is a bond R4I4 can additionally be hydrogen; R2I4 is selected from:
-hydrogen; -alkyl;
-alkenyl;
-aryl;
-substituted aryl;
-heteroaryl; -substituted heteroaryl;
- alkyl-O-alkyl; -alkyl-O- alkenyl; and
- alkyl or alkenyl substituted by one or more substituents selected from: -OH;
-halogen;
-N(R3i4)2;
-CO-N(R314)2;
-CO-C1-10 alkyl; -CO-O-C1-10 alkyl;
-N3;
-aryl; -substituted aryl; -heteroaryl;
-substituted heteroaryl; -heterocyclyl; -substituted heterocyclyl;
-CO-aryl;
-CO-(substituted aryl); -CO-heteroaryl; and -CO-(substituted heteroaryl); each R3 I4 is independently selected from hydrogen and Ci-10 alkyl;
R5I4 is selected from hydrogen and Ci-I0 alkyl, or R4I4 and R514 can combine to form a 3 to 7 membered heterocyclic or substituted heterocyclic ring; v is 0 to 4; and each R14 present is independently selected from C1-10 alkyl, Cj.io alkoxy, halogen, and trifluoromethyl; and pharmaceutically acceptable salts thereof.
In another embodiment, the IRM compound can be chosen from lH-imidazo[4,5- c]quinolin-4-amines and tetrahydro- lH-imidazo[4,5-c]quinolin-4-amines defined by Formulas XV, XVI, XVII, XVIII, XIX, XX, XXI, XXII, XXIII, XXIV, XXV, and XXVI below:
Figure imgf000041_0001
XV
wherein: X is -CHR5I5-, -CHR515-alkyl-, or -CHR5i5-alkenyl-;
R115 is selected from:
-R415-CR315-Z-R615- alkyl; -R4I5-CR315-Z-R6I5 — alkenyl; -R415-CR315-Z-R615— aryl ; -R415-CR315-Z-R615— heteroary 1 ; -R415-CR315-Z-R615 — heterocyclyl ; -R415-CR315-Z-H;
-R415-NR715 -CR315-R6I5- alkyl; -R415-NR715 -CR315-R615- alkenyl; -R415-NR715-CR315-R615-OTyI; -R4i5-NR715-CR315-R615-heteroaryl; -R415-NR715-CR315-R6i5-heterocyclyl; and
-R415-NR715 -CR3I5-R8I5; Z is -NR515- -O-, or -S-; R215 is selected from:
-hydrogen; -alkyl;
-alkenyl; -aryl;
-heteroaryl; -heterocyclyl; -alkyl- Y-alkyl;
-alkyl- Y- alkenyl; -alkyl- Y-aryl; and
- alkyl or alkenyl substituted by one or more substituents selected from: -OH;
-halogen; -N(R515)2; -CO-N(R51S)2; -CO-C1-I0 alkyl; -CO-O-C1-10 alkyl;
-N3; -aryl; -heteroaryl;
-heterocyclyl;
-CO-aryl; and
-CO-heteroaryl; R3I5 is =0 or =S;
R4I5 is alkyl or alkenyl, which may be interrupted by one or more -O- groups; each R515 is independently H or C1-10 alkyl;
R615 is a bond, alkyl, or alkenyl, which may be interrupted by one or more - O- groups;
R7I5 is H, C1-10 alkyl, or arylalkyl; or R415 and R715 can join together to form a ring;
R8I5 is H or C1-10 alkyl; or R7J5 and R8I5 can join together to form a ring; Y is -O- or -S(O)0-2-; v is 0 to 4; and each R15 present is independently selected from C1-I0 alkyl, Ci-I0 alkoxy, hydroxy, halogen, and trifluoromethyl;
Figure imgf000043_0001
XVI
wherein: X is -CHR516-, -CHR516-alkyl-, or -CHR5i6-alkenyl-; Rn6 is selected from:
-R4I6-CR3I6-Z-R616 — alkyl; -R416-CR316-Z-R6I6- alkenyl;
-R416-CR316-Z-R616 — aryl; -R416-CR3I6-Z-R616 — heteroaryl; -R416-CR316-Z-R616 — heterocyclyl; -R416-CR316-Z-H; -R416-NR716 -CR316-R6I6- alkyl; -R4I6-NR716 -CR3J6-R6I6 — alkenyl; -R416-NR716-CR316-R6i6-aryl; -R416-NR716-CR316-R6i6-heteroaryl; -R4i6-NR716-CR316-R616-heterocyclyl; and
-R4I6-NR7I6 -CR316-R8I6; Z is -NR5 J6-, -O- or -S-; R216 is selected from:
-hydrogen; -alkyl;
-alkenyl; -aryl;
-heteroaryl; -heterocyclyl; -alkyl- Y-alkyl;
-alkyl-Y- alkenyl; -alkyl- Y-aryl; and
- alkyl or alkenyl substituted by one or more substituents selected from: -OH;
-halogen; -N(R5i6)2; -CO-N(R516)2; -CO-C1-10 alkyl; -CO-O-C1-10 alkyl;
-N3; -aryl;
-heteroaryl; -heterocyclyl; -CO-aryl; and
-CO-heteroaryl; R3I6 is =0 or =S; R416 is alkyl or alkenyl, which may be interrupted by one or more
-O- groups; each R516 is independently H or C1-10 alkyl;
R616 is a bond, alkyl, or alkenyl, which may be interrupted by one or more - O- groups;
R716 is H, C1-10 alkyl, arylalkyl; or R416 and R716 can join together to form a ring;
R816 is H or C1-10 alkyl; or R716 and R816 can join together to form a ring;
Y is -O- or -S(O)0-2-; v is 0 to 4; and each R16 present is independently selected from C1-10 alkyl, Ci-1O alkoxy, hydroxy, halogen, and trifiuoromethyl;
Figure imgf000045_0001
XVII
wherein: X is -CHR317-, -CHR3i7-alkyl-, or -CHR3 π-alkenyl-; Ri17 is selected from:
-alkenyl; -aryl; and
-R4i7-aryl; R217 is selected from: -hydrogen; -alkyl; -alkenyl;
-aryl;
-heteroaryl; -heterocyclyl; -alkyl-Y-alkyl; -alkyl-Y- alkenyl; -alkyl-Y-aryl; and
- alkyl or alkenyl substituted by one or more substituents selected from: -OH;
-halogen;
-N(R317)2;
-CO-N(R317)2;
-CO-Ci-I0 alkyl; -CO-0-Ci-io alkyl;
-N3;
-aryl;
-heteroaryl;
-heterocyclyl; -CO-aryl; and
-CO-heteroaryl;
R4I7 is alkyl or alkenyl, which may be interrupted by one or more -O- groups; each R317 is independently H or C1-10 alkyl; each Y is independently -O- or -S(O)0-2-; v is 0 to 4; and each R17 present is independently selected from C1-10 alkyl, Ci-10 alkoxy, hydroxy, halogen, and trifluoromethyl;
Figure imgf000046_0001
XVIII
wherein: X is -CHR318-, -CHR3i8-alkyl-, or -CHR3i8-alkenyl-; Rn8 is selected from: -aryl;
-alkenyl; and
Figure imgf000047_0001
R218 is selected from: -hydrogen;
-alkyl; -alkenyl; -aryl;
-heteroaryl; -heterocyclyl;
-alkyl-Y-alkyl; -alkyl-Y-aryl;
- alkyl-Y- alkenyl; and
- alkyl or alkenyl substituted by one or more substituents selected from:
-OH; -halogen; -N(R3Ig)2; -CO-N(R318)2; -CO-C1-10 alkyl;
-CO-O-C1-10 alkyl; -N3; -aryl;
-heteroaryl; -heterocyclyl;
-CO-aryl; and -CO-heteroaryl;
R418 is alkyl or alkenyl, which may be interrupted by one or more -O- groups; each R318 is independently H or C1-1O alkyl; each Y is independently -O- or -S(O)0-2-; v is 0 to 4; and each R18 present is independently selected C1-10 alkyl, Ci-I0 alkoxy, hydroxy, halogen, and trifluoromethyl;
Figure imgf000048_0001
wherein: X is -CHR319-, -CHR319-alkyl-, or -CHR319-alkenyl-;
R119 is selected from:
-heteroaryl; -heterocyclyl;
-R419- heteroaryl; and
-R419-hetero cy cly 1 ; R219 is selected from:
-hydrogen; -alkyl;
-alkenyl;
-aryl;
-heteroaryl;
-heterocyclyl; -alkyl- Y-alkyl;
-alkyl- Y- alkenyl;
-alkyl- Y-aryl; and
- alkyl or alkenyl substituted by one or more substituents selected from: -OH;
-halogen;
-N(R3W)2; -CO-N(R319)2; -CO-C1-10 alkyl; -CO-O-C1-I0 alkyl;
-N3;
-aryl;
-heteroaryl; -heterocyclyl;
-CO-aryl; and
-CO-heteroaryl;
R419 is alkyl or alkenyl, which may be interrupted by one or more -O- groups; each R319 is independently H or C1-Io alkyl; each Y is independently — O— or -S(0)o-2-; v is 0 to 4; and each R19 present is independently selected from C1-10 alkyl, Ci-10 alkoxy, hydroxy, halogen, and trifluoromethyl;
Figure imgf000049_0001
XX
wherein: X is -CHR320-, -CHR^o-alkyl-, or -CHR32o-alkenyl-; Ri20 is selected from:
-heteroaryl;
-heterocyclyl;
-R420- heteroaryl; and
-R42o-heterocyclyl ; R220 is selected from:
-hydrogen;
-alkyl;
-alkenyl;
-aryl; -heteroaryl; -heterocyclyl; -alkyl-Y-alkyl; -alkyl-Y- alkenyl; -alkyl-Y-aryl; and
- alkyl or alkenyl substituted by one or more substituents selected from:
-OH; -halogen; -N(R32O)2;
Figure imgf000050_0001
-CO-C1-I0 alkyl; -CO-O-C1-10 alkyl; -N3; -aryl;
-heteroaryl; -heterocyclyl; -CO-aryl; and -CO-heteroaryl; R420 is alkyl or alkenyl, which may be interrupted by one or more
-O- groups; each R320 is independently H or C1-1O alkyl; each Y is independently -O- or -S(O)0-2-; v is 0 to 4; and each R20 present is independently selected from C1-1O alkyl, C1-1O alkoxy, hydroxy, halogen, and trifluoromethyl;
Figure imgf000051_0001
XXI
wherein: X is -CHR521-, -CHR52i-alkyl-, or -CHR52J -alkenyl-; R121 is selected from:
-R421- NR321- SO2- R621- alkyl;
-R421- NR32I- SO2- R621- alkenyl;
-Rm-NR^i-SOr-R^-aryl;
-R42i-NR321-SO2-R62i-heteroaryl; -R42i-NR321-SO2-R621-heterocyclyl;
-R421-NR321-SO2-R721;
-R421-NR321-SO2-NR521-R621"^!;
-R421-NR321-SO2-NR521-R621-alkenyl;
-R421-NR321-SO2-NR521-R621-aryl; -R421-NR321-SO2-NR521-R621-heteroaryl;
-R421-NR321-SO2-NR52i-R621-heterocyclyl; and
-R421-NR321-SO2-NH2; R221 is selected from:
-hydrogen; -alkyl;
-alkenyl;
-aryl;
-heteroaryl;
-heterocyclyl; -alkyl- Y-alkyl;
-alkyl-Y- alkenyl;
-alkyl- Y-aryl; and
- alkyl or alkenyl substituted by one or more substituents selected from: -OH;
-halogen;
-N(R521)2;
-CO-N(R521)2; -CO-C1-10 alkyl;
-CO-O-C1-10 alkyl;
-N3;
-aryl;
-heteroaryl; -heterocyclyl;
-CO-aryl; and
-CO-heteroaryl; Y is -O- or -S(O)0-2-; R321 is H, C1-IO alkyl, or arylalkyl; each R421 is independently alkyl or alkenyl, which may be interrupted by one or more — O- groups; or R321 and R421 can join together to form a ring; each R521 is independently H, C1-10 alkyl, or C2-10 alkenyl; R621 is a bond, alkyl, or alkenyl, which may be interrupted by one or more O- groups; R721 is C1-1O alkyl; or R321 and R721 can join together to form a ring; v is 0 to 4; and each R21 present is independently selected from C1-10 alkyl, Ci-10 alkoxy, hydroxy, halogen, and trifiuoromethyl;
Figure imgf000052_0001
XXII
wherein: X is -CHR522-, -CHR522-alkyl-, or -CHR522-alkenyl-; Ri22 is selected from: -R422- NR322- SO2- R622- alkyl; -R422— NR322- SO2- Rδ22— alkenyl; -R422-NR322-SO2-R622-aryl; -R422-NR322-SO2-R622-heteroaryl;
5 -R422-NR322-SO2-R622-heterocyclyl;
-R422 — NR322 — SO2 — R722; -R422-NR322-SO2-NR522-R622-alkyl; -R422-NR322-SO2-NR522-R622-alkenyl; -R422-NR322-Sθ2-NR522-R622-aryl; 10 -R422-NR322-SO2-NR522-R622-heteroaryl;
-R422-NR322-Sθ2-NR522-R622-heterocyclyl; and -R422-NR322-SO2-NH2; R222 is selected from:
-hydrogen;
15 -alkyl;
-alkenyl; -aryl;
-heteroaryl; -heterocyclyl; 20 -alkyl-Y-alkyl;
-alkyl- Y- alkenyl; -alkyl- Y-aryl; and
- alkyl or alkenyl substituted by one or more substituents selected from: 25 -OH;
-halogen; -N(R522)2; -CO-N(R522)2; -CO-C1-10 alkyl;
30 -CO-O-C1-10 alkyl;
-N3; -aryl; -heteroaryl;
-heterocyclyl;
-CO-aryl; and
-CO-heteroaryl; Y is -O- or -S(O)0-2-;
R322 is H, C1-I0 alkyl, or arylalkyl; each R422 is independently alkyl or alkenyl, which may be interrupted by one or more -O- groups; or R322 and R422 can join together to form a ring; each R522 is independently H, C1-10 alkyl, or C2-10 alkenyl; R622 is a bond, alkyl, or alkenyl, which may be interrupted by one or more
O- groups;
R722 is C1-10 alkyl; or R322 and R722 can join together to form a ring; v is 0 to 4; and each R22 present is independently selected from C1-J0 alkyl, C1-1O alkoxy, hydroxy, halogen, and trifluoromethyl;
Figure imgf000054_0001
XXIII
wherein: X is -CHR323-, -CHR323-alkyl-, or -CHR323-alkenyl-; Z is -S-, -SO-, Or-SO2-; R123 is selected from:
-alkyl;
-aryl; -heteroaryl;
-heterocyclyl;
-alkenyl;
-R423-aryl;
-R423- heteroaryl; and -R^-heterocyclyl; R223 is selected from: -hydrogen; -alkyl; -alkenyl;
-aryl;
-heteroaryl; -heterocyclyl; -alkyl-Y-alkyl; - alkyl- Y- alkenyl;
-alkyl- Y-aryl; and
- alkyl or alkenyl substituted by one or more substituents selected from:
-OH; -halogen;
-N(R323)2; -CO-N(R323)2; -CO-C1-I0 alkyl; -CO-O-Ci-10 alkyl; -N3;
-aryl;
-heteroaryl; -heterocyclyl; -CO-aryl; and -CO-heteroaryl; each R323 is independently H or C1-10 alkyl; each R423 is independently alkyl or alkenyl; each Y is independently -O- or -S(O)0-2-; v is 0 to 4; and each R23 present is independently selected from Ci-10 alkyl, Ci-I0 alkoxy, hydroxy, halogen, and trifluoromethyl;
Figure imgf000056_0001
XXIV
wherein: X is -CHR324-, -CHR324-alkyl-, or -CHR324-alkenyl-; Z is -S-, -SO-, or -SO2-;
R124 is selected from: -alkyl; -aryl;
-heteroaryl; -heterocyclyl;
-alkenyl; -R424-aryl;
-R424- heteroaryl; and -R424-heterocyclyl; R224 is selected from:
-hydrogen; -alkyl; -alkenyl; -aryl; -heteroaryl;
-heterocyclyl; -alkyl-Y-alkyl; - alkyl- Y- alkenyl; -alkyl-Y-aryl; and - alkyl or alkenyl substituted by one or more substituents selected from:
-OH;
-halogen;
-N(R324)2; -CO-N(R324)2;
-CO-C1-10 alkyl;
-CO-O-Ci-10 alkyl;
-N3; -aryl;
-heteroaryl;
-heterocyclyl;
-CO-aryl; and
-CO-heteroaryl; each R324 is independently H or C1-I0 alkyl; each R424 is independently alkyl or alkenyl; each Y is independently -O- or -S(O)0-2-; v is 0 to 4; and each R24 present is independently selected from Ci-10 alkyl, C1-1O alkoxy, hydroxy, halogen, and trifluoromethyl;
Figure imgf000057_0001
XXV
wherein: X is -CHR525-, -CHR525-alkyl-, or -CHR525-alkenyl-;
Ri25 is selected from:
-R425-NR825-CR325- NR525-Z-R625-alkyl;
-R425-NR825-CR325- NR525-Z-R625-alkenyl;
-R425-NR825-CR325- NR525-Z-R625-aryl; -R425-NR825-CR325- NR525-Z-R625-heteroaryl;
-R425-NR825-CR325- NR525-Z-R625-heterocyclyl;
-R425-NR825 — CR325 — NR525R725;
-R425-NR825-CR325- NR925-Z- R625-alkyl;
-R425-NR825-CR325- NR925-Z- R625-alkenyl; -R425-NR825-CR325-NR925-Z — R625-aryl; -R425-NR825-CR325 — NR925-Z — R625-heteroaryl; and -R425-NR825-CR325-NR925-Z — R625-heterocyclyl; R225 is selected from: -hydrogen;
-alkyl; -alkenyl; -aryl;
-heteroaryl; -heterocyclyl;
-alkyl-Y-alkyl; -alkyl-Y- alkenyl; -alkyl-Y-aryl; and
- alkyl or alkenyl substituted by one or more substituents selected from:
-OH; -halogen; -N(R525)2; -CO-N(R525)2; -CO-C1-10 alkyl;
-CO-O-C1-10 alkyl; -N3; -aryl;
-heteroaryl; -heterocyclyl;
-CO-aryl; and -CO-heteroaryl; each R325 is =0 or =S; each R425 is independently alkyl or alkenyl, which may be interrupted by one or more -O- groups; each R525 is independently H or Ci-10 alkyl; R625 is a bond, alkyl, or alkenyl, which may be interrupted by one or more -
O— groups;
R725 is H or Ci-I0 alkyl which may be interrupted by a hetero atom, or R725 can join with R525 to form a ring; R825 is H, Ci-I0 alkyl, or arylalkyl; or R425 and R825 can join together to form a ring;
R925 is C1-10 alkyl which can join together with R825 to form a ring; each Y is independently -O- or -S(0)o-2-;
Z is a bond, -CO-, or -SO2-; v is 0 to 4; and each R25 present is independently selected Ci-I0 alkyl, Ci-I0 alkoxy, hydroxy, halogen, and trifluoromethyl;
Figure imgf000059_0001
XXVI
wherein: X is -CHR526-, -CHR526-alkyl-, or -CHR526-alkenyl-; R126 is selected from:
-R426-NR826-CR326- NR526-Z-R626-alkyl; -R426-NR826-CR326- NR526-Z-R626-alkenyl;
-R426-NR826-CR326- NR526-Z-R626-aryl;
-R426-NR826-CR326 — NR526-Z-R626-heteroaryl;
-R426-NR826-CR326 — NR526-Z-R626-heterocyclyl;
-R426-NR826-CR326-NR526R726; -R426-NR826-CR326- NR926-Z- R626-alkyl;
-R426-NR826-CR326- NR926-Z- R626-alkenyl;
-R426-NR826-CR326- NR926-Z- R626-aryl;
-R426-NR826-CR326 — NR926-Z — R626-heteroaryl; and
-R426-NR826-CR326 — NR926-Z — R626-heterocyclyl; R226 is selected from: -hydrogen; -alkyl; -alkenyl; -aryl;
-heteroaryl; -heterocyclyl; -alkyl-Y-alkyl; -alkyl- Y- alkenyl; -alkyl- Y-aryl; and
- alkyl or alkenyl substituted by one or more substituents selected from:
-OH; -halogen; -N(R526)2;
-CO-N(R526)2; -CO-Ci-io alkyl; -CO-O-C1-I0 alkyl; -N3; -aryl;
-heteroaryl; -heterocyclyl; -CO-aryl; and -CO-heteroaryl; each R326 is =0 or =S; each R426 is independently alkyl or alkenyl, which may be interrupted by one or more -O- groups; each R526 is independently H or C1-Io alkyl;
R626 is a bond, alkyl, or alkenyl, which may be interrupted by one or more - O- groups;
R726 is H or Ci-10 alkyl which may be interrupted by a hetero atom, or R726 can join with R526 to form a ring; R826 is H, C1-10 alkyl, or arylalkyl; or R426 and R826 can join together to form a ring;
R926 is C1-I0 alkyl which can join together with R826 to form a ring; each Y is independently -O- or -S(O)0-2-; Z is a bond, -CO-, or -SO2-; v is 0 to 4; and each R26 present is independently selected from C1-10 alkyl, C1-10 alkoxy, hydroxy, halogen, and trifluoromethyl; and pharmaceutically acceptable salts of any of the foregoing. In another embodiment, the IRM compound can be chosen from lH-imidazo[4,5- c]pyridin-4-amines defined by Formula XXVII below:
Figure imgf000061_0001
XXVII
wherein X is alkylene or alkenylene;
Y is -CO- or -CS;
Z is a bond, -O-, or -S-;
R127 is aryl, heteroaryl, heterocyclyl, alkyl or alkenyl, each of which may be unsubstituted or substituted by one or more substituents independently selected from:
-alkyl;
-alkenyl;
-aryl;
-heteroaryl; -heterocyclyl;
-substituted cycloalkyl;
-substituted aryl;
-substituted heteroaryl; -substituted heterocyclyl;
-O-alkyl;
-O-(alkyl)0-i-aryl;
-0-(alkyl)o-i-(substituted aryl); 5 -O-(alkyl)0-i -heteroaryl;
-O-(alkyl)0-1-(substituted heteroaryl);
-O-(alkyl)0-i-heterocyclyl;
-O-(alkyl)0- 1 -(substituted heterocyclyl) ;
-COOH; 10 -CO-O-alkyl;
-CO-alkyl;
-S(O)0-2 -alkyl;
-S(O)0-2 -(alkyl)0-1-aryl;
-S(O)0-2 -(alkyl)0-1-(substituted aryl); 15 -S(O)0-2 -(alkyl)0-1-heteroaryl;
-S(O)0-2 -(alkyl)o-i-(substituted heteroaryl);
-S(O)0-2 -(alkyl)0-1-heterocyclyl;
-S(O)0-2 -(alkyl)o-i -(substituted heterocyclyl);
-(alkyl)0-1-N(R627)2; 20 -(alkyl)0-1-NR627-CO-O-alkyl;
-(alkyl)0-1-NR627-CO-alkyl;
-(alkyl)0-1-NR627-CO-aryl;
-(alkyl)0-1-NR627-CO-(substituted aryl);
-(alkyl)0-1-NR627-CO-heteroaryl; 25 -(alkyl)0-1-NR627-CO-(substituted heteroaryl);
-N3;
-halogen;
-haloalkyl;
-haloalkoxy; 30 -CO-haloalkyl;
-CO-haloalkoxy;
-NO2; -CN;
-OH;
-SH; and in the case of alkyl, alkenyl, and heterocyclyl, oxo; R227 is selected from: 5 -hydrogen;
-alkyl;
-alkenyl;
-aryl;
-substituted aryl; 10 -heteroaryl;
-substituted heteroaryl;
-alkyl-O-alkyl;
-alkyl-S-alkyl;
-alkyl-O-aryl; 15 -alkyl-S-aryl:
-alkyl-O- alkenyl;
-alkyl-S- alkenyl; and
-alkyl or alkenyl substituted by one or more substituents selected from: 20 -OH;
-halogen;
-N(R627)2; -CO-N(R627)2;
-CS-N(Re2V)2;
25 -SO2-N(R627)2;
-NR627-CO-Ci-10 alkyl;
-NR627-CS-C1-10 alkyl;
-NR627-SO2-C1-10 alkyl;
-CO-C1-10 alkyl; 30 -CO-O-C1-10 alkyl;
-N3;
-aryl; -substituted aryl; -heteroaryl;
-substituted heteroaryl; -heterocyclyl; -substituted heterocyclyl;
-CO-aryl;
-CO-(substituted aryl); -CO-heteroaryl; and -CO-(substituted heteroaryl); R327 and R427 are independently selected from hydrogen, alkyl, alkenyl, halogen, alkoxy, amino, alkylamino, dialkylamino, and alkylthio;
R527 is H or C1-10 alkyl, or R527 can join with X to form a ring that contains one or two heteroatoms; or when R127 is alkyl, Rs27 and R127 can join to form a ring; each R627 is independently H or C1-loalkyl; and pharmaceutically acceptable salts thereof.
In another embodiment, the IRM compound can be chosen from lH-imidazo[4,5- c]pyridin-4-amines defined by Formula XXVIII below:
Figure imgf000064_0001
XXVIII
wherein X is alkylene or alkenylene;
Y is -SO2-;
Z is a bond or -NR628-; R128 is aryl, heteroaryl, heterocyclyl, alkyl or alkenyl, each of which may be unsubstituted or substituted by one or more substituents independently selected from: -alkyl; -alkenyl;
-aryl;
-heteroaryl;
-heterocyclyl; 5 -substituted cycloalkyl;
-substituted aryl;
-substituted heteroaryl;
-substituted heterocyclyl;
-O-alkyl; 10 -O-(alkyl)0-1-aryl;
-O-(alkyl)0-1-(substituted aryl);
-O-(alkyl)0-i -heteroaryl;
-O-(alkyl)0-i-(substituted heteroaryl);
-0-(alkyl)o-i -heterocyclyl; 15 -O-(alkyl)0-1-(substituted heterocyclyl);
-COOH;
-CO-O-alkyl;
-CO-alkyl;
-S(O)0-2 -alkyl; 20 -S(O)0-2 -(alkyl)0-1-aryl;
-S(O)0-2 -(alkyl)0-1 -(substituted aryl);
-S(O)0-2 -(alkyl)0-1-heteroaryl;
-S(O)0-2 -(alkyl)0-1 -(substituted heteroaryl);
-S(O)0-2 -(alkyl)0-1-heterocyclyl; 25 -S(O)0-2 -(alkyl)0-1 -(substituted heterocyclyl);
-(alkyl)0-1-N(R628)2;
-(alkyl)o-i-NR628-CO-0-alkyl;
-(alkyl)0-1-NR628-CO-alkyl;
-(alkyl)0-1-NR628-CO-aryl; 30 -(alkyl)o-1-NR628-CO-(substituted aryl);
-(alkyl)0-1-NR628-CO-heteroaryl;
-(alkyl)0-1-NR628-CO-(substituted heteroaryl); -N3;
-halogen; -haloalkyl; -haloalkoxy;
5 -CO-haloalkyl;
-CO-haloalkoxy; -NO2; -CN; -OH;
10 -SH; and in the case of alkyl, alkenyl, and heterocyclyl, oxo;
R228 is selected from: -hydrogen; -alkyl; -alkenyl; 15 -aryl;
-substituted aryl; -heteroaryl; -substituted heteroaryl; -alkyl-O-alkyl;
20 -alkyl-S-alkyl;
-alkyl-O-aryl; -alkyl-S-aryl: -alkyl-O- alkenyl; -alkyl-S- alkenyl; and
25 -alkyl or alkenyl substituted by one or more substituents selected from:
-OH; -halogen; -N(R62Js)2;
30 -CO-N(R628)2;
-CS-N(R628)2; -SO2-N(R62S)2; -NR628-CO-Ci-I0 alkyl; -NR628-CS-Ci-10 alkyl; -NR628-SO2-C1-10 alkyl; -CO-C1-10 alkyl; -CO-O-Ci-10 alkyl;
-N3; -aryl;
-substituted aryl; -heteroaryl; -substituted heteroaryl;
-heterocyclyl; -substituted heterocyclyl; -CO-aryl;
-CO-(substituted aryl); -CO-heteroaryl; and
-CO-(substituted heteroaryl);
R328 and R428 are independently selected from hydrogen, alkyl, alkenyl, halogen, alkoxy, amino, alkylamino, dialkylamino, and alkylthio;
R528 is H or C1-Io alkyl, or R528 can join with X to form a ring; or when R128 is alkyl, R528 and R128 can join to form a ring; each R628 is independently H or C1-10alkyl; and pharmaceutically acceptable salts thereof.
In another embodiment, the IRM compound can be chosen from lH-imidazo[4,5- c]pyridin-4-amines defined by Formula XXIX below:
Figure imgf000067_0001
XXIX
wherein X is alkylene or alkenylene; Y is -CO- or -CS;
Z is -NR629-, -NR629-CO-, -NR629-SO2-, or -NR729-;
R129 is aryl, heteroaryl, heterocyclyl, alkyl or alkenyl, each of which may be unsubstituted or substituted by one or more substituents independently selected from:
-alkyl;
-alkenyl;
-aryl;
-heteroaryl; -heterocyclyl;
-substituted cycloalkyl;
-substituted aryl;
-substituted heteroaryl;
-substituted heterocyclyl; -O-alkyl;
-O-(alkyl)0-i-aryl;
-0-(alkyl)o-i -(substituted aryl);
-O-(alkyl)0-1 -heteroaryl;
-O-(alkyl)0-1 -(substituted heteroaryl); -O-(alkyl)0-1-heterocyclyl;
-O-(alkyl)0-1-(substituted heterocyclyl);
-COOH;
-CO-O-alkyl;
-CO-alkyl; -S(O)0-2 -alkyl;
-S(O)0-2 -(alkyl)0-1-aryl;
-S(O)0-2 -(alkyl)0-1-(substituted aryl);
-S(O)0-2 -(alkyl)0-1-heteroaryl;
-S(O)0-2 -(alkyl)0-1-(substituted heteroaryl); -S(O)0-2 -(alkyl)0-1 -heterocyclyl;
-S(O)0-2 -(alkyl)o. j -(substituted heterocyclyl);
-(alkyl)0-i-N(R629)2; -(alkyl)0-i-NR629-CO-O-alkyl;
-(alkyl)0-i-NR629-CO-alkyl;
-(alkyl)0-i-NR629-CO-aryl;
-(alkyl)o-i -NR629-CO-(substituted aryl); 5 -(alkyl)0-1-NR629-CO-heteroaryl;
-(alkyl)o-i -NR629-CO-(substituted heteroaryl);
-P(O)(O-alkyl)2;
-N3;
-halogen; 10 -haloalkyl;
-haloalkoxy;
-CO-haloalkyl;
-CO-haloalkoxy;
-NO2; 15 -CN;
-OH;
-SH; and in the case of alkyl, alkenyl, and heterocyclyl, oxo; R229 is selected from:
-hydrogen; 20 -alkyl;
-alkenyl;
-aryl;
-substituted aryl;
-heteroaryl; 25 -substituted heteroaryl;
-alkyl-O-alkyl;
-alkyl-S-alkyl;
-alkyl-O-aryl;
-alkyl-S-aryl: 30 -alkyl-O- alkenyl;
-alkyl-S- alkenyl; and -alkyl or alkenyl substituted by one or more substituents selected from:
-OH; -halogen; -N(R629)2;
-CO-N(R629)2; -CS-N(R629)2; -SO2-N(R629)2; -NR629-CO-C1-10 alkyl; -NR629-CS-C1-10 alkyl;
-NR629-SO2-C1-10 alkyl; -CO-C1-10 alkyl; -CO-O-Ci-Io alkyl; -N3; -aryl;
-substituted aryl; -heteroaryl; -substituted heteroaryl; -heterocyclyl; -substituted heterocyclyl;
-CO-aryl;
-CO-(substituted aryl); -CO-heteroaryl; and -CO-(substituted heteroaryl); R329 and R429 are independently selected from hydrogen, alkyl, alkenyl, halogen, alkoxy, amino, alkylamino, dialkylamino, and alkylthio;
R529 is H or Ci-1O alkyl, or R529 can join with X to form a ring that contains one or two heteroatoms; each R629 is independently H or Q-ioalkyl; R729 is H or C1-1O alkyl which may be interrupted by a heteroatom; or when
R129 is alkyl, R729 and R129 can join to form a ring; and pharmaceutically acceptable salts thereof. In another embodiment, the IRM compound can be chosen from 1 -position ether or thioether substituted lH-imidazo[4,5-c]pyridin-4-amines defined by Formula XXX below:
Figure imgf000071_0001
XXX
wherein:
X is -CH(R530)-, -CH(R530)-alkylene-, -CH(R530)-alkenylene-, or CH(R53O)-alkylene-Y-alkylene-; Y iS -O- Or -S(O)0-2-;
-W-Ri30 is selected from -0-R130-I-S and -S(O)O-2-R130-6; R130-1-S is selected from
-R630-C(R73O)-Z-R830- alkyl; -R630-C(R73O)-Z-R830- alkenyl;
-R63O-C(R73O)-Z-R830- aryl; -R630-C(R73O)-Z-R830- heteroaryl; -R630-C(R73O)-Z-R830- heterocyclyl; -R630-C(R73O)-Z-H; -R630-N(R93o)-C(R73o)-R83o— alkyl;
-R63O-N(R93o)-C(R73O)-R83o— alkenyl; -R63o-N(R93o)-C(R73o)-R830-aryl; -R63o-N(R930)-C(R73o)-R830-heteroaryl; -R63o-N(R93o)-C(R730)-R83o-heterocyclyl; -R63o-N(R93o)-C(R73O)-R1O3o;
-R630- N(R930)- SO2- R830- alkyl; -R630 — N(R930) — SO2 — R830- alkenyl; -R630-N(R93o)-S02-R83o-aryl; -R630-N(R93o)-S02-R83o-heteroaryl; -R63o-N(R930)-S02-R83o-heterocyclyl;
-R63O-N(R93O)-SO2-R1030;
-R630-N(R93o)-S02-N(R53o)-R83o-alkyl; -R63o-N(R93o)-S02-N(R53o)-R83o-alkenyl;
-R630-N(R93o)-S02-N(R53o)-Rs30-aryl;
-R63o-N(R93o)-S02-N(R53o)-R83o-heteroaryl;
-R630-N(R93o)-S02-N(R53o)-R83o-heterocyclyl;
-R630-N(R93O)-SO2-NH2; -R630-N(R93O)-C(R730)- N(R53O)-Q-Rs3o-alkyl;
-R630-N(R93O)-C(R730)- N(R530)-Q-R830-alkenyl;
-R630-N(R93O)-C(R730)- N(RS3o)-Q-R83o-aryl;
-R630-N(R93O)- C(R730)- N(R530)-Q-R830-heteroaryl;
-R630-N(R93O)- C(R730)- N(R530)-Q-R830-heterocyclyl; -R630-N(R93O)-C(R73O)-N(R53O)2;
Figure imgf000072_0001
-R630-N(R93O)-C(R73O)- N A ;
-R630-N(R93O)-C(R730)- N(Ri13O)-Q- Rs3o-alkyl;
-R630-N(R93Q)-C(R730)- N(R1130)-Q— R830-alkenyl;
-R63O-N(R93O)-C(R73O)-N(R113O)-Q-R830-OTyI; -R630-N(R930)- C(R730)- N(R113o)-Q— Rs3o-heteroaryl;
-R630-N(R930)- C(R73O)-N(R1130)-Q— R830-heterocyclyl;
-R630-N(R930)- C(R73Q)-N(R1130)H;
-alkenyl;
-aryl; -R630-aryl;
-heteroaryl;
-heterocyclyl;
-R630- heteroaryl; and
-R630-heterocyclyl; Z is-N(R530)-, -O- or -S-;
Q is a bond, -CO-, or -SO2-; A represents the atoms necessary to provide a 5- or 6-membered heterocyclic or heteroaromatic ring that contains up to three heteroatoms; Ri3O-6 is selected from:
-alkyl; -aryl;
-heteroaryl; -heterocyclyl; -alkenyl; -R630-aryl; -R63O- heteroaryl; and
-R630-heterocyclyl; each R53o is independently hydrogen, C1-10 alkyl, or C2-1O alkenyl; R630 is alkylene, alkenylene, or alkynylene, which may be interrupted by one or more -O- groups; R730 is =0 or =S;
R830 is a bond, alkylene, alkenylene, or alkynylene, which may be interrupted by one or more -O- groups;
Rg30 is hydrogen, C1-10 alkyl, or arylalkyl; or Rg30 can join together with any carbon atom OfR630 to form a ring of the formula
Figure imgf000073_0001
RiO30 is hydrogen or C1-10 alkyl; or R930 and R1030 can join together to form a ring selected from
Figure imgf000073_0002
Rn30 is C1-10 alkyl; or R930 and Rn30 can join together to form a ring having the structure
Figure imgf000073_0003
R123O is C2-7 alkylene which is straight chain or branched, wherein the branching does not prevent formation of the ring; and
R230, R330 and R430 are independently selected from hydrogen and non-interfering substitutents; and pharmaceutically acceptable salts thereof.
Illustrative non-interfering R230 substituents include: -alkyl; -alkenyl; -aryl; -heteroaryl;
-heterocyclyl; -alkylene- Y-alkyl; -alkylene- Y- alkenyl; -alkylene- Y-aryl; and - alkyl or alkenyl substituted by one or more substituents selected from the group consisting of: -OH; -halogen; -N(R53O)2; -C(O)-C1-10 alkyl;
-C(O)-O-C1-10 alkyl; -N3; -aryl;
-heteroaryl; -heterocyclyl;
-C(O)-aryl; and -C(O)-heteroaryl.
Illustrative non-interfering R330 and R430 substitutents include: Ci-I0 alkyl, C2-10 alkenyl, C2-10 alkynyl, CMO alkoxy, C1-I0 alkylthio, amino, alkylamino, dialkylamino, halogen, and nitro.
In another embodiment, the IRM compound can be chosen from lH-imidazo dimers of the formula (XXXI):
Figure imgf000075_0001
wherein:
A is a divalent linking group selected from the group consisting of: straight or branched chain C4-20 alkylene; straight or branched chain C4-20 alkenylene; straight or branched chain C4-20 alkynylene; and
-Z-Y-W-Y-Z-; each Z is independently selected from the group consisting of: straight or branched chain C2-2O alkylene; straight or branched chain C4-20 alkenylene; and straight or branched chain C4-20 alkynylene; any of which may be optionally interrupted by -O-, -N(R531)-, or -S(O)2-; each Y is independently selected from the group consisting of: a bond;
-N(R531)C(O)-;
-C(O)N(R531)-;
-N(R531)C(O)N(R531)-;
- N(R53OS(O)2-;
-S(O)2N(R531)-;
-OC(O)O-;
-OC(O)-;
-C(O)O-;
-N(R531)C(O)O-; and
-OC(O)N(R53O-; W is selected from the group consisting of: straight or branched chain C2-20 alkylene; straight or branched chain C2-20 alkenylene; straight or branched chain C4-20 alkynylene; straight or branched chain perfluoro C2-20 alkylene;
C1-4 alkylene-O-C1-4 alkylene;
-C(O)-;
-S(O)2-;
-OC(O)O-;
-N(R531)C(O)N(R53,)-;
Figure imgf000076_0001
1,5-naphthylene; 2,6-pyridinylene; 1 ,2-cyclohexylene; 1,3-cyclohexylene;
1,4-cyclohexylene; trans- 1 ,4-cyclohexylene;
Figure imgf000076_0002
trans-5-norbornen-2,3-diyl; wherein n is 0 - 4; each R is independently selected from the group consisting OfCj-4 alkyl, C1-4 alkoxy, and halogen; and Q is selected from the group consisting of a bond, -CH2-, and -0-; R231 is selected from the group consisting of: -hydrogen; -alkyl; -alkenyl; -aryl; -substituted aryl;
-heteroaryl;
-substituted heteroaryl; -alkyl-X-alkyl; -alkyl-X-aryl; -alkyl -X- alkenyl; and
-alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:
-OH;
-halogen; -N(R631)2;
-C(O)-N(R631)2;
-C(S)-N(R63O2;
-S(O)2-N(R63O2;
-N(R63O-C(O)-Ci-10 alkyl; -N(R63O-C(S)-Ci-10 alkyl;
-N(R631)- S(O)2-Ci-I0 alkyl;
-C(O)-C1-10 alkyl;
-C(O)-O-C1-10 alkyl;
-N3; -aryl;
-substituted aryl;
-heteroaryl;
-substituted heteroaryl;
-heterocyclyl; -substituted heterocyclyl;
-C(O)-aryl;
-C(O)-(substituted aryl); -C(O)-heteroaryl; and -C(O)-(substituted heteroaryl); R33 I and R43I are each independently selected from the group consisting of:
-hydrogen; -halogen;
-alkyl; -alkenyl; -X-alkyl; and -N(R631)2; or when taken together, R331 and R431 form a fused aryl or heteroaryl ring that is unsubstituted or substituted by one or more substituents selected from the group consisting of: -halogen; -alkyl; -alkenyl;
-X-alkyl; and -N(R631)2; or when taken together, R331 and R431 form a fused 5 to 7 membered saturated ring, containing 0 to 2 heteroatoms and unsubstituted or substituted by one or more substituents selected from the group consisting of:
-halogen; -alkyl; -alkenyl; -X-alkyl; and
-N(R63O2; each R53i is independently selected from the group consisting of: hydrogen;
C1-6 alkyl; C3-7 cycloalkyl; and benzyl; or when Y is -N(R531)C(O)-, -C(O)N(R531)-, -N(R531)C(O)N(R53O-, -N(R53OS(O)2-, -S(O2)N(R531)-, -N(R53OC(O)O-, or -OC(O)N(R531)- and the nitrogen of the N(R53O group is bonded to Z, then R531 can join with Z to form a ring having the structure
Figure imgf000079_0001
each R631 is independently hydrogen or C1-1O alkyl;
R731 is C3-8 alkylene; and X is -O- or -S-; with the proviso that if W is -C(O)-, -S(O)2-, -OC(O)O-, or -N(R531)C(O)N(R531)- then each Y is a bond; and pharmaceutically acceptable salts thereof.
In another embodiment, the IRM compound can be chosen from 6-, 7-, 8-, or 9- position aryl or heteroaryl substituted lH-imidazo[4,5-c]quinolin-4-amines of the following Formula (XXXII):
Figure imgf000079_0002
wherein:
R32 is selected from the group consisting of alkyl, alkoxy, hydroxy, and trifluoromethyl; n is O or 1 ;
Ri32 and R232 are independently selected from the group consisting of hydrogen and non-interfering substitutents;
R332 is selected from the group consisting of: -Z-Ar,
-Z-Ar^Y-R432, -Z-Ar^X-Y-R432, -Z-Ar'-R532, and -Z-Af-X-R532;
Ar is selected from the group consisting of aryl and heteroaryl both of which can be unsubstituted or can be substituted by one or more substituents independently selected from the group consisting of alkyl, alkenyl, alkoxy, methylenedioxy, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, hydroxyalkyl, mercapto, cyano, carboxy, formyl, aryl, aryloxy, arylalkoxy, heteroaryl, heteroaryloxy, heteroarylalkoxy, heterocyclyl, heterocyclylalkyl, amino, alkylamino, and dialkylamino;
Ar' is selected from the group consisting of arylene and heteroarylene both of which can be unsubstituted or can be substituted by one or more substituents independently selected from the group consisting of alkyl, alkenyl, alkoxy, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, hydroxyalkyl, mercapto, cyano, carboxy, formyl, aryl, aryloxy, arylalkoxy, heteroaryl, heteroaryloxy, heteroarylalkoxy, heterocyclyl, heterocyclylalkyl, amino, alkylamino, and dialkylamino; X is selected from the group consisting of alkylene, alkenylene, alkynylene, arylene, heteroarylene, and heterocyclylene wherein the alkylene, alkenylene, and alkynylene groups can be optionally interrupted or terminated with arylene, heteroarylene, or heterocyclylene, and optionally interrupted by one or more -O- groups;
Y is selected from the group consisting of: -S(O)0-2-,
-S(O)2-N(R832)-, -C(R632)-, -C(R632)-O-, -0-C(R632)-, -0-C(O)-O-,
-N(R832)-Q-, -C(R632)-N(R832)-, -O-C(R632)-N(R832)-, -C(R632)-N(OR932)-,
Figure imgf000080_0001
Figure imgf000081_0001
Z is selected from the group consisting of a bond, alkylene, alkenylene, and alkynylene;
R432 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl wherein the alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, mercapto, cyano, aryl, aryloxy, arylalkyleneoxy, heteroaryl, heteroaryloxy, heteroarylalkyleneoxy, heterocyclyl, amino, alkylamino, dialkylamino,
(dialkylamino)alkyleneoxy, and in the case of alkyl, alkenyl, alkynyl, and heterocyclyl, oxo;
R532 is selected from the group consisting of:
-
Figure imgf000081_0002
each R632 is independently selected from the group consisting of =0 and =S; each R732 is independently C2-7 alkylene; each R832 is independently selected from the group consisting of hydrogen, alkyl, alkoxyalkylenyl, and arylalkylenyl;
R932 is selected from the group consisting of hydrogen and alkyl; each R1032 is independently C3-8 alkylene;
A is selected from the group consisting of -O-, -C(O)-, -S(O)0-2-, -CH2-, and - N(R432)-;
Q is selected from the group consisting of a bond, -C(R632)-, -C(R632)-C(R632), -S(O)2-, -C(R632)-N(R832)-W-, -S(O)2-N(R832)-, -C(R632)-O-, and - C(R632)-N(OR932)-;
V is selected from the group consisting of -C(R632)-, -0-C(R632)-, -N(R832K(R632)-, and -S(O)2-;
W is selected from the group consisting of a bond, -C(O)-, and -S(O)2-; and a and b are independently integers from 1 to 6 with the proviso that a + b is < 7; and pharmaceutically acceptable salts thereof.
Illustrative non-interfering R132 substituents include: -Rm, -X-Rrø, -X-Y-R432,
-X-Y-X-Y-R432, and -X-R532; wherein: each X is independently selected from the group consisting of alkylene, alkenylene, alkynylene, arylene, heteroarylene, and heterocyclylene wherein the alkylene, alkenylene, and alkynylene groups can be optionally interrupted or terminated with arylene, heteroarylene, or heterocyclylene, and optionally interrupted by one or more -O- groups; each Y is independently selected from the group consisting of: -S(O)0-2-,
-S(O)2-N(R832)-, -C(R632)-, -C(R632)-O-, -0-C(R632)-, -0-C(O)-O-,
-N(R832Kh -C(R632)-N(R832)-, -0-C(R63Z)-N(R832)-, -C(R632)-N(OR932)-,
Figure imgf000083_0001
R432 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl wherein the alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, mercapto, cyano, aryl, aryloxy, arylalkyleneoxy, heteroaryl, heteroaryloxy, heteroarylalkyleneoxy, heterocyclyl, amino, alkylamino, dialkylamino, (dialkylamino)alkyleneoxy, and in the case of alkyl, alkenyl, alkynyl, and heterocyclyl, oxo;
R532 is selected from the group consisting of:
-N- C(R632)
Figure imgf000083_0002
each R632 is independently selected from the group consisting of =0 and =S; each R732 is independently C2-7 alkylene; each R832 is independently selected from the group consisting of hydrogen, alkyl, alkoxyalkylenyl, and arylalkylenyl; each R932 is independently selected from the group consisting of hydrogen and alkyl; each R1032 is independently C3-8 alkylene;
A is selected from the group consisting of -O-, -C(O)-, -S(0)o-2~, -CH2-, and - N(R432)-; each Q is independently selected from the group consisting of a bond, -C(R632)-, -C(R632K(R632)-, -S(O)2-, -C(R632)-N(R832)-W-, -S(O)2-N(R832)-, -C(R632)-O-, and -C(R632)-N(OR932)-; each V is independently selected from the group consisting of -C(R632)-, -0-C(R632)-, -N(R832)-C(R632)-, and -S(O)2-; each W is independently selected from the group consisting of a bond, -C(O)-, and -S(O)2-; and a and b are independently integers from 1 to 6 with the proviso that a + b is < 7;
Illustrative non-interfering R232 substitutents include:
-R432, -X-R432, -X-Y-R432, and -X-R532; wherein:
X is selected from the group consisting of alkylene, alkenylene, alkynylene, arylene, heteroarylene, and heterocyclylene wherein the alkylene, alkenylene, and alkynylene groups can be optionally interrupted or terminated with arylene, heteroarylene, or heterocyclylene, and optionally interrupted by one or more -O- groups; Y is selected from the group consisting of: -S(O)0-2-, -S(O)2-N(R832)-, -C(R632)-, -C(R632)-O-,
-0-C(R632)-, -0-C(O)-O-, -N(R832)-Q-, -C(R632)-N(R832)-, -O-C(R632)-N(R832)-, -C(R632)-N(OR932)-,
Figure imgf000085_0001
-V-N
V R
Ki032 , and
Figure imgf000085_0002
R432 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl wherein the alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, mercapto, cyano, aryl, aryloxy, arylalkyleneoxy, heteroaryl, heteroaryloxy, heteroarylalkyleneoxy, heterocyclyl, amino, alkylamino, dialkylamino, (dialkylamino)alkyleneoxy, and in the case of alkyl, alkenyl, alkynyl, and heterocyclyl, oxo;
R532 is selected from the group consisting of:
-N C(R632) -N- S(O)2 -- rCe(RR632 λ)
Figure imgf000085_0003
each R632 is independently selected from the group consisting of =0 and =S; each R732 is independently C2-7 alkylene; each R832 is independently selected from the group consisting of hydrogen, alkyl, alkoxyalkylenyl, and arylalkylenyl; R932 is selected from the group consisting of hydrogen and alkyl; each R1032 is independently C3-8 alkylene; A is selected from the group consisting of -O-, -C(O)-, -S(O)0-2-, -CH2-, and -
N(R432)-;
Q is selected from the group consisting of a bond, -C(R632)-, -C(R632)-C(R632)-, -S(O)2-, -C(R632)-N(R832)-W-, -S(O)2-N(R832)-, -C(R632)-O-, and - C(R632)-N(OR932)-;
V is selected from the group consisting Of-C(R632)-, -0-C(R632)-, -N(R832)-C(R632K and -S(O)2-;
W is selected from the group consisting of a bond, -C(O)-, and -S(O)2-; and a and b are independently integers from 1 to 6 with the proviso that a + b is < 7;
Herein, "non-interfering" means that the ability of the compound or salt to modulate (e.g., induce or inhibit) the biosynthesis of one or more cytokines is not destroyed by the non-interfering substituent. As used herein, the terms "alkyl", "alkenyl", "alkynyl" and the prefix "alk-" are inclusive of both straight chain and branched chain groups and of cyclic groups, i.e. cycloalkyl and cycloalkenyl. Unless otherwise specified, these groups contain from 1 to
20 carbon atoms, with alkenyl and alkynyl groups containing from 2 to 20 carbon atoms.
In some embodiments, these groups have a total of up to 10 carbon atoms, up to 8 carbon atoms, up to 6 carbon atoms, or up to 4 carbon atoms. Cyclic groups can be monocyclic or polycyclic and preferably have from 3 to 10 ring carbon atoms. Exemplary cyclic groups include cyclopropyl, cyclopropylmethyl, cyclopentyl, cyclohexyl, adamantyl, and substituted and unsubstituted bornyl, norbornyl, and norbornenyl.
Unless otherwise specified, "alkylene", "alkenylene", and "alkynylene" are the divalent forms of the "alkyl", "alkenyl", and "alkynyl" groups defined above. Likewise,
"alkylenyl", "alkenylenyl", and "alkynylenyl" are the divalent forms of the "alkyl", "alkenyl", and "alkynyl" groups defined above. For example, an arylalkylenyl group comprises an alkylene moiety to which an aryl group is attached.
The term "haloalkyl" is inclusive of groups that are substituted by one or more halogen atoms, including perfluorinated groups. This is also true of other groups that include the prefix "halo-". Examples of suitable haloalkyl groups are chloromethyl, trifluoromethyl, and the like. Similarly, the term "fluoroalkyl" is inclusive of groups that are substituted by one or more fluorine atoms, including perfluorinated groups (e.g., trifluoromethyl) .
The term "aryl" as used herein includes carbocyclic aromatic rings or ring systems. Examples of aryl groups include phenyl, naphthyl, biphenyl, fluorenyl and indenyl. The term "heteroatom" refers to the atoms O, S, or N.
The term "heteroaryl" includes aromatic rings or ring systems that contain at least one ring heteroatom (e.g., O, S, N). Suitable heteroaryl groups include furyl, thienyl, pyridyl, quinolinyl, isoquinolinyl, indolyl, isoindolyl, triazolyl, pyrrolyl, tetrazolyl, imidazolyl, pyrazolyl, oxazolyl, thiazolyl, benzofuranyl, benzothiophenyl, carbazolyl, benzoxazolyl, pyrimidinyl, benzimidazolyl, quinoxalinyl, benzothiazolyl, naphthyridinyl, isoxazolyl, isothiazolyl, purinyl, quinazolinyl, pyrazinyl, 1-oxidopyridyl, pyridazinyl, triazinyl, tetrazinyl, oxadiazolyl, thiadiazolyl, and so on.
The term "heterocyclyl" includes non-aromatic rings or ring systems that contain at least one ring heteroatom (e.g., O, S, N) and includes all of the fully saturated and partially unsaturated derivatives of the above mentioned heteroaryl groups. Exemplary heterocyclic groups include pyrrolidinyl, tetrahydrofuranyl, morpholinyl, thiomorpholinyl, piperidinyl, piperazinyl, thiazolidinyl, imidazolidinyl, isothiazolidinyl, tetrahydropyranyl, quinuclidinyl, homopiperidinyl, homopiperazinyl, and the like. The terms "arylene," "heteroarylene," and "heterocyclylene" are the divalent forms of the "aryl," "heteroaryl," and "heterocyclyl" groups defined above. Likewise, "arylenyl," "heteroarylenyl," and "heterocyclylenyl" are the divalent forms of the "aryl," "heteroaryl," and "heterocyclyl" groups defined above. For example, an alkylarylenyl group comprises an arylene moiety to which an alkyl group is attached. Unless otherwise specified, the aryl, heteroaryl, and heterocyclyl groups of
Formulas IX-XXXI can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, methylenedioxy, ethylenedioxy, alkylthio, haloalkyl, haloalkoxy, haloalkylthio, halogen, nitro, hydroxy, mercapto, cyano, carboxy, formyl, aryl, aryloxy, arylthio, arylalkoxy, arylalkylthio, heteroaryl, heteroaryloxy, heteroarylthio, heteroarylalkoxy, heteroarylalkylthio, amino, alkylamino, dialkylamino, heterocyclyl, heterocycloalkyl, alkylcarbonyl, alkenylcarbonyl, alkoxycarbonyl, haloalkylcarbonyl, haloalkoxycarbonyl, alkylthiocarbonyl, arylcarbonyl, heteroarylcarbonyl, heterocyclylcarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, arylthiocarbonyl, heteroarylthiocarbonyl, alkanoyloxy, alkanoylthio, alkanoylamino, aroyloxy, aroylthio, aroylamino, alkylaminosulfonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aryldiazinyl, alkylsulfonylamino, arylsulfonylamino, arylalkylsulfonylamino, alkylcarbonylamino, alkenylcarbonylamino, arylcarbonylamino, arylalkylcarbonylamino, heteroarylcarbonylamino, heteroarylalkycarbonylamino, alkylsulfonylamino, alkenylsulfonylamino, arylsulfonylamino, arylalkylsulfonylamino, heteroarylsulfonylamino, heteroarylalkylsulfonylamino, alkylaminocarbonyl, dialkylaminocarbonyl, arylaminocarbonyl, arylalkylaminocarbonyl, alkenylaminocarbonyl, heteroarylaminocarbonyl, heteroarylalkylaminocarbonyl, alkylaminocarbonylamino, alkenylaminocarbonylamino, arylaminocarbonylamino, arylalkylaminocarbonylamino, heteroarylaminocarbonylamino, heteroarylalkylaminocarbonylamino and, in the case of heterocyclyl, oxo. If any other groups are identified as being "substituted" or "optionally substituted", then those groups can also be substituted by one or more of the above enumerated substituents.
When a group (or substituent or variable) is present more that once in any Formula described herein, each group (or substituent or variable) is independently selected, whether explicitly stated or not. For example, for the formula -N(R63 O2 each R631 group is independently selected. In another example, when an R232 and an R332 group both contain an R432 group, each R432 group is independently selected. In a further example, when more than one Y group is present (i.e., R232 and R332 both contain a Y group) and each Y group contains one or more R832 groups, then each Y group is independently selected, and each R832 group is independently selected.
In certain embodiments, the immune response modifier is selected from the group consisting of imidazoquinoline amines, tetrahydroimidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, 1,2-bridged imidazoquinoline amines, imidazonaphthyridine amines, imidazotetrahydronaphthyridine amines, oxazoloquinoline amines, thiazoloquinoline amines, oxazolopyridine amines, thiazolopyridine amines, oxazolonaphthyridine amines, thiazolonaphthyridine amines, IH- imidazo dimers fused to pyridine amines, quinoline amines, tetrahydroquinoline amines, naphthyridine amines, or tetrahydronaphthyridine amines, and combinations thereof.
EXAMPLES
Objects and advantages of this invention are further illustrated by the following examples, but the particular materials and amounts thereof recited in these examples, as well as other conditions and details, should not be construed to unduly limit this invention. Unless otherwise provided, all percentages are given as w/w% (i.e., weight percents or wt- %).
Table 1
Figure imgf000089_0001
# This compound is not specifically exemplified but can be readily prepared using the synthetic methods disclosed in the cited reference.
Systemic Formulation
Formulations of IRMl are prepared as described in Table 2 and Table 3 capable of being administered intra-venously or subcutaneously as follows:
Table 2
Figure imgf000089_0002
Figure imgf000090_0001
Table 3
Figure imgf000090_0002
Topical Formulation
IRM compounds are prepared as a 0.01, 0.3, 1.0, or 3% cream formulation as disclosed in US Patent Publication No. US 2003/0199538 and International Patent Publication No. WO 03/045391.
Example 1
Following surgical excision of their lesions, patients with melanoma cutaneous metastasis or lentigo maligna melanoma lesions are treated at the excision site with IRMl or IRM2 at a concentration of 0.01, 0.3, 1.0, or 3% cream formulation as disclosed in US Patent Publication No. US 2003/0199538 and International Patent Publication No. WO 03/045391. The placebo, IRMl, or IRM2 cream formulation is applied three times a week for four weeks.
• Following the four weeks of topical application, patients are treated with an intravenous (LV.) formulation of IRMl as described in Table 2 and Table 3. The LV. formulation is injected three times a week for two to eight weeks with the placebo or a dosing level of 0.008, 0.016, or 0.032 mg/kg.
Example 2 Following surgical excision of their lesions, patients with melanoma cutaneous metastasis or lentigo maligna melanoma lesions are treated with the intra-venous (LV.) formulation as described above. The I. V. formulation is injected three times a week for two weeks with the placebo or a dosing level of 0.004 to 0.108 mg/kg. Following the two weeks of systemic administration of IRMl , patients are treated topically with IRMl or IRM2 at a concentration of 0.01, 0.3, 1.0, or 3% cream formulation as described above. The placebo, IRMl, or IRM2 cream formulations is applied three times a week for four weeks.
Once the four weeks of topically applied IRMl or IRM2 is completed, patients resume systemic administration of IRMl for an additional two to 24 weeks. Example 3
Patients with melanoma cutaneous metastasis or lentigo maligna melanoma lesions are treated at the lesion site with IRMl or IRM2 at a concentration of 0.01, 0.3, 1.0, or 3% cream formulation as disclosed in US Patent Publication No. US 2003/0199538 and International Patent Publication No. WO 03/045391. The placebo, IRMl , or IRM2 cream formulation is applied three times a week for four weeks.
Following the four weeks of topical application, patients are treated with an intravenous (LV.) formulation of IRMl as described in Table 2 or Table 3. The LV. formulation is injected three times a week for two to eight weeks with the placebo or a dosing level of 0.004 to 0.108 mg/kg. Example 4
Patients with melanoma cutaneous metastasis or lentigo maligna melanoma lesions are treated with an intra-venous (LV.) formulation as described above. The LV. formulation is injected three times a week for two weeks with the placebo or a dosing level of 0.004 to 0.108 mg/kg.
Following the two weeks of systemic administration of IRMl, patients are treated topically with IRMl or IRM2 at a concentration of 0.01, 0.3, 1.0, or 3% cream formulation as described above. The placebo, IRMl, or IRM2 cream formulations is applied three times a week for four weeks. Once the four weeks of topically applied IRMl or IRM2 is completed, patients resume systemic administration of IRMl for an additional two to 24 weeks. Example 5 Topical formulations of IRM 1 and a vehicle were formulated as shown in Table 3.
Table 3
Figure imgf000092_0001
Eleven-week-old female Balb/c mice (Charles River Laboratories, Wilmington, MA) were injected intra-dermally with 5χ105 mouse colon carcinoma-26 cells (MC26) expressing luciferase (ATCC, Manassas, VA) on day 0. Mice were divided into five groups: topical vehicle, subcutaneous vehicle (SQ vehicle), IRMl topical (topical IRMl), IRMl subcutaneous (SQ IRMl), and IRMl topical and subcutaneous (topical + SQ IRMl). Eighteen hours after injection of the cells, 30 microliters of vehicle or 5% IRMl topical formulations, described in Table 3, was applied to the tumor site. Six hours later, mice were injected subcutaneously with 10 millograms per kilogram of IRMl in a 1 milligram per milliliter IRMl, 0.03M citrate buffered saline solution or a vehicle 0.03M citrate buffered saline solution. On days 1, 5, and 6 mice were anesthetized with vaporized 3% isoflurane and in vivo photon counts of luciferin were measured using a Xenogen IVIS imaging system (Alameda, CA) following the manufacturer's protocol. The tumor growth index for each treatment group was calculated by dividing each group's day 5 or day 6 tumor photon counts by their day 1 tumor photon counts. The results indicate a surprising benefit when a combination of topical and systemic routes were used. The results for the day 6 tumor growth are found in Figure 1 , in which the topical and SQ vehicles were averaged together (vehicles).
The complete disclosures of the patents, patent documents, and publications cited herein are incorporated by reference in their entirety as if each were individually incorporated. Various modifications and alterations to this invention will become apparent to those skilled in the art without departing from the scope and spirit of this invention. It should be understood that this invention is not intended to be unduly limited by the illustrative embodiments and examples set forth herein and that such examples and embodiments are presented by way of example only with the scope of the invention intended to be limited only by the claims set forth herein as follows.

Claims

WHAT IS CLAIMED IS:
1. A method of treating disease with immune response modifiers (IRMs) by administering at least one IRM compound via at least two different routes of delivery.
2. The method of claim 1 , wherein there is only one IRM compound active moiety is used.
3. The method of claim 2, wherein two different salt forms of the IRM compound active moiety are used.
4. The method of claim 1 , wherein at least two different IRM compound active moieties are used.
5. The method of claim 1 , wherein the routes of delivery include local delivery and systemic delivery.
6. The method in claim 5, wherein the local route of delivery is topical delivery.
7. The method of claim 6, wherein topical delivery is achieved using an IRM- containing gel or cream formulation.
8. The method of claim 5, wherein systemic delivery is achieved by injection or oral delivery.
9. The method of claim 1, wherein the disease being treated is cancer.
10. The method of claim 9, wherein an IRM is delivered locally directly to the cancer and an IRM is delivered systemically to the entire body.
11. The method of claim 10, wherein the IRM delivered locally is injected directly into the cancer.
12. The method of claim 1, wherein the disease is a viral, fungal, protazoal, or bacterial infection.
13. A method of treating melanoma with an immune response modifier (IRM), the method comprising: applying at least one IRM topically to a melanoma lesion on a subject in combination with separately administering at least one IRM to the subject systemically.
14. The method of claim 13 , wherein the IRM administered topically is administered to a dermal or mucosal tissue.
15. The method of claim 14 wherein the IRM administered topically is administered to a vaginal, rectal, nasal, buccal, or pulmonary surface.
16. The method of claim 13 wherein the IRM is a compound having a 2-aminopyridine fused to a five membered nitrogen-containing heterocyclic ring.
17. The method of claim 16 wherein the immune response modifier is selected from the group consisting of imidazoquinoline amines, tetrahydroimidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, 1 ,2-bridged imidazoquinoline amines, imidazonaphthyridine amines, imidazotetrahydronaphthyridine amines, oxazoloquinoline amines, thiazoloquinoline amines, oxazolopyridine amines, thiazolopyridine amines, oxazolonaphthyridine amines, thiazolonaphthyridine amines, IH- imidazo dimers fused to pyridine amines, quinoline amines, tetrahydroquinoline amines, naphthyridine amines, or tetrahydronaphthyridine amines, and combinations thereof.
18. The method of claim 16, wherein the immune response modifier is selected from the group consisting of imidazoquinoline amines, tetrahydroimidazoquinoline amines, imidazopyridine amines, and combinations thereof.
19. The method of claim 16, wherein the immune response modifier is selected from the group consisting of amide substituted imidazoquinoline amines, sulfonamide substituted imidazoquinoline amines, urea substituted imidazoquinoline amines, aryl ether substituted imidazoquinoline amines, heterocyclic ether substituted imidazoquinoline amines, amido ether substituted imidazoquinoline amines, sulfonamido ether substituted imidazoquinoline amines, urea substituted imidazoquinoline ethers, thioether substituted imidazoquinoline amines, 6-, 7-, 8-, or 9-aryl or heteroaryl substituted imidazoquinoline amines, amide substituted tetrahydroimidazoquinoline amines, sulfonamide substituted tetrahydroimidazoquinoline amines, urea substituted tetrahydroimidazoquinoline amines, aryl ether substituted tetrahydroimidazoquinoline amines, heterocyclic ether substituted tetrahydroimidazoquinoline amines, amido ether substituted tetrahydroimidazoquinoline amines, sulfonamido ether substituted tetrahydroimidazoquinoline amines, urea substituted tetrahydroimidazoquinoline ethers, thioether substituted tetrahydroimidazoquinoline amines, amide substituted imidazopyridine amines, sulfonamide substituted imidazopyridine amines, urea substituted imidazopyridine amines, aryl ether substituted imidazopyridine amines, heterocyclic ether substituted imidazopyridine amines, amido ether substituted imidazopyridine amines, sulfonamido ether substituted imidazopyridine amines, urea substituted imidazopyridine ethers, thioether substituted imidazopyridine amines, and combinations thereof.
20. The method of claim 19, wherein the immune response modifier is selected from the group consisting of amide substituted imidazoquinoline amines, sulfonamide substituted imidazoquinoline amines, urea substituted imidazoquinoline amines, thioether substituted imidazoquinoline amines, 7-aryl substituted imidazoquinoline amines, 7- heteroaryl substituted imidazoquinoline amines, sulfonamide substituted tetrahydroimidazoquinoline amines, and combinations thereof.
21. The method of claim 17, wherein the immune response modifier is an imidazoquinoline amine.
22. The method of claim 19, wherein the immune response modifier is a sulfonamide substituted imidazoquinoline amine.
23. The method of claim 16, wherein the immune response modifier is selected from the group consisting of N-[4-(4-amino-2-ethyl-l//-imidazo[4,5-c]quinolin-l- yl)butyl]methanesulfonamide, N- {2- [4-amino-2-(ethoxymethyl)- 1 H-imidazo [4,5 - c]quinolin- 1 -y l)butyl]- 1 , 1 -dimethyleethyl } methanesulfonamide, pharmaceutically acceptable salts thereof, and combinations thereof.
24. The method of any preceding claim, wherein an IRM is administered systemically in a formulation comprising: a pharmaceutically acceptable acid; a tonicity adjuster; sterile water; and optionally a pH adjuster; with the proviso that the IRM is other than l-(2-methylpropyl)-lH-imidazo[4,5- c]quinolin-4-amine or 4-ammo-α,α-dimethyl-lH-imidazo[4,5-c]quinoline-l-ethanol.
25. The method of claim 24, wherein the formulation comprises 0.4 wt-% to 0.5 wt-% citric acid, 4 wt-% to 5 wt-% mannitol, and water, wherein the formulation is adjusted to a pH of 5 with the pH adjuster.
26. The method of claim 24, wherein the formulation comprises 0.2 wt-% to 0.5 wt-% acetic acid, 4 wt-% to 5 wt-% mannitol, and water, wherein the formulation is adjusted to a pH of 5 with the pH adjuster.
PCT/US2005/047069 2004-12-30 2005-12-28 Multi-route administration of immune response modifier compounds WO2006073940A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2005323024A AU2005323024A1 (en) 2004-12-30 2005-12-28 Multi-route administration of immune response modifier compounds
US11/722,585 US20080119508A1 (en) 2004-12-30 2005-12-28 Multi-Route Administration Of Immune Response Modifier Compounds
EP05855599A EP1830880A4 (en) 2004-12-30 2005-12-28 Multi-route administration of immune response modifier compounds
CA002592573A CA2592573A1 (en) 2004-12-30 2005-12-28 Multi-route administration of immune response modifier compounds
JP2007549552A JP2008526752A (en) 2004-12-30 2005-12-28 Multipath administration of immune response modifier compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64087304P 2004-12-30 2004-12-30
US60/640,873 2004-12-30

Publications (2)

Publication Number Publication Date
WO2006073940A2 true WO2006073940A2 (en) 2006-07-13
WO2006073940A3 WO2006073940A3 (en) 2006-11-30

Family

ID=36648022

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2005/047374 WO2006074045A2 (en) 2004-12-30 2005-12-28 Immune response modifier formulations and methods
PCT/US2005/047069 WO2006073940A2 (en) 2004-12-30 2005-12-28 Multi-route administration of immune response modifier compounds

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US2005/047374 WO2006074045A2 (en) 2004-12-30 2005-12-28 Immune response modifier formulations and methods

Country Status (8)

Country Link
US (3) US20080207674A1 (en)
EP (2) EP1835915A4 (en)
JP (2) JP2008526752A (en)
CN (1) CN101443005A (en)
AU (2) AU2005322843B2 (en)
CA (2) CA2592575A1 (en)
WO (2) WO2006074045A2 (en)
ZA (1) ZA200706251B (en)

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7879849B2 (en) 2003-10-03 2011-02-01 3M Innovative Properties Company Pyrazolopyridines and analogs thereof
US7897609B2 (en) 2004-06-18 2011-03-01 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
US7897767B2 (en) 2003-11-14 2011-03-01 3M Innovative Properties Company Oxime substituted imidazoquinolines
US7897597B2 (en) 2003-08-27 2011-03-01 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted imidazoquinolines
US7906506B2 (en) 2006-07-12 2011-03-15 3M Innovative Properties Company Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods
US7915281B2 (en) 2004-06-18 2011-03-29 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method
US7923429B2 (en) 2003-09-05 2011-04-12 3M Innovative Properties Company Treatment for CD5+ B cell lymphoma
US7943610B2 (en) 2005-04-01 2011-05-17 3M Innovative Properties Company Pyrazolopyridine-1,4-diamines and analogs thereof
US7943609B2 (en) 2004-12-30 2011-05-17 3M Innovative Proprerties Company Chiral fused [1,2]imidazo[4,5-C] ring compounds
US7943636B2 (en) 2005-04-01 2011-05-17 3M Innovative Properties Company 1-substituted pyrazolo (3,4-C) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
US7968563B2 (en) 2005-02-11 2011-06-28 3M Innovative Properties Company Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
US8017779B2 (en) 2004-06-15 2011-09-13 3M Innovative Properties Company Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
US8026366B2 (en) 2004-06-18 2011-09-27 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
US8034938B2 (en) 2004-12-30 2011-10-11 3M Innovative Properties Company Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds
US8598192B2 (en) 2003-11-14 2013-12-03 3M Innovative Properties Company Hydroxylamine substituted imidazoquinolines
US8673932B2 (en) 2003-08-12 2014-03-18 3M Innovative Properties Company Oxime substituted imidazo-containing compounds
US8691837B2 (en) 2003-11-25 2014-04-08 3M Innovative Properties Company Substituted imidazo ring systems and methods
US8697873B2 (en) 2004-03-24 2014-04-15 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
US8735421B2 (en) 2003-12-30 2014-05-27 3M Innovative Properties Company Imidazoquinolinyl sulfonamides
US8802853B2 (en) 2003-12-29 2014-08-12 3M Innovative Properties Company Arylalkenyl and arylalkynyl substituted imidazoquinolines
US8871782B2 (en) 2003-10-03 2014-10-28 3M Innovative Properties Company Alkoxy substituted imidazoquinolines
US9248127B2 (en) 2005-02-04 2016-02-02 3M Innovative Properties Company Aqueous gel formulations containing immune response modifiers
WO2017184735A1 (en) * 2016-04-19 2017-10-26 Ifm Therapeutics, Inc Nlrp3 modulators
US10533005B2 (en) 2017-02-17 2020-01-14 Innate Tumor Immunity, Inc. NLRP3 modulators
US10556903B2 (en) 2016-04-19 2020-02-11 Innate Tumor Immunity, Inc. NLRP3 modulators

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040265351A1 (en) 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
CA2540598C (en) 2003-10-03 2013-09-24 3M Innovative Properties Company Pyrazolopyridines and analogs thereof
US8541438B2 (en) 2004-06-18 2013-09-24 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
US20080207674A1 (en) * 2004-12-30 2008-08-28 Coley Pharmaceutical Group, Inc. Immune Response Modifier Formulations And Methods
US20080318998A1 (en) 2005-02-09 2008-12-25 Coley Pharmaceutical Group, Inc. Alkyloxy Substituted Thiazoloquinolines and Thiazolonaphthyridines
AU2006338521A1 (en) 2005-02-09 2007-10-11 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted thiazolo(4,5-c) ring compounds and methods
US8658666B2 (en) 2005-02-11 2014-02-25 3M Innovative Properties Company Substituted imidazoquinolines and imidazonaphthyridines
JP2008538203A (en) 2005-02-23 2008-10-16 コーリー ファーマシューティカル グループ，インコーポレイテッド A method for preferentially inducing biosynthesis of interferon
CA2598639A1 (en) 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazonaphthyridines
EP1851224A2 (en) 2005-02-23 2007-11-07 3M Innovative Properties Company Hydroxyalkyl substituted imidazoquinolines
AU2006216798A1 (en) 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazoquinoline compounds and methods
ZA200803029B (en) 2005-09-09 2009-02-25 Coley Pharm Group Inc Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
JP2009507856A (en) 2005-09-09 2009-02-26 コーリー ファーマシューティカル グループ，インコーポレイテッド Amide and carbamate derivatives of N- {2- [4-amino-2- (ethoxymethyl) -1H-imidazo [4,5-c] quinolin-1-yl] -1,1-dimethylethyl} methanesulfonamide and Method
JP5247458B2 (en) 2005-11-04 2013-07-24 スリーエム・イノベイティブ・プロパティーズ・カンパニー Hydroxy and alkoxy substituted 1H-imidazoquinolines and methods
US8951528B2 (en) 2006-02-22 2015-02-10 3M Innovative Properties Company Immune response modifier conjugates
WO2007106854A2 (en) 2006-03-15 2007-09-20 Coley Pharmaceutical Group, Inc. Hydroxy and alkoxy substituted 1h-imidazonaphthyridines and methods
WO2008030511A2 (en) 2006-09-06 2008-03-13 Coley Pharmaceuticial Group, Inc. Substituted 3,4,6,7-tetrahydro-5h, 1,2a,4a,8-tetraazacyclopenta[cd]phenalenes
WO2010088924A1 (en) * 2009-02-06 2010-08-12 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
EP2411521B1 (en) 2009-03-25 2015-01-14 The Board of Regents of The University of Texas System Compositions for stimulation of mammalian innate immune resistance to pathogens
US20100331812A1 (en) * 2009-06-29 2010-12-30 Nitric Biotherapeutics, Inc. Pharmaceutical Formulations for Iontophoretic Delivery of an Immunomodulator
HUE033901T2 (en) 2010-08-17 2018-01-29 3M Innovative Properties Co Lipidated immune response modifier compound compositions, formulations, and methods
JP6415979B2 (en) 2011-06-03 2018-10-31 スリーエム イノベイティブ プロパティズ カンパニー Hydrazino 1H-imidazoquinolin-4-amine and complexes prepared therefrom
CA2838158C (en) 2011-06-03 2019-07-16 3M Innovative Properties Company Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom
EP3065741B1 (en) * 2013-11-05 2021-09-22 3M Innovative Properties Company Sesame oil based injection formulations
WO2016019232A1 (en) * 2014-08-01 2016-02-04 John Vasilakos Methods and therapeutic combinations for treating tumors
WO2016044839A2 (en) 2014-09-19 2016-03-24 The Board Of Regents Of The University Of Texas System Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
JP7197244B2 (en) 2017-12-20 2022-12-27 スリーエム イノベイティブ プロパティズ カンパニー Amido-substituted imidazo[4,5-C]quinoline compounds with branched chain linking groups for use as immune response modifiers

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA704419B (en) * 1969-07-21 1971-04-28 Ici Australia Ltd Injectable aqueous solutions of tetramisole
DE2423389A1 (en) * 1974-05-14 1975-12-04 Hoechst Ag PSYCHOTROPIC MEDICINAL PRODUCTS AND THE METHOD OF MANUFACTURING THEREOF
US4826830A (en) * 1985-07-31 1989-05-02 Jui Han Topical application of glyciphosphoramide
IL105325A (en) * 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
FR2732605B1 (en) * 1995-04-07 1997-05-16 Pasteur Merieux Serums Vacc COMPOSITION FOR INDUCING MUCOSAL IMMUNE RESPONSE
US6616927B2 (en) * 1997-05-29 2003-09-09 Agresearch Limited Processes for production of immunoglobulin A in milk
US6110929A (en) * 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
US6331539B1 (en) * 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US6692745B2 (en) * 2000-01-28 2004-02-17 Arogenics Pharmaceuticals, Inc. Compositions and methods for inhibition of HIV-1 infection
WO2003094836A2 (en) * 2001-10-12 2003-11-20 University Of Iowa Research Foundation Methods and products for enhancing immune responses using imidazoquinoline compounds
US6677349B1 (en) * 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
GB0211649D0 (en) * 2002-05-21 2002-07-03 Novartis Ag Organic compounds
AU2004244962A1 (en) * 2003-04-10 2004-12-16 3M Innovative Properties Company Delivery of immune response modifier compounds using metal-containing particulate support materials
MY157827A (en) * 2003-06-27 2016-07-29 3M Innovative Properties Co Sulfonamide substituted imidazoquinolines
WO2005016275A2 (en) * 2003-08-05 2005-02-24 3M Innovative Properties Company Formulations containing an immune response modifier
CU23404A1 (en) * 2003-11-19 2009-08-04 Ct Ingenieria Genetica Biotech NEISSERIA MENINGITIDIS CAPSULAR POLYSACARIDS AS MUCOSOPT IMMUNOPOTENTIZERS AND RESULTING FORMULATIONS
US20080207674A1 (en) * 2004-12-30 2008-08-28 Coley Pharmaceutical Group, Inc. Immune Response Modifier Formulations And Methods

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of EP1830880A4 *

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8673932B2 (en) 2003-08-12 2014-03-18 3M Innovative Properties Company Oxime substituted imidazo-containing compounds
US7897597B2 (en) 2003-08-27 2011-03-01 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted imidazoquinolines
US7923429B2 (en) 2003-09-05 2011-04-12 3M Innovative Properties Company Treatment for CD5+ B cell lymphoma
US7879849B2 (en) 2003-10-03 2011-02-01 3M Innovative Properties Company Pyrazolopyridines and analogs thereof
US8871782B2 (en) 2003-10-03 2014-10-28 3M Innovative Properties Company Alkoxy substituted imidazoquinolines
US7897767B2 (en) 2003-11-14 2011-03-01 3M Innovative Properties Company Oxime substituted imidazoquinolines
US8598192B2 (en) 2003-11-14 2013-12-03 3M Innovative Properties Company Hydroxylamine substituted imidazoquinolines
US8691837B2 (en) 2003-11-25 2014-04-08 3M Innovative Properties Company Substituted imidazo ring systems and methods
US8802853B2 (en) 2003-12-29 2014-08-12 3M Innovative Properties Company Arylalkenyl and arylalkynyl substituted imidazoquinolines
US8735421B2 (en) 2003-12-30 2014-05-27 3M Innovative Properties Company Imidazoquinolinyl sulfonamides
US8697873B2 (en) 2004-03-24 2014-04-15 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
US8017779B2 (en) 2004-06-15 2011-09-13 3M Innovative Properties Company Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
US8026366B2 (en) 2004-06-18 2011-09-27 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
US7915281B2 (en) 2004-06-18 2011-03-29 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method
US7897609B2 (en) 2004-06-18 2011-03-01 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
US8034938B2 (en) 2004-12-30 2011-10-11 3M Innovative Properties Company Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds
US7943609B2 (en) 2004-12-30 2011-05-17 3M Innovative Proprerties Company Chiral fused [1,2]imidazo[4,5-C] ring compounds
US9248127B2 (en) 2005-02-04 2016-02-02 3M Innovative Properties Company Aqueous gel formulations containing immune response modifiers
US10071156B2 (en) 2005-02-04 2018-09-11 3M Innovative Properties Company Aqueous gel formulations containing immune response modifiers
US7968563B2 (en) 2005-02-11 2011-06-28 3M Innovative Properties Company Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
US7943636B2 (en) 2005-04-01 2011-05-17 3M Innovative Properties Company 1-substituted pyrazolo (3,4-C) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
US7943610B2 (en) 2005-04-01 2011-05-17 3M Innovative Properties Company Pyrazolopyridine-1,4-diamines and analogs thereof
US7906506B2 (en) 2006-07-12 2011-03-15 3M Innovative Properties Company Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods
WO2017184735A1 (en) * 2016-04-19 2017-10-26 Ifm Therapeutics, Inc Nlrp3 modulators
US10533007B2 (en) 2016-04-19 2020-01-14 Innate Tumor Immunity, Inc. NLRP3 modulators
US10556903B2 (en) 2016-04-19 2020-02-11 Innate Tumor Immunity, Inc. NLRP3 modulators
US10533005B2 (en) 2017-02-17 2020-01-14 Innate Tumor Immunity, Inc. NLRP3 modulators
US11827632B2 (en) 2017-02-17 2023-11-28 Innate Tumor Immunity, Inc NLRP3 modulators

Also Published As

Publication number Publication date
EP1830880A2 (en) 2007-09-12
US20080119508A1 (en) 2008-05-22
WO2006074045A3 (en) 2006-10-12
CA2592575A1 (en) 2006-07-13
US20080207674A1 (en) 2008-08-28
AU2005323024A1 (en) 2006-07-13
EP1835915A2 (en) 2007-09-26
WO2006074045A2 (en) 2006-07-13
AU2005322843B2 (en) 2012-03-08
CN101443005A (en) 2009-05-27
JP2008526757A (en) 2008-07-24
JP2008526752A (en) 2008-07-24
US20110021554A1 (en) 2011-01-27
EP1830880A4 (en) 2008-03-26
AU2005322843A1 (en) 2006-07-13
WO2006073940A3 (en) 2006-11-30
CA2592573A1 (en) 2006-07-13
ZA200706251B (en) 2008-11-26
EP1835915A4 (en) 2010-02-24

Similar Documents

Publication Publication Date Title
EP1830880A2 (en) Multi-route administration of immune response modifier compounds
AU2005222995B2 (en) Immune response modifier formulations and methods
AU2004264336B2 (en) Formulations containing an immune response modifier
AU2005244260B2 (en) Methods, compositions, and preparations for delivery of immune response modifiers
EP1844201B1 (en) Aqueous gel formulations containing immune response modifiers
CN102985421B (en) Naphthridine derivatives as pi3k inhibitors for the treatment of cancer and immune - inflammatory diseases
MXPA01006876A (en) Formulations and methods for treatment of mucosal associated conditions with an immune response modifier.
JP2001247459A (en) Combination therapy for cancer
AU2009210655A1 (en) Treatment of bladder diseases with a TLR7 activator
JP2006070032A (en) Anti-angioplastic medicament composition
WO2012075957A1 (en) Use of phenethyl caffeate derivatives in the preparation of a medicament against tumor angiogenesis
WO2022228497A1 (en) Use of medicament in treatment of tumor disease
JP2738979B2 (en) Non-small cell lung cancer treatment
JPH06505487A (en) Pharmaceutical composition for treatment of esophageal cancer
JP2778632B2 (en) Pharmaceutical composition for treating ovarian cancer
CN103037842B (en) Novel pharmaceutical compounds
WO2005011674A1 (en) Preventive and/or therapeutic agents for bronchial asthma

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 11722585

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2592573

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007549552

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2005855599

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2005323024

Country of ref document: AU

Date of ref document: 20051228

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2005323024

Country of ref document: AU